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ABSTRACT 
Over 100 years ago, X-ray crystallography gave scientists a window to the 
atomic world with varied applications in biology, chemistry and physics among 
other subjects. Macromolecular crystallography is now considered an essential 
tool for solving the three-dimensional structure of proteins and understanding 
their physiological role at the atomic level. As crystal growth remains a 
bottleneck in crystallography, various other techniques are often employed to 
help understand the protein structure and function. These methods range from 
simple analysis of the protein sequence to experiments such as dynamic light 
scattering, isothermal titration calorimetry, activity assays, and analytical 
ultracentrifugation. The additional knowledge gained about proteins from these 
methods can then assist in the modification of the protein to facilitate its 
crystallisation. The structural biology of proteins belonging to two diverse 
families; Galectins and Sirtuins, both involved in the regulation of cancer, was 
studied in this thesis.  
 Galectins are evolutionarily conserved and ubiquitously present animal lectins 
with a high affinity for -galactose containing oligosaccharides. To date, 15 
mammalian galectins have been identified. Their involvement in cell–cell and 
cell–matrix interactions has highlighted their importance in signal transduction 
and other intracellular processes. Human Galectin-7 (hGal-7) is a 16 kDa 
prototype galectin which is involved in the stimulation and development of 
cancer. The crystal structure of native hGal-7 and its complex with galactose 
and lactose have been reported. In this study, cross-linking of hGal-7 by 
glycodendrons and the resulting clustering and lattice formation have been 
studied. For this purpose, the high resolution X-ray structures of hGal-7 in 
complex with carbohydrate-based multivalent dendrons have been elucidated 
and analysed. Also discussed in this thesis are preliminary binding affinity 
results obtained using isothermal calorimetry. Supramolecular assembly 
formation was also assessed using dynamic light scattering. These experiments 
reveal how multivalent glycodendendrons interact with and form cross-links 
with hGal-7 molecules. Understanding how these dendrimeric compounds 
v 
interact with hGal-7 would help in the design of new tools to investigate the 
recognition of multivalent carbohydrates by lectins and their resulting role in 
aggregation processes in tumour embolisation and survival.  
Sirtuins are NAD+-dependent deacylases that are involved in the regulation of 
diverse biological functions such as ageing, metabolism and stress resistance, in 
normal cellular physiology. Their role in ageing and ageing-related diseases, 
including cancer and neurodegenerative diseases among others, has received 
much attention and sirtuins have been extensively studied to help in extension 
of human lifespan. Seven members of the sirtuin family (SIRT1-7) are known, 
which are diversely sub-localised in the cell. A myriad of questions regarding 
their deacylation activity, their interplay and their role in various diseases still 
remain unanswered. In this study, structural biology techniques have been used 
to understand the role of SIRT1, SIRT2 and SIRT7. The cloning, expression, 
purification and crystallisation of these sirtuins are presented in this thesis. 
Various supporting techniques used to confirm the identity and activity of the 
proteins are also discussed. A brief discussion of the methods that can be 
employed to overcome various barriers in structural biology is also presented in 
this thesis. Elucidating the structure of full length sirtuins would help in the 
development of highly selective modulators of sirtuins to aid in the 
understanding of their role in ageing and ageing-related diseases.  
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Galectins are a family of proteins belonging to the lectin superfamily. They 
behave as signalling molecules by binding to β-galactose containing 
glycoconjugates at their carbohydrate recognition domains. This chapter 
describes the diversity of lectins and more specifically the galectin family. It 
also presents an overview of the biological activities and structural similarities 
of galectins and the functionality of human galectin–7 (hGal-7). This is followed 
by a brief description of carbohydrates and dendrimers, and finally the aims 
and objectives of this project. 
1.1.1. The history of lectins 
The 20th century witnessed many important scientific breakthroughs, one of 
which was understanding the occurrence of erythrocyte agglutinating proteins 
in nature (Franz, 1988). The ability of these proteins to agglutinate other 
proteins and their high level of sugar specificity came to light in the 1960s. The 
potentiality of plant agglutinins to distinguish between erythrocytes of different 
blood types led Boyd and Shapleigh to name them lectins (from the Latin legere, 
“to select”) (Boyd and Shapleigh, 1954). This term was generalised by Sharon 
and Lis to include all sugar-specific agglutinins of non-immune origin, 
irrespective of source and blood type specificity (Sharon and Lis, 1972). 
Boyd and Shapleigh‘s work was then followed by the two major discoveries 
which led to understanding the role of lectins in mitogenic stimulation of 
lymphocytes and agglutination of cancer cells. Peter C. Nowell found that 
phytohaemagglutinin (PHA), the lectin of red kidney beans (Phaseolus vulgaris), 
possessed the ability to stimulate lymphocytes to undergo mitosis i.e. PHA is 
mitogenic (Nowell, 1960). The second discovery, made by Joseph C. Aub 
demonstrated that wheat germ agglutinin (WGA) has the ability to 
preferentially agglutinate malignant cells (Aub et al., 1965, Aub et al., 1963).  
By the 1970s the presence of haemagglutinins had mainly been reported in 
plants (Sharon and Lis, 2004). Among animal lectins, only haemagglutinins in 
eels, snails and the horseshoe crabs had been isolated and characterised by this 
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time. In 1952 Watkins and Morgan showed the specificity of the eel 
haemagglutinin for L-fucose (a sugar) (Watkins and Morgan, 1952). The first 
mammalian lectin, the galactose-specific hepatic asialo-glycoprotein receptor, 
was isolated in 1974 (Hudgin et al., 1974, Stockert et al., 1974) and resulted in 
our understanding of the mechanisms that control the lifetime of glycoproteins 
in blood circulation. 
Following the discovery of the hepatic asialo-glycoprotein receptor, a C-type 
lectin, the first member of -galactose specific lectins from the electric eel 
termed, electrolectin was identified in 1975 (Teichberg et al., 1975). This protein 
required the inclusion of β-mercaptoethanol in isolation buffers to maintain its 
activity, which suggested the presence of one or more reduced sulfhydryl 
cysteine residues. These lectins were formally termed S-type lectins due to their 
sulphydryl dependency. This family of proteins were later termed galectins 
(Barondes et al., 1994a) of which 15 members have now been characterised. The 
first mammalian galectin, now known as galectin-1, was isolated in 1976 from 
chick muscle and extracts of calf heart and lung (de Waard et al., 1976) .  
1.1.2. Animal lectins 
Lectins are non-enzymatic, sugar binding proteins. They are ubiquitously 
present in animals, plants and microorganisms. Their specificity and ability to 
discriminate among the myriad of complex carbohydrates found on cell 
surfaces, extracellular matrices and attached to soluble glycoproteins, makes 
them an important tool in the structural and functional analysis of animal cell 
glycoconjugates (Drickamer and Taylor, 1993). These complex saccharides have 
both structural and non-structural roles. The non-structural role of sugars 
requires the participation of sugar-binding proteins, which is ascribed to a 
single protein module within the lectin polypeptide. This module is called the 
carbohydrate recognition domain (CRD) (Drickamer and Taylor, 1998). Lectins 
serve as a bridge between cells and their environment through their recognition 
of these diverse complex oligosaccharides. Their main function is in the 
mediation of cell-cell adhesion, intracellular routing of glycoproteins and 
promotion of cell-cell interactions contributing to signal transductions (Liu and 
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Rabinovich, 2005, Vasta, 2009). In addition to recognising carbohydrates 
endogenous to the animal cell, they also recognise those presented by microbial 
invaders and contribute to the initiation of the host defence. It is believed that 
lectins mediate the interactions by decoding the information present in 
saccharides (Drickamer and Taylor, 1993). In 1991 Gabius demonstrated the 
abundance and variety of animal lectins through the large number of 
polypeptides that were isolated on immobilised sugars (Gabius, 1991). 
In the past, animal lectins have been classified based on the nature of their 
carbohydrate ligands, the biological processes in which they participate, their 
sublocalisation and their dependence on divalent cations (Drickamer and 
Taylor, 1993). However, their classification based on sequence characteristics, 
specifically their CRDs, is now most widely accepted (Drickamer, 1988, 
Drickamer and Taylor, 1993, 1998). To date, eight groups of animal lectins have 
been described. Of these eight groups, four contain lectins that are 
predominantly intracellular. The intracellular lectins; calnexin family, M-type, 
L-type and P-type, are located in luminal compartments of secretory pathways. 
Their functions include trafficking, sorting and targeting of maturing 
glycoproteins. The four predominantly extracellular lectins include C-type, R-
type, siglecs (I-type) and galectins [Figure 1.1]. These four lectin types are 
typically present in the extracellular matrix, secreted in body fluids, or are 
localized to the plasma membrane. They mediate a range of functions including 
cell adhesion, cell signalling, glycoprotein clearance and pathogen recognition. 
Several additional groups of animal lectins have been proposed, including F-
box lectins, ficolins, chitinase-like lectins, F-type lectins and intelectins 
(Drickamer and Taylor, 1998). 
1.1.2.1. Extracellular animal lectins 
Among the four predominantly extracellular lectins, the calcium-dependent (C-
type) lectins, are involved in sugar recognition in a variety of cell surface and 
other extracellular lectins (Cummings and McEver, 2009). These lectins are 
associated with biological processes such as adhesion, endocytosis and 
complement fixation. The binding of oligosaccharides at the CRD of C-type 
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lectin involves a Ca2+ ion that is essential for the interaction and stabilization of 
the local conformation of the protein. Members of this family of lectins include 
lecticans, selectins and collectins, among others.  
The R-type lectins, named after the castor bean protein ricin, are the only sugar 
binding protein modules among animal lectins to be found in prokaryotes 
(Cummings and Etzler, 2009). Ricin was the first lectin to be identified in this 
family and is the prototypical protein for this family. It is present in plants, 
animals and bacteria. The plant lectins usually contain a module that is a potent 
toxin.  
The I-type lectins bind to oligosaccharides through the immunoglobulin 
superfamily domain. The siglec family of sialic acid – binding cell surface 
adhesion receptors are the most studied of this family (Crocker et al., 1998). 
Galectins are globular proteins which are characterised by a galectin–like CRD, 




Figure 1. 1: Schematic example of major types of extracellular animal lectins.  
Example of domain and topology of some extracellular animal lectins. The defined carbohydrate recognition domains (CRDs) are shown: 
GL: Galectin CRD, CL: C-type lectins CRD and IL: I-type lectin CRD. Other domains are immunoglobulin C2-set domain (IG2), 
complement regulatory repeat (C3), transmembrane region (TM) and EGF-like domain (EG). The number of domains underlying the 
CRD can vary among family members of this family of proteins. 
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1.1.3. Galectins 
Galectins are a family of animal lectins with an evolutionarily conserved CRD, 
specific for -galactose containing oligosaccharides, and exhibit high sequence 
similarity (Barondes et al., 1994b, Cooper, 2002, Danguy et al., 2002, Leffler et al., 
2004, Liu et al., 2002, Liu and Rabinovich, 2005, Rabinovich, 1999). They are 
ubiquitously present in living organisms and are involved in essential cellular 
events including signal transduction, cell development, differentiation, cell-cell 
adhesion, cell-matrix interactions, growth regulation and apoptosis (Liu and 
Rabinovich, 2005, Rabinovich and Toscano, 2009, St-Pierre et al., 2012, Vasta, 
2009). The polysaccharide chains present on various cell surfaces and serum 
proteins play a role in glycan presentation and their distribution has been 
implicated in various diseases (Gabius, 2000, Rabinovich and Croci, 2012, 
Reuter and Gabius, 1999, Varki, 1993). The selective recognition of N-glycans 
and other β-galactosides by members of the galectin family and their 
involvement in pathological conditions have been extensively studied and 
highlighted their role in infection, immunity, atherosclerosis and cancer 
development, through protein-glycan and protein-protein interactions 
(Delacour et al., 2009, Rabinovich et al., 2002, Rabinovich and Toscano, 2009, 
Vasta, 2009). The CRD of galectins comprises an α/β sandwich similar to the 
overall topology of L-type lectins. However, the lack of sequence similarity and 
the orientation of the sugar-binding sites in these two families suggests that this 
topological similarity results from convergent evolution. Mammalian galectins 
lack conventional signal sequences. They reach the cell surface by non-
traditional mechanisms before binding to glycoconjugates on the plasma 
membrane and in the extracellular matrix.  
Galectins are synthesised on free polysomes in the cytoplasm and accumulate 
there prior to secretion. Unlike other animal lectins, they can be found in the 
nucleus, cytoplasm, outer plasma membrane and the extracellular matrix. 
Galectins isolated from the cytoplasm of cells bind to β-galactosides which is 
indicative of their synthesis and functionality in this organelle. Glycan presence 
is however, not detected in the cytoplasm, which suggests an alternative role 
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and binding partner of galectins in this compartment (Cummings and Liu, 
2009). 
Galectins do not contain membrane-anchoring domains or signal peptides 
required for endoplasmic reticulum (ER)/Golgi-mediated secretion, in their 
primary structure (Couraud et al., 1989). Moreover, the synthesis of galectins on 
free ribosomes in the cytoplasm and its subsequent secretion is not blocked by 
inhibitors such as brefeldin A or monensin which block the ER/Golgi-mediated 
secretion (Hughes, 1999, Lindstedt et al., 1993, Sato et al., 1993). Therefore, it has 
been suggested that galectins are secreted through a non-classical pathway in 
which they first accumulate underneath the plasma membrane of the cell and 
cause the formation of exosomes [Figure 1.2] (Delacour et al., 2009, Nickel, 
2003). Exosomes are vesicles that are formed on the outer surface of the cell in a 
process termed membrane blebbing (Nickel, 2003). These exosomes are labile 
structures which then release the protein into the extracellular space.  
Galectins are reported to form homogenous lattices at the cell surface through 
cross-linking that can activate signalling pathways in the control of receptor 
endocytosis, host-pathogen interactions and activation of immune cells (Brewer, 
2002, Vasta, 2009). In human T-cells, the bivalent galectin-1 crosslinks specific 
glycoprotein counter-receptors on the surface of the cells resulting in apoptosis 
(Sacchettini et al., 2001). 
 
Figure 1. 2: Animal cell undergoing membrane blebbing.  
Galectins are secreted through a non-classical pathway involving the formation 
of exosomes, vesicles that form on the outer surface of the cell.  
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1.1.3.1 Members of the galectin family 
Fifteen members of the galectin family have been identified to date (Gal 1-15) 
(Hirabayashi and Kasai, 1993). They all have a globular fold consisting of 2 
antiparallel -sheets of 5 or 6 strands and a CRD which forms a concave surface. 
Based on the structural design of the CRD they are classified into three 
subgroups: prototype which contain one CRD (Gal -1, -2, -5, -7, -10, -11, -13, -14 
and -15), tandem repeat type which contain two CRDs in tandem (Gal -4, -6, -8, 
-9 and -12) and chimera type which contain one CRD and an additional non-
lectin domain (Gal -3) (Hirabayashi and Kasai, 1993, Leffler et al., 2004) [Figure 
1.3]. Due to the high level of conservation of the CRD, the disparity in their 
binding affinity to -galactosides is characterised by the variation in the 
surrounding loop regions and -strands.  
 
Figure 1. 3: Members of the galectin family. 
 
Most galectins behave as either bivalent or multivalent molecules for ligand 
binding. The galectins with just one CRD, i.e. prototype galectins, tend to 
dimerise in solution and present as bivalent molecules (Liu and Rabinovich, 
2005). The tandem repeat type galectins consist of two CRDs while the chimeric 
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galectin, i.e. galectin-3, oligomerises when it binds to multivalent carbohydrates 
(Liu and Rabinovich, 2005).  
Galectins contribute to cell-cell and cell-matrix interactions. Galectin signalling 
at the cell surface results in modulation of various cellular functions [Figure 
1.4]. Also, in normal cellular physiology, intracellular galectins interact with 
intracellular ligands and help in the regulation of cellular activities and 
fundamental processes such as pre-mRNA splicing. 
Role of galectins in immune responses  
Galectins regulate immune and inflammatory responses. They are expressed by 
activated T- and B-cells, regulatory T-cells, dendritic cells, mast cells, 
eosinophils, monocytes/macrophages and neutrophils (Cummings and Liu, 
2009). Depending on the inflammatory stimulus, microenvironment and target 
cells, galectins also promote pro– and anti-inflammatory responses. A short list 
of the functions and biological roles of galectins in association with their role in 
immune responses is summarised in the table 1.1. 
Role of galectins in apoptosis 
Several galectins show the ability to regulate apoptosis. While some galectins 
can induce apoptosis when added exogenously to cells, others regulate 
apoptosis through intracellular mechanisms (Liu and Rabinovich, 2005). 
Galectins affect the process of tumour metastasis through the modulation of cell 
adhesion and cell migration. 




Figure 1. 4: Schematic representation of galectins function 
Functional interactions of galectins with cell-surface glycoconjugates and extracellular glycoconjugates can lead to modulation of cell 




Table 1. 1: A list of functions and biological activities of galectins.  
Modified from (Cummings and Liu, 2009) 
Galectin Function 
Gal-1 reduces TNF-α, IL-1, IL-2, IL-12, IL-2 and IFN-γ 
increases IL-10 production in T-cells 
reduces acute inflammatory responses 
inhibits mast cell degranulation 
inhibits chemotaxis of neutrophils 
inhibits extravasation of neutrophils 
suppression of Th1 and Th17 immune responses 
activate apoptosis in T-cells 
induces apoptosis - independent phosphatidyl serine exposure 
(Ca2+ dependent) in neutrophils  
Gal-2 induces T-cell apoptosis under some conditions 
decreases IFN-γ and TNF-α while increasing IL-10 and IL-5 
involved in the pathogenesis of atheroma formation 
induces apoptosis - independent phosphatidyl serine exposure 
(Ca2+ dependent) in neutrophils  
Binds selectively to β-galactosides of T cells to induce apoptosis 
Gal-3 induces release of IL-8 of neutrophils 
blocks apoptosis of T-cells when overexpressed intracellularly 
endogenously involved in T-cell viability 
extracellularly induces apoptosis of T-cells 
enhances Th2 immune responses 
inhibits IL-5 production in eosinophils 
induces mast cell degranulation independent of antigen-mediated 
IgE stimulation 
expressed on surface of macrophages 
exacerbates Th2 immune responses 
enhances phagocytosis of macrophages 
enhances respiratory burst of marcophages 
blocks IL-4 induced survival of activated B-cells 
favours plasma cell differentiation 
induces apoptosis intracellularly 
induces chemotaxis of neutrophils 
enhances extravasation of neutrophils 
induces activation of neutrophils 
enhances leukocyte adhesion to endothelium 
Gal-4 induces IL-6 production in T-cells 
induces apoptosis-independent phosphatidyl serine exposure 
(Ca2+ independent) in neutrophils  
Gal-7 intracellular expression induces apoptosis of tumour cells  
extracellularly can inhibit growth of cells 
Gal-8 activates Rac-1 in T cells 
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activates NADPH- dependent respiratory burst of neutrophils  
modulates integrin-mediated neutrophil adhesion of neutrophils 
acts as a danger receptor in defence against intracellular pathogens 
Gal-9 induces apoptosis in thymocytes and T-cells 
induces selective loss of CD4+ Th1 cells 
induces selective loss of CD8+ T cells 
induces eosinophil chemotaxis, activation, superoxide generation 
induces moderate degranulation of eosinophil 
induces maturation of dendritic cells 
expression in endothelial cells induced by virus infection 
Gal-10 highly expressed in eosinophils 
involved in Treg function 
Gal-12 intracellular expression induces apoptosis of tumour cells 
can cause cell cycle arrest and growth suppression  
  
 
Galectin-1 (Gal-1) is among the most widely studied member of the galectin 
family. It is expressed by normal and pathological tissues and is involved in a 
wide range of biological activities. It is active both intra- and extra-cellularly. 
The implication of Gal-1 and its ligands in the regulation of immune responses 
such as T-cell homeostasis and survival, T–cell immune disorders, 
inflammation, allergies and host-pathogen interaction has been documented 
(Camby et al., 2006). It also plays an important role in creating immune 
tolerance in pregnancy and is expressed throughout the menstrual cycle by 
endometrium stromal cells (Munoz-Suano et al., 2011). Its expression and 
overexpression in tumours and their surrounding tissues (stroma) is considered 
a sign of malignancy. Gal-1’s other roles include establishment and 
maintenance of T-cell tolerance and homeostasis in vivo, and neuronal cell 
differentiation and survival in the central and peripheral nervous system. 
Hence, the involvement of Gal-1 in a myriad of pathological conditions makes it 
a viable target for novel treatments. Gal-1 has been studied as a potential 
therapeutic agent in neurological disorders (Chang-Hong et al., 2005, Kadoya et 
al., 2005) and muscular dystrophy (Cerri et al., 2008, Goldring et al., 2002). The 
increased expression of Gal-1 and its delivery has been explored for the 
treatment of inflammation and allied diseases such as arthritis (Rabinovich et 
al., 1999), nephritis (Tsuchiyama et al., 2000) and colitis (Santucci et al., 2003). 
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The delivery of anti-Gal-1 compounds in addition to current cytotoxic drugs to 
down-regulate Gal-1 in cancer related processes is another frontier that is being 
explored to inhibit metastasis (Ingrassia et al., 2006, Ion et al., 2005, Stowell et al., 
2004).  
Galectin-2 (Gal-2) is structurally closely related to Gal-1, but its expression and 
activity are thought to be contained to the gastrointestinal tract (Oka et al., 1999, 
Sturm et al., 2004). It is an inducer of apoptosis in activated T cells and plays a 
functional role in T cell homeostasis (Sturm et al., 2004). Gal-2 therefore 
provides a therapeutic alternative for the treatment of CD8–mediated 
inflammatory disorders such as contact allergy (Loser et al., 2009). Gal-2 has 
also been identified as a novel inhibitor of arteriogenesis (van der Laan et al., 
2012). 
Galectin-3 (Gal-3) contains an unusual tandem repeat of proline and glycine 
rich stretches of ~120 amino acids, which are fused onto the CRD. It has also 
been reported that galectin–3 oligomerises via its N terminal collagen-like 
extension after ligand binding (Ahmad et al., 2004, Nieminen et al., 2008). Recent 
work on galectin-3 showed a different type of self-association upon ligand-
binding via its carbohydrate recognition site (Lepur et al., 2012). The formation 
of galectin oligomers through supermolecular assembly is therefore an essential 
element of galectin function, which relies on the multivalence of galectins or 
ligands (Nagae and Yamaguchi, 2014). Gal-3 plays an important role in various 
biological function and diseases including fibrosis, cardiovascular diseases, 
inflammatory diseases and cancer. It is commonly up- and down-regulated in 
different cancers and is implicated in tumour formation and proliferation, 
apoptosis and B-cell activation (Califice et al., 2004, Ochieng et al., 2004, Stillman 
et al., 2006). The up-regulation of Gal-3 in liver and renal idiopathic pulmonary 
fibrosis has been identified. Gal-3 is a proposed prognostic marker in patients 
with chronic heart failure (Lok et al., 2010). Gal-3 interacts with the poly-N-
acetyllactosamine-containing N-glycans on the T-cell receptor and is thus 
associated with the activation of T-cells (Cummings and Liu, 2009). It is also 
involved in the inhibition of IL-5 production in immune cells such as human 
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eosinophils. Moreover, Gal-3 also activates mast cells, neutrophils and 
monocytes leading to mediator release and production of reactive oxygen 
species (Cummings and Liu, 2009). Its function as a pro-inflammatory mediator 
and regulator of inflammatory responses has been widely explored. The 
modulation of Gal-3 expression in cancer has also been extensively studied.  
Galectin-8 (Gal-8) has recently been shown to play a role in cellular defence, 
against both bacterial cytosolic infection and damage of vacuoles. Thus, Gal-8 
acts as a danger receptor in defence against intracellular pathogens (Thurston et 
al., 2012).  
Galectin-9 (Gal-9) plays a role in the regulation of various diseases, including 
T-cell mediated diseases, such as autoimmunity and asthma. Its involvement in 
tumour progression and control of antiviral and antibacterial infections has also 
been reported (Wiersma et al., 2013). 
1.1.4. Galectin -7 
Galectin -7 (Gal-7) is a prototype galectin which was first identified in 1995 by 
Madsen et al. (1995) in their attempt to identify markers associated with the 
normal keratinocyte phenotype. In humans, Gal-7 is encoded by the LGALS7 
gene on chromosome 19 (Madsen et al., 1995). Expression of Gal-7 has been 
shown to be down-regulated in SV40-transformed cells (Madsen et al., 1995) as 
well as TR146 and SCC13 squamous carcinoma cells (Magnaldo et al., 1995, 
Magnaldo et al., 1998). A screening, by serial analysis of gene expression, 
suggested that Gal-7 is coded by 14 of 7202 identified transcripts which were 
either up- or down-regulated before the onset of p53-induced apoptosis in the 
colorectal cell line DLD-1 (Polyak et al., 1997). Gal-7, which was known as a 
marker of epithelial stratification was then referred as PIG1 (p53-induced gene 
1) after its role in a model of p53-induced apoptosis (Polyak et al., 1997, Sigal 
and Rotter, 2000). Subsequently, Gal-7 expression was linked to p53-related 
induction of epidermal apoptosis by using SCC13 cell transfection using a sense 
vector and UVB-irradiation as genotoxic stress (Bernerd et al., 1999).  
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Early reports suggested that Gal-7 existed as a monomer (Madsen et al., 1995). 
However, the first crystal structure of hGal-7, reported by Leonidas et al., 
demonstrated that Gal-7 exists as a dimer in crystals (Leonidas et al., 1998). 
Morris et al. (2004) later confirmed the relevance of the dimer complex using 
ultracentrifugation techniques and a dimer was also observed in the NMR 
structure reported by Nesmelova et al. (2012). Recent analysis by NMR, circular 
dichroism and molecular dynamic simulations showed that ligand binding to 
galectin-7 caused long-range effects resulting in the stabilization of the dimer 
(Ermakova et al., 2013).  
The high degree of tissue specificity exhibited by Gal-7 is unique to this 
member of the galectin family. It is found in various types of epithelial cells 
such as the mammary myoepithelial cells, the Hassall’s corpuscules of the 
thymus, the urinary system, the epithelial cells of the oesophagus, hair follicles, 
oral epithelia and the cornea, among others (Demers et al., 2010, Magnaldo et al., 
1998, Nio-Kobayashi et al., 2009). The expression of Gal-7 is exclusively 
exhibited by stratified epithelial cells of the oesophagus, tongue, lip and 
epidermis (Magnaldo et al., 1998, Sato et al., 2002) and, like other members of 
the galectin family, is moderately controlled by epigenetic mechanisms such as 
DNA methylation (Salvatore et al., 2000, St-Pierre et al., 2012). In addition to its 
regulation by p53 (Polyak et al., 1997), GATA-3 (Demers et al., 2010) and NF-κB 
(Bemmo et al., 2010, Karin, 2006, St-Pierre et al., 2012) may also regulate Gal-7 
expression. However, this exact mechanism of Gal-7 expression and the 
involvement of the transcription factors in normal cells and/or tumour cells is 
yet to be determined.  
Functions of Gal-7 
Gal-7 is expressed with the first onset of epidermal stratification (Magnaldo et 
al., 1998) and marks the differentiation levels of keratinocyte. It is involved in 
the migration of epithelial cells and re-epithelisation of corneal and/or 
epidermal wounds (Cao et al., 2003). The presence of Gal-7 in the areas of cell-
cell contact, especially in the upper layers of the epidermis and their 
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downregulation in transformed keratinocytes, suggests its therapeutic value 
due to its involvement in physiological cell growth through modulation of cell-
cell and cell-matrix interactions.  
Gal-7 is distributed uniformly through the epidermis and shows no difference 
in intensity in the basal and supra-basal layers (Magnaldo et al., 1998). Unlike 
the complete elimination effect of retinoic acid on standard epidermal markers, 
the amount of Gal-7 is reduced but not eliminated (Magnaldo et al., 1995), thus 
distinguishing it from other markers. This exclusivity of Gal-7 is augmented by 
its unique basal-supra-basal distribution which is not displayed by other 
markers (Magnaldo et al., 1995, Magnaldo et al., 1998). This suggests that Gal-7 
is a keratinocyte cell type marker (Magnaldo et al., 1995).  
The possible role of Gal-7 in cell-mucus contact and growth of the ovarian 
follicles has been suggested due to its presence in the trachea and the ovary 
(Sato et al., 2002). Gal-7 modulates cell proliferation and cell interactions 
irrespective of keratinisation or regional specialisation and is thus important for 
both the formation and maintenance of all stratified epithelia (Timmons et al., 
1999). Recently, Gal-7 and actin were detected in the water-soluble fractions 
prepared from skin lesions of patients with primary and secondary localized 
cutaneous amyloidosis and have been considered as candidates with 
therapeutic value (Miura et al., 2013).  
Gal-7, in addition to Gal-3, but unlike Gal-1, has been shown to stimulate the re-
epithelialization of corneal wounds (Cao et al., 2002a, Cao et al., 2003, Cao et al., 
2002b). The extent of acceleration of re-epithelialization of wounds was 
reported to be greater than that observed in most of the published studies using 
growth factors (Cao et al., 2002a). Additionally, Gal-7 and Gal-3 have been 
shown to induce cell mitosis in epithelial cells (Cao et al., 2002a, Cao et al., 2003). 
Thus, these studies provide a platform for the development of novel therapeutic 
tools for the treatment of non-healing wounds.  
Gal-7 expression in women has been studied extensively in recent years. It is 
produced by the premenstrual and menstrual endometrium. Here, it facilitates 
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post-menstrual endometrial re-epithelialization by accumulating in the 
menstrual fluid and acts as a paracrine factor (Evans et al., 2014). An abnormal 
elevation of Gal-7 levels in the endometrium of women with a history of 
miscarriage is often observed. Studies suggest that Gal-7 facilitates the adhesion 
of the embryo to the endometrium and elevated levels of Gal-7 result in 
abnormal adhesion, which can lead to miscarriage (Menkhorst et al., 2014b).  
Additionally, due to the elevated levels of Gal-7 levels in the serum of pregnant 
women who subsequently developed pre-eclampsia, compared to women with 
healthy pregnancies, it is considered as a prognostic serum biomarker for this 
condition (Menkhorst et al., 2014a).  
Role in cancer 
The modulatory effect of galectins on apoptosis has been widely studied. This 
modulation of apoptosis is either through the regulation of apoptosis by 
binding to cell surface glycoproteins or through the interactions with relevant 
intracellular proteins (Liu and Rabinovich, 2005). While Gal-3 has anti-apoptotic 
activity, Gal-1,-2, -7 and -9 show pro-apoptotic activity (Saussez and Kiss, 2006). 
De novo expression of Gal-7 by p53 is associated with apoptosis, thereby 
inhibiting cancer progression. Gal-7 has a pro-apoptotic intracellular function 
that plays a role upstream of the c-Jun N-terminal kinases (JNK) activation 
pathway and cytochrome c release (Kuwabara et al., 2002). Gal-7 can also inhibit 
cell proliferation without its pro-apoptotic role. The inhibition of proliferation 
in neuroblastoma cells by mediation of Gal-7 has been attained without any 
signs of apoptosis (Kopitz et al., 2003). The improved outcome of cervical cancer 
patients after radiotherapy has been shown to be associated with high levels of 
Gal-7 (Tsai et al., 2013). Gal-7 is also significantly down-regulated in gastric 
cancer as the gene is epigenetically modified by DNA methylation (Kim et al., 
2013c). Thus, the role of Gal-7 as a tumour suppressor with potential 
therapeutic activity supports its expression being induced by p53, an important 
tumour antigen.  
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Over the recent years, in addition to the tumour suppressive role of Gal-7, its 
tumour progressive effects have also come to light. Gal-7 is known to interfere 
with Smad3, a key regulatory protein in the transforming growth factor – β 
(TGF-β) signalling pathway which is known to exert tumour suppressive and 
promoting effects (Inagaki et al., 2008). Gal-7 has also shown to aid tumour 
growth by not inducing apoptosis in certain cases. Studies have shown that Gal-
7 expression is induced in breast cancer by mutant p53 (Campion et al., 2013). 
Gal-7 is overexpressed in mammary tumours compared to normal mammary 
tissues, when subjected to chemical induction of mammary carcinoma (Lu et al., 
1997). Increased levels of Gal-7 have been observed in mature B-cell lymphoid 
neoplasms but not in normal B-lymphocytes (Demers et al., 2007). Gal-7 has also 
been shown to be a negative growth regulator for neuroblastoma cells (Kopitz 
et al., 2003). High Gal-7 levels have been associated with poor survival outcome 
in patients with epithelial ovarian cancer, in addition to being functionally 
involved in cell proliferation (Kim et al., 2013a). Gal-7 moderates the aggressive 
behaviour of lymphoma cells by modulating the expression of a metastic gene, 
matrix metallopeptidase (MMP-9) (Demers et al., 2005) and increases metastasis. 
Induction of MMP-9 by galectins modulates the microenvironment by 
promoting integrin mediated cell adhesion and migration of tumours cells, that 
may be exploited by cancer cells. In such cases, Gal-7 expression may be 
induced by nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-
κB), a gene expressed in highly aggressive cancer cells and a positive regulator 
of MMP-9 (St-Pierre et al., 2012). 
The dual role of hGal-7 [Figure 1.5] in the modulation of tumour and cancer cell 
migration provides an excellent therapeutic opportunity for understanding and 
controlling tumour growth and metastasis. However, more studies are needed 
to further delineate the precise role of hGal-7 in cancer. Identifying and 
understanding specific environment, secondary structure, oligomerisation or 
supramolecular formation and binding partners of hGal-7 at each stage of 
cancer progression will help precise modulation of hGal-7 and in turn aid 
rational design of novel therapeutics against cancer.  
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Figure 1. 5: Dual role of hGal-7 in cancer.  
hGal-7 plays a role in tumour suppression as well as its progression. Its 
expression by p53 is associated with apoptosis and inhibition of tumour 
growth. hGal-7may also modulate cancer progression by interfering with 
Smad3, an important regulatory protein of TGF-β pathway which is involved in 
both, tumour suppression and tumour progression. Induction of hGal-7 
expression by NF-κB can in turn induce MMP-9, which is involved in 
modulation of the extracellular matrix (ECM) environment, that cancer cells 
may exploit to their advantage. Modified from (St-Pierre et al., 2012) 
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1.2. Structural features of galectins 
The structures of several galectins have been elucidated at the atomic level. The 
protein data bank (PDB) includes approximately 170 X-ray and NMR structures 
of full or specified individual domains of galectins in their native form or in 
complex with various ligands. These galectin structures are from a wide range 
of organisms which include Homo sapiens (human), Agrocybe aegerita (fungus), 
Mus musculus (house mouse), Coprinopsis cinerea (fungus), Porcine adenovirus, 
and several others. Significant similarities between the tertiary structures of 
lectins from various species have been noticed in spite of the lack of primary 
sequence similarity. The structures of human galectins that have been reported 
include crystal or NMR structures for native and/or complexes with ligands for 
hGal - 1, 3, 4, 7, 8, 9.  
Galectins are known to be involved in signal mediation, cell-cell and cell-matrix 
interactions which may be brought about by the cross-linking of N-
acetyllactosamine-containing structures found at cell surfaces and in the 
extracellular surfaces. Generally, the canonical CRD of galectins consists of 
nearly 130 amino acids of which only a few residues directly interact with the 
ligand. A PRALINE (Bawono and Heringa, 2014) sequence and ConSurf 
(Celniker et al., 2013) analysis of these residues reveals conservation primarily 
of the inward facing hydrophobic residues in β-strands in the β-sandwich of the 
galectin fold [Figures 1.6 and 1.7]. Sequences of the galectins were obtained 






Figure 1. 6: PRALINE sequence analysis of hGal-1, hGal-2, hGal-3, hGal-4, 
hGal-7, hGal-8, hGal-9, hGal-10 and hGal-12.  
The analysis elucidates the high degree of conservation of the CRD composed 
of residues ~305 – 400. The residues are coloured by their conservation grades 
using the colour coding bar, with blue-through-red indicating unconserved-
through-conserved residues.  
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Figure 1. 7: A ConSurf analysis of hGal-7 in complex with galactose  
(PDB code: 2GAL). Galactose is shown as sticks in green bound at the CRD. The 
amino-acids are coloured by their conservation grades using the colour-coding 






The galectin CRD is composed of five and six stranded antiparallel β-sheets 
arranged in a β-sandwich or a ‘jelly-roll’ topology that completely lacks α-
helices [Figure 1.8]. The monomeric subunits of dimeric prototype galectins: 
hGal-1, hGal-2 and hGal-7 are related by a two-fold rotational axis 
perpendicular to the plane of the β-sheets. The N- and the C- termini of each 
monomer are generally positioned at the dimeric interface. The CRDs in the 
dimer are located at opposite ends of the dimer and constitute a long and 
negatively charged cleft in the cavity. The compact arrangement of the CRD 
elucidates the high degree of conservation of this domain . 
A structural alignment of the galectins using GESMAT (Krissinel, 2012) 
revealed a high degree of conservation of the secondary structure [Figure 
1.9]. The corresponding residues to H49, R53, N62, W69, E72 and R74 that 
interact with the ligand at the CRD of hGal-7 are observed at equivalent 
positions in the other human galectin structures. Table 1.2 lists the 
corresponding residues of galectins involved in ligand binding. Both, 
secondary structural and primary sequential conservation of these residues 
are observed.  
Table 1. 2: Residues of hGal-7 that interact with the ligand with the 
corresponding residues in other human galectin structures.  
Galectin PDB code H R N W E R 
1 3W59 44 48 61 68 71 73 
3 3ZSM 158 162 174 181 184 186 
7 3ZXF 49 53 62 69 72 74 
8 2YV8 235 239 248 255 258 260 
9 3NV1 72 76 86 93 96 - 
Gal-1 (PDB code: 3W59) (Saburi et al., unpublished results), Gal-3 (PDB code: 
3ZSM) (Saraboji et al., 2012), Gal-7 (PDB code: 3ZXF) (Masuyer et al., 2012), 
Gal-8 (PDB code: 2YV8) (Kishishita et al., unpublished) and Gal-9 (PDB code: 




Figure 1. 8: Ribbon diagram of the crystal structure of hGal-7 in complex with galactose  
(PDB code: 2GAL). The homodimer is shown. Each monomer is coloured differently and orthogonal views have also been presented.  
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Figure 1. 9: Superposition of hGal-1, -3, -8 and -9 with respect to hGal-7.  
The residues involved in the binding of the ligand (galactose in green) at the 
CRD are shown as sticks and labelled as per hGal-7 residue numbering. A high 
degree of secondary structural features among galectins are observed including 
the important residues involved in ligand binding at the CRD. The PDB codes 
for hGal-1 (wheat), hGal-3 (pale green), hGal-7 (light pink), hGal-8 (light 




1.3. Carbohydrates  
Carbohydrates are one of the four major classes of biomolecules along with 
proteins, nucleic acids and lipids. They play a vital role in mediating 
interactions among cells and between cells and other elements in normal cell 
physiology. For this purpose, they are either linked to proteins or lipids. 
Glycoproteins are proteins derivatised with carbohydrates. They are 
components of the cell membranes. Their structural diversity and location 
within proteins enables carbohydrates to act as mediators in a wide range of 
cellular interactions. The extensive structural polymorphism of long chain 
carbohydrates is due to variations in its monosaccharide composition, 
carbohydrate sequence, branching, linkage position and linkage anomericity.  
Carbohydrates are carbon compounds with an empirical formula Cm(H2O)n, 
(where m may or may not be equal to n) forming a “carbon-hydrate” in most 
cases. Monosaccharides form the building blocks of complex carbohydrates. 
They are aldoses or ketoses with multiple hydroxyl groups. Two to ten 
monosaccharides linked by glycosidic bonds make up an oligosaccharide while 
hundreds of monosaccharide units form polysaccharides. The abundance of 
hydroxyl groups aid their interaction with the aqueous environment and 
facilitate in hydrogen bonding between chains. Mostcarbohydrates contain at 
least one chiral (asymmetrical) carbon and are therefore optically active. 
Generally speaking, only the D-enantiomer of a carbohydrate is physiologically 
relevant, albeit with a few exceptions. The mirror image conformation, called an 




Figure 1. 10: Fisher projections of the enantiomers of glyceraldehyde. 
 
Monosaccharides  
Monosaccharides commonly found in humans are classified based on the 
number of carbon atoms they contain in their backbone structure [Table 1.3]. 
The major carbohydrates contain four to six carbon atoms.  
Intramolecular hemiacetals and hemiketals are formed when the aldehyde or 
ketone moieties of the carbohydrate react with alcohol groups present in 
neighbouring carbons. This results in the formation of five or six-membered 
rings which are called furanose or pyranose forms, respectively. 
The opening and re-closing of the rings results in freedom of rotation about the 
carbon bearing the reactive carbonyl. This rotation yields two distinct 
configurations (called anomers) of the hemiacetals and hemiketals: α- and β-
anomers. The carbon about which this rotation occurs is referred to as the 
anomeric carbon and the process of spontaneous change between these two 
configurations is termed mutarotation. Figure 1.11 shows the cyclic and chair 




Table 1. 3: Carbohydrate classification 
No. of Carbons Category Examples 
3 Triose Glyceraldehyde 
4 Tetrose Erythrose 
5 Pentose Ribose, Ribulose 
6 Hexose Glucose, Galactose 
7 Heptose Sedoheptulose 
9 Nonose 
Neuraminic acid 
( a.k.a. sialic acid) 
 
 
Figure 1. 11: Cyclic and chair conformation of β-D-glucose.  
Cyclic projection given for simplicity, while the chair conformation is an 
example of a more biologically relevant conformation.  
 
Disaccharides 
The linkage of two monosaccharides through a glycosidic bond results in a 
disaccharide. Glycosidic bonds are covalent bonds between the anomeric 
hydroxyl of a cyclic sugar and a hydroxyl of a second sugar or another alcohol 
containing compound. Lactose [Figure 1.12], found in the milk of mammals, is a 




Figure 1. 12: Structure of lactose.  
 
Oligosaccharides 
A saccharide polymer containing a small number of monosaccharides (usually 
two to ten) are called oligosaccharides. Each monosaccharide is linked to the 
adjoining sugar via glycosidic bonds. Oligosaccharides are commonly found on 
the plasma membrane of animal cells and play an important role in cell-cell 
recognition.  
Oligosaccharides are components of glycoproteins and glycolipids. They are 
used as chemical markers and for cell recognition. The blood type specificity is 
dictated by the oligosaccharide glycolipid forming the cell membrane of the red 
blood cells. Blood type A and type B have different pentasaccharides while type 
AB have both and type O has a tetrasaccharide. 
As carbohydrates are recognised by various proteins, carbohydrate based tools 
such as glycodendrimers used in this thesis, are used in a diverse range of 
explorative studies to decipher the mechanistic role of proteins.  
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1.3.1. Glycodendrimers and galectins 
Dendrimers are synthetic, monodisperse macromolecules consisting of three 
distinguishing structural features: the core, the branches or arms of the 
molecule and the termini which can all harbour a variety of chemical functions 
(Newkome et al., 2001, Villalonga-Barber et al., 2008, Vögtle et al., 2009). The 
polyvalent nature of dendrimers and their flexibility make them unique 
nanodevices for biochemical applications (Boas et al., 2006, Gardikis et al., 2012).  
Glycodendrimers constitute a class of dendrimers that incorporate 
carbohydrate into their structures (Roy et al., 1993) and have potential 
biomedical applications such as, for example, anti-adhesion drugs (Touaibia 
and Roy, 2007), drug delivery systems (Chabre and Roy, 2012), functional 
antigens and antitumor vaccines (Shiao and Roy, 2012, Teo et al., 2012), 
biosensors (Kikkeri et al., 2009, Kikkeri et al., 2010a) and gold nanoparticle 
conjugates (Gorityala et al., 2012, Lyu et al., 2008, Reynolds et al., 2006). 
Inhibition of the cholera toxin through recognition of the carbohydrate group 
has also been reported (Branderhorst et al., 2007), demonstrating the potential of 
these molecules as direct interacting partner for a protein target of choice.  
The ability of amphiphilic dendrimers designed with either a D-mannose, D-
galactose or D-lactose termini, named Janus glycodendrimers, to self-assemble 
in water has been demonstrated (Percec et al., 2013). The results revealed the 
potential use of glycodendrimers as mimics of biological membranes with 
programmable glycan ligand presentations as supramolecular lectin blockers, 
vaccines and targeted delivery devices. The binding affinity of glycodendrimers 
with lectins is enhanced compared with the corresponding monosaccharides 
and this has been ascribed to a “cluster glycoside effect” (Dimick et al., 1999, 
Mouline et al., 2014, Varki, 1993), and led to the synthesis of many dendrimeric 
glycoconjugate compounds (Kikkeri et al., 2010b, Roy and Kim, 1999, 
Wolfenden and Cloninger, 2005). The polyvalent nature of dendrimers may 
help in selective modulation of galectins as diverse substrate specificity and 
binding affinity is observed among its various members (Hirabayashi et al., 
2002).  
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The cross-linking of galectin-1, -3 and -7 by dendrimeric glycoconjugates in 
solution has been reported (Andre et al., 1999, Andre et al., 2001, Michel et al., 
2014, Percec et al., 2013). Glycodendrimers have been studied as inhibitors of 
binding of mammalian galectins (galectin-1, -3 and -7) to glycoproteins, lactose 
clusters and cell-surface glycoconjugates with relevance to inflammation and 
tumour embolisation (Andre et al., 2001). Michel et al., reported that 
glycodendrimers could mediate the interaction between galectin-3 and mucin-1 
which is overexpressed and highly glycosylated in cancer cells (Michel et al., 
2014). The tunable multivalent lactose-functionalised dendrimers used in this 
study was shown to modulate the level of cellular aggregation in lung 
carcinoma, prostate cancer and fibrosarcoma cell lines.  




1.4. Aims and objectives  
Human Galectin-7 (hGal-7) is a prototype galectin which dimerises in solution. 
The X-ray crystal structure of hGal-7, in which its dimerisation was first 
observed, was first elucidated by Leonidas et al. (1998). Ultracentrifugation 
techniques and NMR analysis later confirmed the dimerisation of hGal-7 in 
solution (Morris S et al., 2004, Nesmelova et al., 2012). Its involvement in cell – 
cell and cell – matrix interactions has highlighted their importance in signal 
transduction and other intracellular processes. The natural substrates of hGal-7 
are yet to be identified. It does however show a high affinity for galactose in 
vitro. With its inherent self-assembling capability, hGal-7 represents an ideal 
prototype lectin for studying the formation of ligand-associated supramolecular 
assemblies. 
Monovalent binding between galectins and carbohydrates is of relative low 
affinity. However, polyvalent crosslinking of glycoconjugates leads to the 
formation of galectin-carbohydrate lattices of high affinity at the cell surface 
(Brewer, 2002, Rabinovich et al., 2007) as shown in Figure 1.13.  
The study of galectin and carbohydrate based dendrimers presents a novel path 
to design new tools to investigate the recognition of carbohydrates by galectins 
and their supramolecular formations. Understanding the structural 
composition of these complexes and the binding affinity of hGal-7 to 
glycodendrons will provide a platform for the design of molecular markers for 
cellular interactions and as therapeutic targets. X-ray crystallography is 
considered the gold standard to decipher and understand these interactions at 
the atomic level. Molecular details unearthed using this technique can then be 
applied for the rational design of synthetic, highly-specific molecules to target 
lectins.  
In order to perform detailed biochemical and structural analyses, the expression 
and purification of recombinant hGal-7 was initially optimised. To investigate 
the supramolecular formation of hGal-7 through carbohydrate recognition, 
synthetic multivalent galactose based dendrons of varying size and 
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composition were employed. The purified protein in complex with a range of 
ligands, was prepared for investigation by X-ray crystallography as a means to 
understand the recognition of dendrons and the resulting lattice formations. 
Additionally, isothermal titration calorimetry studies were performed to study 
the binding affinity of glycodendrons to hGal-7. This led to preliminary binding 
affinity studies which may offer a basis for future investigations. Dynamic light 
scattering experiments were also performed to assess the supramolecular 

















Sirtuins have been widely explored as elixirs of life. Their involvement in 
numerous cellular functions in normal cell physiology and pathological 
conditions make them a fascinating subject of scientific study. They form part of 
a feedback mechanism that enhances cell survival during times of stress, for 
example during calorie restriction, and they serve as guardians of the cell. 
Sirtuins have been extensively explored to understand their role in ageing and 
ageing related diseases. This chapter provides a brief introduction to the 
present understanding of sirtuins. 
2.1.1. Discovery of the Sir2 family 
Nearly eighty years ago, Clive McCay et al. first reported that restriction of 
calories without malnutrition prolongs lifespan in rats compared with ad libitum 
feeding (McCay et al., 1935). Despite the advances in science since then, the 
molecular mechanism that drives lifespan has been elusive. In addition to rats, 
many other model organisms have been used to study the molecular 
mechanism of ageing.  
One such model is yeast, a simple eukaryotic organism that shows a high 
degree of conservation of numerous essential cellular processes when 
compared to humans. Yeast has been used as a model organism to identify 
various cellular factors that are required for transcriptional silencing. The 
proteins encoded by the yeast SIR genes, which are responsible for maintaining 
silent chromatin, have been identified as important cellular factors (Shore et al., 
1984). It was observed that SIR2, SIR3 and SIR4 are required for silencing at the 
mating-type loci (Rine and Herskowitz, 1987) and telomeres (Gottschling et al., 
1990), but only SIR2, is required for silencing in the rDNA (Bryk et al., 1997, 
Smith and Boeke, 1997). Silencing of chromatin results in a more closed, 
inaccessible regional structure. In an active chromatin, specific lysine residues 
in the amino-terminal tail of histones H3 and H4 are acetylated. The 
deacetylation of these lysines silences the chromatin which results in the 
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histones folding into a compact closed nucleosome structure (Braunstein et al., 
1996, Hecht et al., 1995, Thompson et al., 1994).  
Studies have shown that overexpression of SIR2 leads to global deacetylation of 
yeast histones (Braunstein et al., 1993). Thus, SIR2 was suggested to be a histone 
deacetylase. Initial attempts to demonstrate histone deacetylase activity were 
however unsuccessful (Blander and Guarente, 2004). SIR2, unlike SIR3 and 
SIR4, is highly conserved in a wide range of organisms and consequently 
studies on a bacterial homolog CobB were initiated (Brachmann et al., 1995). It 
was revealed that this gene could substitute for CobT, a bacterial gene that 
encodes an enzyme responsible for transfer of a ribose-phosphate moiety from 
nicotinic acid mononucleotide (NMN) to dimethyl benzimidazole in the 
pathway of cobalamin synthesis (Tsang and Escalante-Semerena, 1998). As the 
cobalamin pathway is not present in yeast or mammals, it was suggested that 
Sir2 might catalyse a closely related reaction. The adenosine diphosphate 
(ADP)-riboyltransferase activity of Sir2 proteins from bacteria, yeast and 
mammals to transfer an ADP-ribose (ADPR) group from nicotinamide adenine 
dinucleotide (NAD+) to a protein carrier was reported (Frye, 1999). This activity 
was shown to be essential for chromatin silencing in vivo (Tanny et al., 1999). 
Additionally, it was shown that the amino-terminal tails of histones H3 and H4 
peptides can accept ADPR from NAD+ when the peptides are acetylated (Imai 
et al., 2000). However, mass spectrometry was used to confirm that the major 
function of Sir2 proteins is deacetylation and not ADP-ribosylation. This 
deacetylation activity of Sir2 proteins is NAD+-dependent and it was shown to 
occur only in the presence of NAD+ and not NADH, NADP and NADPH. These 
studies led to Sir2 proteins being classified as NAD+-dependent histone 
deacetylases (Imai et al., 2000, Smith et al., 2000). 
Originally described as a silencing factor (silent mating type information 
regulator 2) in yeast, Sir2 came on top in a screen for modulators of yeast 
lifespan (Kaeberlein et al., 1999). Additionally, Sir2 is required for the lifespan of 
yeast to be extended by calorie restriction (Lin et al., 2000). This led to 
investigation of Sir2 and its homologues in mammals called sirtuins. The 
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catalytic mechanism of sirtuins and its role in various diseases are discussed in 
detail below.  
 
Figure 2. 1: Chemical structures of NAD+, NADH, NADP+, NADPH  
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2.1.2. Classification and localisation of Sirtuins 
Histone deacetylases (HDACs) are coded for by 18 genes and are grouped into 
classes I-IV based on their homology to their respective yeast homologues. 
Classes I, II and IV are termed ‘classical’ HDACs and comprise 11 members 
(Witt et al., 2009). They are zinc dependent enzymes that harbour a catalytic 
domain with a Zn2+ ion at its base that can be inhibited by chelating agents such 
as hydroxamic acids. Sirtuins are class III HDACs which require NAD+ as an 
essential cofactor. Seven mammalian sirtuins have been identified to date. They 
are defined by their conserved core domain, and some contain additional N- 
and/or C-terminal sequences [Figure 2.2].  
Based on the molecular phylogenetic analysis of 60 sirtuin core domain 
sequences from prokaryotes and eukaryotes, eukaryotic Sir2-like proteins are 
grouped into four main branches (Frye, 2000) as shown in Table 2.1. Prokaryotic 
sirtuins include members of classes II and III. Sacchromyces cerevisiae has five 
class I sirtuins. The seven human sirtuin genes include all four classes: SIRT1, 
SIRT2 and SIRT3 are class I, SIRT4 is class II, SIRT 5 is class III and SIRT6 and 
SIRT7 are class IV. A fifth class of sirtuin is present in several gram positive 
bacteria as well as in the gram negative hyperthermophilic bacterium 
Thermatoga maritima.  
Mammalian sirtuins are widely expressed and located in different cellular 
compartments [Figure 2.3]. Sirtuins in the same compartment, such as 
mitochondrial SIRT3, SIRT4 and SIRT5 have different sequences and have 
unique cellular functions and interact with diverse targets (Frye, 2000, Haigis 
and Guarente, 2006, Michan and Sinclair, 2007). Sirtuins contain nuclear 
localisation signals (NLSs) as well as nuclear export signals (NESs). Their 
intracellular localisation is determined by cell/ tissue type and physiological 
conditions. SIRT1 contains 2 NLS and 2 NES domains while SIRT6 and SIRT7 
each contain a single NLS domain (Liszt et al., 2005, Tanno et al., 2007). SIRT3, 
SIRT4 and SIRT5 contain N-terminal mitochondrial targeting sequences which 
ensure their localization within the mitochondrial matrix (Onyango et al., 2002, 
Schwer et al., 2002). This signal sequence is cleaved in the mitochondria which 
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activates the enzymatic function of the protein. However, under stress, SIRT3 
can translocate from the mitochondria to the nucleus (Nakamura et al., 2008, 
Scher et al., 2007).  
Table 2. 1: Classification of sirtuins.  
Class Subclass 
Species Intracellular 





Sirt1 SIRT1 Nucleus, Cytoplasm 
B 
 Hst2 Sirt2 SIRT2 Cytoplasm 






   
II    Sirt4 SIRT4 Mitochondria 
III    Sirt5 SIRT5 Mitochondria 
IV 
A   Sirt6 SIRT6 Nucleus 
B   Sirt7 SIRT7 Nucleus 
U  CobB     
 
 
Figure 2. 2: Primary structure of sirtuins.  
The seven mammalian sirtuins (SIRT1-7) are aligned with yeast Sir2 (yeast has 
four other SIR2 paralogs HST1-4). Sizes range from SIRT5 at 33.9 kDa to SIRT 1 
at 81.7 kDa. The conserved, catalytic core domain that all sirtuins have in 
common is in blue. Numbers refer to amino acid residues in the proteins.  
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Figure 2. 3: Sirtuin subcellular localization.  
SIRT1 is predominantly present in the nucleus and also in the cytosol. SIRT2 is 
located in the cytosol. SIRT3, SIRT4 and SIRT5 are mitochondrial proteins. 
However, SIRT3 is also found in the nucleus and cytosol under different 





2.2. Catalytic mechanism of sirtuins 
The Sir-2 dependent deacetylation reaction is different from other classical 
HDACs due to their NAD+ dependency. They dynamically regulate 
transcription, metabolism and cellular responses through 
deacetylation/deacylation of various substrates. The members of the sirtuin 
family have a highly conserved common catalytic domain which allows these 
proteins to recognise a ubiquitously present, metabolically central and 
abundant compound, NAD+. The most widely studied reaction catalysed by 
sirtuins is the NAD+ dependent protein deacetylation of acetyllysine. For each 
acetyl lysine that becomes deacetylated, one molecule of NAD+ is cleaved and 
effects an acetyl group transfer to ADPR to form 2’-O-acetyl-ADPR (2’-AADPR) 
(Landry et al., 2000, Tanny and Moazed, 2001). The reaction additionally 
produces deacetylated lysine residues and nicotinamide as reaction products 
(Jackson and Denu, 2002). Thus, sirtuins have two coupled enzymatic activities, 
deacetylation and NAD+ breakdown [Figure 2.4]. Kinetic and biochemical 
studies show that the acetyl lysine substrate binds to the enzyme prior to 
NAD+. Nicotinamide is cleaved from NAD+ and is the first product released, 
followed by deacetylated lysine and 2’-AADPR. In aqueous solution, 
spontaneous non-enzymatic equilibration of AADPR isomers, 2’- and 3’-
AADPR occurs. Several AADPR metabolising enzymes have been reported, 
including nucleoside diphosphate linked to moiety x (NUDIX) hydrolases, 
ADP-ribosyl hydrolase-3 (ARH3) and Macro domain proteins (Tong and Denu, 
2010). NUDIX hydrolases cleaves the pyrophosphate bond of AADPR forming 
AMP and 2- and 3- O-acetylribose-5-phosphate. Human Macro domain proteins 
hydrolyse AADPR to form free acetate and ADPR. In lower organisms, sirtuins 
and Marco domain proteins are present as fusion proteins or are genetically 
connected via the same operon, suggesting that another pathway may involve 
AADPR, sirtuins and Macro domain proteins. AADPR is a less explored 
metabolite that exhibits signalling functions and is suggested to act as a 
substrate for downstream enzymatic processes. It has been linked with gene 
silencing, ion-channel activation and decreased reactive oxygen species (Tong 
and Denu, 2010).  
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The first step catalysed by sirtuins leading towards acetyl-lysine deacetylation 
is ADP-ribosylation of acetyllysine which results in the formation of an ADP-
ribosyl-peptidylimidate. Various mechanisms have been proposed for the 
formation of this species. Three main mechanisms have been shown in figure 
2.5 which include SN1, concerted SN2 or dissociative asynchronous mechanisms 
(Sauve, 2010). Data in support of each of these mechanisms have been 
produced, although there is a lack of firm consensus on which of the 
mechanisms best explains sirtuin chemistry (Sauve, 2010).  
The characterised general nucleophiles for NAD+ include acetyl lysine 
substrates or thioacetyl lysine inhibitors (Sauve, 2010). The formation of an 
akylamidate intermediate is supported by biochemical studies (Feldman et al., 
2012). Upon formation of the C1’-O-akylamidate intermediate, the 2’- hydroxyl 
group of NAD+ ribose is activated by a conserved active-site histidine. The 
activated hydroxyl attacks the O-akylamidate carbon to form a 1’2’-cyclic 
intermediate. A base activated water molecule attacks the cyclic intermediate to 
form deacetylated lysine and AADPR [Figure 2.6].  
In addition to the deacetylase activity, certain sirtuins also catalyse other 
reactions such as protein ADP-ribosyl transfer, NAD+ hydrolysis and many if 
not all catalyse acetyl lysine-dependent nicotinamide base exchange into NAD+ 
(Sauve, 2010). Understanding the mechanistic details of sirtuin-catalysed 
reactions is an important step towards a complete understanding of sirtuin 
functions. This in turn would help the development of novel chemical tools to 





Figure 2. 4: Sirtuin catalysed reactions with a common intermediate.  
The key intermediate is an imidate which can be processed into different products depending on the attacking nucleophiles. 
(a)Deacetylation: The major reaction in the presence of acetylated substrates. (b) ADP-ribosylation and in some cases self ribosylation of 
sirtuins. (c) Liberation of ADPR. Adapted from (Du et al., 2009, Sauve, 2010)  
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Figure 2. 5: Proposed transition states for ADP-ribosylation of acetyl-lysine.  
(a) SN1 mechanism: Complete dissociation of nitocinamide takes place and an enzyme-stabilising oxacarbenium ion is formed, followed 
by collapse of the oxacarbenium ion by reaction with acetyllysine. (b)Dissociative asynchronous mechanism: Oxacarbenium ion is 
formed at the transition state but with extensive bond cleavage to the leaving group and weak bond formation to the nucleophile. This 
reaction is not stepwise as it lacks a discrete intermediate between the reactants and the imidate. As the leaving group is largely cleaved 
prior to bond formation with the nucleophile, this reaction is asynchronous. (c) SN2 mechanism: A penta-coordinate transition state with 
significant bond orders to both the nucleophile and the leaving group is formed. Hence, this mechanism is characterised by associative 
effects of the nucleophile at the transition state, consistent with an SN2 mechanism. Adapted from (Sauve, 2010)  
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Figure 2. 6: Mechanism of sirtuin catalysed deacetylation 
Nucleophilic addition of the acetyl oxygen to the 1’-carbon of the nicotinamide ribose affords alkylamidate intermediate. The 2’-OH is 
activated by a conserved histidine residue that attacks the alkylamidate carbon to afford a cyclic intermediate. A base activated water 
molecule degrades the intermediate forming deacetylated lysine and AADPR. (Feldman et al., 2012, Sauve, 2010)  
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2.3. Sirtuin activity and their targets 
Sirtuins are involved in regulation of a wide range of processes in normal 
cellular physiology through NAD+-dependent deacetylation /deacylation of 
various substrates. Lysine acetylation is a global post-translational modification 
that regulates diverse cellular processes and has been extensively studied 
(Feldman et al., 2012). A number of sirtuin targets have been identified and the 
number is continually increasing [Table 2.2, Figure 2.7].  
Table 2. 2: Substrates of sirtuins  
Modified from (Blander and Guarente, 2004, Feldman et al., 2012, Houtkooper et 
al., 2012, McGuinness et al., 2011) 
Sirtuin Class Activity Targets 
SIRT1 I Deacetylation 
Histones (H1, H2, H3 and H4)  
proliferator-activated receptor γ 
coactivator-1α (PGC1α), Forkhead box 
(FOXO), p53, Notch, Nuclear factor- κB 
(NF-κB), Hypoxia inducible factor 1α 
(HIF1α), Liver X receptor (LXR), 
Farnesoid X receptor (FXR), Sterol-
response element-binding protein 1c 
(SREBP1c), p300, Ku70, Peroxisome 
proliferator-activate receptor γ 
(PPARγ), Trans-activator of 
transcription (Tat), Estrogen receptor 
(ERα), Androgen receptor (AR), 
Mothers against decapentaplegic 
homolog 7 (SMAD7), p73, Sex 
determining region Y- box 9 (Sox9), 
Hairy /enhancer of split-1 (HES1), 
Hairy/enhancer of split related with 
YRPW motif protein 2 (HEY2), Nuclear 
receptor co-repressor 2/ Thyroid 
hormone receptor (NcoR/SMRT), p65, 
Phosphoglycerate mutase 1 (PGAM-1), 
Acetyl-CoA synthase 1 (AceCS1), 
among others 
SIRT2 I Deacetylation 
α-tubulin, FOXO, 
Phosphoenolpyruvate carboxykinase 




SIRT3 I Deacetylation 
Long-chain acyl CoA dehydrogenase 
(LCAD), 3-hydroxy-3-methylglutaryl 
CoA synthase 2 (HMGCS2), Glutamate 
dehydrogenase (GDH), Oxidative 
phosphorylation (OXPHOS) 
complexes, Superoxide dismutase 2 
(SOD2), Isocitrate dehydrogenase 2 
(IDH2), Acetyl-CoA synthase 2 
(AceCS2), Ornithine transcarbamylase 
(OTC), Succinate dehydragenase 
(SDH) 
SIRT4 II ADP-ribosylation 
GDH, Insulin degrading enzyme (IDE), 





Carbamoyl phosphate synthetase 1 




H3, NF-κB, HIF1α, helicase, DNA 
polymerase β, Choline transporter-like 
protein (CtlP), Poly[ADP-ribose] 
polymerase 1 (PARP1), PPARγ 
SIRT7 IV Deacetylation 
RNA polymerase type I, Adenovirus 
early region 1A (E1A), SMAD6 
 
SIRT1 is an NAD+-dependent deacetylase localised in the nucleus (Imai et al., 
2000). SIRT1 deacetylates a number of histone and non-histone proteins 
including histone H3 and H4, p53, NF-κB, PGC-1α, PPARγ, MyoD (a protein 
involved in regulating muscle differentiation) and HIF1α, among others 
(Blander and Guarente, 2004, Feldman et al., 2012, Houtkooper et al., 2012, 
McGuinness et al., 2011). These targets imply SIRT1 plays an important role in 
glucose metabolism, fatty acid and cholesterol metabolism, differentiation, 
insulin secretion and neuroprotection.  
SIRT1 plays a vital role in the regulation of homeostasis, cell metabolism, cell 
signalling and stress responses. It can affect the core histones (H1, H2, H3 and 
H4) but it preferentially deactylates H3 (K9, K14 and K56), H4 (K16) and H1 
(K26) (McGuinness et al., 2011).The deacetylation of lysine residues at H3K9, 
H4K16 and H1K26 have been associated with gene silencing and chromatin 
remodelling. Deacetylation of histones facilitates its methylation which has 
been linked to global transcriptional repression which is enhanced by SIRT1 
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(Bartova et al., 2008). SIRT1 binds to histone-lysine N-methyltransferase 
Suv39H1 (suppressor of variegation 3-9 homologue 1) and enables binding of 
this protein to chromatin. SIRT1 is then activated by deacetylation of Suv39H1 
(McGuinness et al., 2011, Vaquero et al., 2007). DBC1 (deleted in breast cancer 1) 
inhibits SIRT1 and Suv39H1 and disrupts the interaction between these two 
molecules which increases the methylation of H3K9. This, in turn, regulates the 
chromatin silencing mediated by SIRT1-Suv39H1 complex (Kim et al., 2008). 
SIRT1 is also involved in the epigenetic regulation of gene expression. This is 
due to its interaction with DNA methyltranferases, DNMT3 and DMNT1, 
which results in aberrant expression of methylated genes (Espada et al., 2007, 
O'Hagan et al., 2008). The ability of SIRT1 to deacetylate and interact with a 
broad range of transcription factors [Table 2.2] and its ability to remodel 
chromatin, suggests that SIRT1 plays a vital role in the regulation of organism 
homeostasis, stress responses, endocrine signalling and cell metabolism.  
SIRT2 deacetylation targets include acetylated lysine residues H4K16 and H3K9 
when the nuclear envelope disassembles during the mitosis (Vaquero et al., 
2006). Thus, SIRT2 acts as a regulator of the cell cycle and is involved in the 
promotion of chromatin condensation. SIRT2 is known to co-localise with 
microtubules, deacetylate K40 of α-tubulin and SIRT2 RNAi results in 
hyperacetylation of tubulin (North et al., 2003).  
SIRT3-5 localise in the mitochondria and play important roles as metabolic 
sensors that respond to changes in the energy status of the cell. They are 
involved in the modulation of activity of key metabolic enzymes via protein 
deacetylation (Martinez-Pastor and Mostoslavsky, 2012, Newman et al., 2012). 
SIRT3 is also involved in ATP production and fatty acid oxidation. The roles of 
SIRT4 in insulin secretion and SIRT5 in the urea cycle have also been 
established (McGuinness et al., 2011).  
SIRT6 is involved in the deacetylation of H3K9 at the telomeres suggesting its 
involvement in the modulation of cellular senescence and ageing induced 
chromosomal abnormalities (Michishita et al., 2009).   
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Figure 2. 7: Sirtuins in mammalian cells.  
Sirtuins regulate a wide range of processes in the human cells. In the nucleus, 
SIRT1 modulates chromatin structure by deacetylating specific lysine residues 
in histones and alters gene expression by targeting lysine residues of p300. It 
also promotes HIV-1 replication by deacetylating Tat. SIRT1 protects cells from 
senescence by complexing with PML and mediating p53 deacetylation. In 
complexing with PCAF and by deacetylating K424 of MEF2, SIRT1 supresses 
muscle differentiation. SIRT1 inhibits adipogenesis by interacting PPAR-γ and 
aP2 promoters, as well as with PPAR-γ co-factors NcoR and SMRT. SIRT1 
regulates cell development by interacting with HES1/HEY2. SIRT2 also helps in 
development along with homebox transcription factor HOX10. Deacetylation of 
PCG-1α modulates glucose metabolism. SIRT6 localises to heterochromatin to 
regulate base excision repair. SIRT2 translocates from the cytoplasm to the 
nucleus during mitosis and deacetylates histone H4 K16. In the nucleolus, 
SIRT7 activates RNS polymerase I transcription while SIRT1 inhibits it by 
deacetylating TAFI68. Mitochondrial SIRT3 deacetylates and activates AceCS2 
while SIRT 4 mono-ADP-ribosylates GDH which in turn inhibits amino acid 
stimulates insulin secretion (AASIS). SIRT5 desuccinylates CPS1 to activate the 
urea cycle. Modified from (Michan and Sinclair, 2007)  
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Sirtuins are associated with the regulation of RNA polymerase II transcribed 
genes and the transcription of ribosomal RNA (McGuinness et al., 2011). SIRT1 
deacetylates TATA box-binding protein associated factor (TAF168) leading to 
the inhibition of polymerase I (Muth et al., 2001). In contradiction to this role of 
SIRT1 on rRNA transcription, SIRT7 directly binds to polymerase I and induces 
enzymatic activity (Ford et al., 2006). Decrease in SIRT7 levels stops cell 
proliferation and triggers apoptosis, thus SIRT7 plays an important role in cell 
viability in mammals.  
In addition to the deacetylation role of sirtuins, SIRT1-3 can catalyse 
depropionylation and debutyrylation but with varying efficiencies compared to 
deacetylation (Garrity et al., 2007, Smith and Denu, 2007). The ability of SIRT5 to 
catalyse desuccinylation and demalonylation rather than deacetylation has also 
been established (Du et al., 2011). Deletion of SIRT5 has shown to increase the 
level of succinylation on carbamoyl phosphate synthase 1 (CPS1), a known 
target of SIRT5 (Du et al., 2011).  
All sirtuin targets identified to date reveal the involvement of sirtuins in cellular 
stress responses which include cell death responses, senescence, stress-related 
transcription regulation, cell-cycle regulation, cell metabolism, genomic 
formation and stability, maintenance of telomeric function and its control, 
among others [Table 2.2]. This understanding of sirtuin targets has unveiled 
their association with telomeric stability and cellular lifespan, and in turn with 
longevity. Understanding sirtuins and their functions might reveal the causes of 
ageing related diseases and help in the design of new tools for their treatment.  
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2.4. Structural basis for sirtuin function: 
The three dimensional structures of several sirtuin homologues in their native 
form and in complex with other ligands have been determined by X-ray 
crystallography to aid in understanding their catalytic mechanism, substrate 
specificity and inhibitory mechanisms. These include sirtuins from archaeon 
Archaeoglobus fulgidus, bacteria Thermotoga maritima and Escherichia coli, yeast 
Sacchaaromyces cerevisiae and several human sirtuins (Bernstein et al., 1977). This 
wealth of structural information together with complementary biochemical 
studies has provided valuable insights into sirtuin activities. A brief summary 
of the salient features of the high resolution structures of human sirtuins 
[Table2.3] is given here.  





SIRT1 4KXQ SIRT1 (residues 234-510 and 641 – 665) – 
ADPR (closed form) 
(Davenport et al., 
2014) 
4IG9 SIRT1 (residues 234-510 and 641 – 665) 
native (open form) 
4I5I SIRT1 (residues 241-516) - NAD+ - 
indole analogue of EX527 (inhibitor) 
(Zhao et al., 2013) 
SIRT2 3ZGV SIRT2 –ADPR (Moniot et al., 
2013) 3ZGO Apo-form SIRT2 
1J8F Native SIRT2 (Finnin et al., 2001) 
4L30 SIRT2 - macrocyclic peptide S2iL5  (Yamagata et al., 
2014) 
SIRT3 4BVE SIRT3 – Thioalkylimidate from thio-
acetllysine ACS2 peptide 
(Gertz et al., 2013) 
4BVB SIRT3 - ADPR – EX527 (inhibitor) 
4BVG SIRT3 with native alkylimidate from 
acetyllysine ACS2 peptide – EX-527 
4BVF SIRT3 - native thioalkylimidate from 
thio-acetyllysine ACS2 peptide – EX527 
4BVH SIRT3 – 2’-AADPR – EX527 (inhibitor) 
4BV3 SIRT3 - NAD+ - EX527 (inhibitor) 
4C78 SIRT3 – Bromoresveratrol- ACS2 
peptide 
(Nguyen et al., 
2013a) 
4C7B SIRT3 – Bromoresveratrol – Fluor-de-lys 
4BN4 SIRT3 – ADPR (Nguyen et al., 
2013b) 4BN5 SIRT3 – SRT1720 (inhibitor) 
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4JSR SIRT3 – ELT inhibitor 11c (Disch et al., 2013) 
4JT8 SIRT3 – ELT inhibitor 28 
4JT9 SIRT3 – ELT inhibitor 3 
4FZ3 SIRT3 – acetyl p53 peptide coupled with 
4-amino-7-methylcoumarin 
(Wu et al., 2013) 
3GLS Native SIRT3 (Jin et al., 2009) 
3GLT SIRT3 – ADPR – ACS2 peptide with 
thioacetyllysine 
3GLU SIRT3 – ACS2 peptide 
3GLR SIRT3 – ACS2 peptide with 
thioacetyllysine 
4HD8 SIRT3- Fluor-de-lys peptide and 
peceatanol 
(Gertz et al., 2012) 
SIRT5 2NYR SIRT5 – suramin (Schuetz et al., 
2007) 
3RIG SIRT5 – Thioacetyl H3K9 (Du et al., 2011) 
3RIY SIRT5 - Succinyl H3K9 - NAD 
4F4U SIRT5 - Succinyl H3K9 (Zhou et al., 2012) 
4F56 SIRT5 – Bicyclic intermediate 
4HDA SIRT5-Fluor-de-lys - Resveratrol (Gertz et al., 2012) 
4G1C SIRT5 – Sicciny IDH2 and Carba-NAD (Szczepankiewicz 
et al., 2012) 
SIRT6 3PKI SIRT6 ADPR (Pan et al., 2011) 
3PKJ SIRT6 2’-N-acetyl ADPR 
 
Primary sequence alignment [Figure 2.8] and ConSurf analysis [Figure 2.9] of 
sirtuin proteins indicate that they contain a conserved catalytic core of 
approximately 270 residues. Additionally, the sirtuin proteins have N- and C-
terminal flanking regions that are variable in length and sequence and have 
various roles in cellular localisation, oilgomerisation and autoregulation 
mechanisms (Brachmann et al., 1995, Frye, 1999, Tennen et al., 2010). Unlike 
other protein deacetylase families that activate a water molecule for hydrolysis 
reactions by using zinc as a cofactor, sirtuin mechanisms utilise NAD+ as a co-
substrate. 
The catalytic core region of sirtuins adopts an elongated oval shaped fold 
composed of two globular subdomains linked by several loops which 
contribute to the active site cleft between the subdomains [Figure 2.10A]. The 
56 
two globular subdomains differ in size. The larger domain is highly conserved 
and consists of a Rossmann-fold domain, which is characteristic of 
NAD+/NADH binding proteins. The Zn-binding motif, bearing the sequence 
Cys-X2-4-Cys-X15-40-Cys-X2-4-Cys, and an α-helical region, show the highest 
diversity among members of the sirtuin family. The loops connecting the two 
domains form a pronounced, extended cleft between the two domains where 
the NAD+ and the acetyl-lysine containing peptide substrate enter from 
opposite sides and bind to the enzyme [Figure 2.10]. The NAD+ binding cleft is 
divided into three regions: site A for adenine binding, site B for nicotinamide-
ribose binding and site C for nicotinamide moiety binding [Figure 2.10C].  
The relative orientations of the small and large domains vary in known sirtuin 
structures and may be attributed to the presence or absence of substrates at the 
substrate binding cleft. The co-factor binding loop shows a high degree of 
flexibility and its conformation was shown to change in close relation to the 
catalytic events during the formation of a covalent 1’-O-alkylamidate 
intermediate between the two substrates under nicotinamide release (Sanders et 
al., 2010). This is followed by the hydrolysis of the intermediate to yield 
deacetylated polypeptide and 2’-AADPR. The amino acids involved in the 
catalysis and the reactive groups of both bound substrate molecules are buried 
within a protein tunnel in the cleft between the two domains which is the 
region with a high degree of conservation. The cofactor binding loop becomes 
ordered upon substrate binding and changes to a more closed conformation 
upon acetyl transfer (Chang et al., 2002, Hoff et al., 2006). This loop-relocation 
suggests that the cofactor binding loop may be involved in ejecting the first 
reaction product, nicotinamide. The rearrangements of the co-factor binding 
loop and the acetyllysine binding tunnel highlight the dynamic structure of the 
sirtuins. The differences in activity and affinity to substrates among the 
members of the sirtuin family is attributed to the differences in shape and 
electrostatics of the peptide binding groove (Sanders et al., 2010). 
The structural and biochemical studies to date have provided insights into the 
activity of the sirtuins. However, to answer specific question such as the 
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difference in the deacetylation and ribosylation activity among mammalian 
sirtuins, the biological role of regions N- and C-terminal to the catalytic core 
and inhibition mechanisms of synthetic sirtuin inhibitors will require the 
structure determination of sirtuin complexes containing reaction intermediates 
at various stages of the reaction. The dynamic nature, wide range of substrate 
recognition and adaptability of the members of the sirtuin family highlight the 
importance of obtaining a reliable picture for understanding their activity and 









Figure 2. 8: Praline sequence analysis of SIRT1-7.  
The analysis elucidates the high degree of conservation of the catalytic core 
consisting of ~270 amino acids. The residues are coloured by their conservation 





Figure 2. 9: A ConSurf analysis of SIRT2 in complex with ADPR.  
(PDB: 3ZGV) ADPR is shown as sticks in orange. The amino-acids are coloured by their conservation grades using the colour-coding bar, 
with turquoise-through-maroon indicating variable-through-conserved. The figure reveals highly conserved substrate binding pocket 
among sirtuins. . 
62 
 
Figure 2. 10: Representative structure of a human sirtuin.  
(A) Overall structure of SIRT3 bound with AceCS2 (acetylCoA synthetase 2) peptide and NAD+ analogue (PDB: 3GLR). Key locations for 
sirtuin modulation are highlighted. The structure of SIRT3 is shown as cartoon model with Rossmann-fold domain and zinc-binding 
domain (cyan) (PDB: 3GLR). (B) The substrate binding cleft in surface representation. AceCS2 shown as pick sticks. (C) The NAD+ 
binding region shown in surface representation. NAD+ analogue shown as blue sticks (PDB: 1SZC).  
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2.5. Sirtuins and their implication in pathological 
conditions.  
Sirtuins have emerged as potential therapeutic targets for the treatment of 
human pathologies such as metabolic, cardiovascular and other ageing-related 
diseases, as well as cancer.  
2.5.1. Sirtuins in ageing 
Sir2 and its orthologues play important roles in ageing and longevity control in 
various model organisms such as nematode Caenorhabditis elegans, fruit fly 
Drosophila melanogaster, and in mice (Kaeberlein et al., 1999, Rogina and 
Helfand, 2004, Tissenbaum and Guarente, 2001). Studies on these organisms 
have also shown that Sir2 and its orthologues mediate calorie restriction–
induced lifespan extension in certain genetic backgrounds. (Anderson et al., 
2003, Lin et al., 2000, Lin et al., 2002, Rogina and Helfand, 2004, Wang and 
Tissenbaum, 2006). Many studies have established a link between SIRT1 
mediated anti-ageing effects of calorie restriction in mice (Guarente, 2013), 
however, SIRT1 overexpression in mice failed to support lifespan extension 
(Herranz et al., 2010). Furthermore, their role in worm and fly lifespan has been 
questioned (Burnett et al., 2011, Viswanathan and Guarente, 2011). Nonetheless, 
recently, a number of studies have reconfirmed the original hypothesis and 
have shown that SIRT1 does appear to promote healthy ageing by protecting 
against several age-related conditions (Banerjee et al., 2012, Guarente, 2013, 
2011, Imai and Guarente, 2014, Kanfi et al., 2012, Satoh et al., 2013, Schmeisser et 
al., 2013, Viswanathan and Guarente, 2011).  
The most accepted link between sirtuins and anti-ageing effects of calorie 
restriction is that of SIRT3 mediating the prevention of age-related hearing loss 
by calorie restriction (Someya et al., 2010). Age-related hearing loss is 
characterised by the gradual loss of spiral ganglion neurons and sensory hair 
cells in the cochlea of the inner ear (Liu and Yan, 2007). Earlier studies revealed 
that calorie restriction prevents hearing loss in a variety of species and Someya 
et al. showed that SIRT3-deficient mice are resistant to the effects of calorie 
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restriction (Someya et al., 2010). Also, SIRT3 is required for calorie restriction 
mediated reduction of oxidative damage in multiple tissues via regulation of 
the glutathione antioxidant system (Someya et al., 2010). Deacetylation of 
manganese superoxide dismutase (MnSOD) by SIRT3 directly modulates 
reactive oxygen species (ROS) (Qiu et al., 2010). Hence, suggesting that SIRT3 
plays a major role in the regulating age-related diseases that depend on cellular 
levels of ROS. 
The targets of the nuclear protein, SIRT1, include transcriptional proteins that 
are vital in energy metabolism such as PCG-1α and FOXO (forkhead box 
subgroup O) (Brunet et al., 2004, Li et al., 2007, Motta et al., 2004, Rodgers et al., 
2005). It also regulates components of the circadian clock, such as BMAL1 (aryl 
hydrocarbon receptor nuclear translocator-like, a.k.a. Arntl) and period 
circadian protein homolog 2 (PER2) (Asher et al., 2008, Nakahata et al., 2008). 
These targets highlight the link between sirtuins, metabolism, circadian rhythm 
and ageing.  
Recent studies on SIRT6 and longevity have revealed that SIRT6 overexpression 
extends lifespan in male but not female transgenic mice (Kanfi et al., 2012). A 
significant difference was observed between male SIRT6-transgenic and male 
wild-type mice. The transgenic males display lower serum levels of insulin like 
growth factor 1 (IGF1), higher levels of IGF-binding protein 1 and altered 
phosphorylation levels if major components of IGF1 signalling, a key pathway 
in regulation of lifespan. A gender specific (males only) modest lifespan 
increase of 10-15% was observed (Kanfi et al., 2012). 
 These studies provide encouraging evidence that mammalian sirtuins may 
play an important role as modulators of lifespan and in ageing related diseases.  
2.5.2. Metabolic Diseases 
As sirtuins are NAD+ dependent enzymes, their activity is directly linked to the 
metabolic state of the cell. All the members of the sirtuin family have been 
shown to play a role in regulating metabolism through their involvement in 
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metabolic pathways and energy homeostasis [Table 2.4]. Sirtuins often play a 
role in helping the cell adapt to periods of low energy input.  
In addition to glucose and lipid metabolism (discussed below), sirtuins have 
important functions in additional metabolic pathways. SIRT3 upregulates the 
electron transport chain via succinate dehydrogenase (SDHA) (Finley et al., 
2011) and the urea cycle via ornithine transcarbamoylase (OTC) (Hallows et al., 
2011). It also activates ketone body synthesis via HMGCS2 (3-hydroxy-3-
methylglutaryl-CoA synthase 2) (Shimazu et al., 2010). SIRT5 regulates the urea 
cycle through demalonylation and desuccinylation of carbamoyl phosphate 
synthetase 1 (CPS1) (Du et al., 2011). 
Table 2. 4: The role of sirtuins in regulating metabolism in various tissues.  
Tissue Sirtuin Function 
Brain SIRT1 Decrease weight gain on high calorie diet intake. 
Liver SIRT1 Decrease lipogenesis (SREBP-1c) 
Increase gluconeogenesis (PCG1α) 
SIRT2 Increase gluconeogenesis (PEPCK) 
SIRT3 Increase fatty acid oxidation (LCAD) 
Increase ketone body production (HMGCS2) 
Increase urea cycle (OTC) 
SIRT5 Increase urea cycle (CPS1) 
SIRT6 Increase fatty acid oxidation 
Pancreas SIRT1 Increase glucose tolerance 
Increase insulin secretion 
SIRT4 Decrease insulin secretion 
Adipose tissue SIRT1 Increase lipolysis (FOXO1) 
Skeletal muscle SIRT1 Increase fatty acid oxidation 
SIRT3 Increase fatty acid oxidation(LCAD) 
SIRT6 Decrease glucose uptake(H3K9Ac) 
 
Glucose and glutamine metabolism 
Gluconeogenesis is the metabolic process by which organisms produce glucose 
from non-carbohydrate carbon precursors such as pyruvate and lactate. 
Glucose, the primary nutrient for cell survival and proliferation, is tightly 
regulated throughout tissues. The liver, muscle and the pancreas act as 
modulators of glucose homeostasis. In the cytoplasm of the cell, glucose gets 
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converted to pyruvate through glycolysis. Pyruvate then enters the citric acid 
cycle (or tricarboxylic acid cycle or TCA cycle in the mitochondria) to generate 
NADH. This molecule is in turn used by the oxidative phosphorylation 
pathway to generate adenosine triphosphate (ATP). 30 mols of ATP per mol of 
glucose is generated in this process. However, in certain situations, pyruvate 
gets diverted in the cell to produce lactate which is a less efficient way to 
produce ATP but a crucial method for ATP production in cases of impairment 
of oxidative phosphorylation (e.g. hypoxia). 
SIRT1 has been reported to modulate both gluconeogenesis and glycolysis by 
regulating important metabolic factors such as PGC1α and FOXO (Canto and 
Auwerx, 2012).  
SIRT2 has shown to promote gluconeogenesis through deacetylation and 
stabilisation of the rate limiting enzyme phosphoenolpyruvate carboxykinase 
(PEPCK), thus participating in glucose metabolism (Jiang et al., 2011). 
Mitochondrial SIRT3, regulates metabolic proteins such as isocitrate 
dehydrogenase 2 (IDH2) which plays an important role in the TCA cycle 
(Someya et al., 2010). SIRT3 also protects the mitochondria from oxidative stress 
by deacetylating FOXO3a which in turn increases the expression of antioxidant 
genes (Tseng et al., 2013).  
Glutamine is the main source of replenishment in the TCA cycle of proliferating 
cells as it is a valuble source of α-ketoglutarate (α-KG). SIRT4 inhibits glutamine 
entry to the TCA cycle under genotoxic stress and prevents dysregulated 
proliferation and genomic instability (Jeong et al., 2013).  
In recent years, the role of SIRT6 as a critical modulator of glucose homeostasis 
has come to light. SIRT6 knockout mice die earlier in life compared to the wild-
type control due to fatal hypoglycemia. These knockout mice exhibited 
increases expression of the glucose transporter GLUT1, leading to increased 
glucose uptake in skeletal and brown adipose tissue (Mostoslavsky et al., 2006, 
Zhong et al., 2010). SIRT6 negatively regulates HIF-1α-dependent transcription 
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by deacetylating H3K9Ac at the promoter of metabolic genes such as GLUT1, 
lactate dehydrogenase A (LDHA), PDH kinase 1 (PDHK1). This suggests that 
the increased glucose uptake seen in SIRT6 knockout mice can be reversed by 
the treatment with HIF-1α inhibitor (Zhong et al., 2010).  
Lipid metabolism 
Lipids are an important constituent of the cellular membrane and is an 
important source of energy in normal cell physiology. Their synthesis, storage 
and expenditure are tightly regulated by various physiological requirements of 
the cell such as fasting and nutrient availability. Lipid synthesis takes place in 
the liver in order to store energy inside white adipose tissue. Fatty acid 
synthesis occurs in the cytoplasm and fatty acid oxidation to produce acetyl-
CoA takes place in the mitochondrial matrix. Acetyl-CoA is a key molecule of 
the TCA cycle and is used to produce ATP. Depending on the subcellular 
localisation of sirtuins, they actively modulate fatty acid synthesis (cytoplasm) 
and oxidation (mitochondria) via transcriptional or posttranslational regulation 
by acting as energy and redox sensors (Lomb et al., 2010).  
Lipid catabolism is important during fasting. Under situations of calorie 
restriction, SIRT1 stimulates lipid breakdown through the transcription factor 
FOXO1 which in turn induces the expression of adipose triglyceride lipase 
(ATGL), a rate-limiting lipolytic enzyme (Chakrabarti et al., 2011). SIRT1 targets 
triglyceride synthesis in the liver by deacetylating and suppressing sterol-
response element-binding protein 1c (SREBP-1c)-dependent transcription 
(Ponugoti et al., 2010, Walker et al., 2010). SIRT1 overexpression was shown to 
protect mice placed on a high-fat diet from hepatic steatosis (fatty liver) (Pfluger 
et al., 2008) in one study, while opposite results were observed in another 
(Qiang et al., 2011). These studies attributed the different outcomes to SIRT1 
induced inhibition of Creb, a transcription factor which activates fatty acid 
metabolism and gluconeogenesis. Like SIRT1, SIRT2 deacetylates FOXO1 and 




Figure 2. 11: Sirtuin involvement in lipid metabolism.  
In white adipose tissue, SIRT1 and SIRT2 repress adipogenesis and promote lipolysis 
by inhibiting PPARγ and FOXO1, respectively. In the liver, SIRT1 promotes β-
oxidation by stimulating PPARα/PGC-1α. SIRT1 also deacetylates LXR thereby 
inducing expression of LXR target genes. In the skeletal muscle, SIRT1 promotes β-
oxidation through PGC-1α. SIRT1 and SIRT4 modulate pancreatic insulin secretion. In 





Metabolic SIRT3 and SIRT4 play key roles in fatty acid oxidation. SIRT3 
expression is upregulated during fasting. Genetic ablation of SIRT3 affects 
various enzymes, including residues K318 and K322 of long-chain acyl-CoA 
dehydrogenase (LCAD), resulting in a decrease in fatty acid oxidation in liver 
mitochondria (Bharathi et al., 2013, Hirschey et al., 2010). SIRT4 is a repressor of 
malonyl-CoA decarboxylase (MCD), a core enzyme that balances malonyl-CoA 
and acetyl-CoA in mitochondria and modulates lipid anabolism and 
catabolism. SIRT4 deacetylates and inhibits MCD activity, favouring fatty acid 
synthesis over oxidation (Laurent et al., 2013). 
SIRT6 along with SIRT1 promotes fatty acid oxidation. SIRT1 and the 
transcription factors FOXO3a and nuclear respiratory factor 1 (NRF1) form a 
complex on the SIRT6 promoter and promote fatty acid oxidation in wild-type 
mice (Kim et al., 2010b). A liver-specific deletion of SIRT6 in mice casues hepatic 
steatosis due to low levels of fatty acid oxidation while transgenic 
overexpression of SIRT6 protects against accumulation of visceral fat when the 
mice are placed on a high-fat diet (Kanfi et al., 2010). 
In a recent study SIRT7, like other members of the sirtuin family, was revealed 
to be involved in lipid metabolism. SIRT7 was shown to alleviate high-fat diet-
induced hepatic steatosis by co-repressing Myc transcriptional activity and 
decreasing endoplasmic reticulum stress in liver (Shin et al., 2013).  
2.5.3. Cancer 
Detecting and responding to life-threatening environmental changes induced 
by metabolic fluctuation and stress remains one of the greatest challenges facing 
organisms. These conditions are linked to the onset of many pathological 
conditions. Sirtuins participate in an elaborate network of interactions and their 
targets that are involved in cell growth, cell cycle progression, genomic 
integrity and cell death. This enables sirtuins to play vital roles as cell sensors, 
modulators and responders to stress. Stress and environmental conditions can 
induce mutations that lead to cell transformation and cancer initiation. This is 
coupled with metabolic reprogramming to compensate for the energy 
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requirement for tumour cell progression. The ability of sirtuins to regulate 
genomic stability and other cellular functions makes them ideal candidates for 
the control of tumourigenesis. In cancer, sirtuins have been reported to have a 
dual role. While some sirtuins prevents organisms from cancer by helping to 
protect DNA from damage and oxidative stress, maintaining genomic stability 
and limiting replicative life span, others promote cell survival under stress 
conditions and promote tumourigenesis. As sirtuins are key modulators in 
various pathways, understanding their function in cancer would unearth new 
targets and tools for the control of tumour growth.  
Sirtuins play a complex role in both promoting and/or supressing 
tumourigenesis. The functional loss of sirtuin genes, which are involved in 
maintaining genome integrity and DNA repair, promotes tumourigenesis due 
to genomic instability upon their loss (Roth and Chen, 2014). This is 
contradicted by the requirement of sirtuins for these same processes to allow 
cancerous cells to survive, proliferate, repair genomic events and evolve. This 
dual role of sirtuins in cancer has been a topic of discussion and has eluded the 
understanding of its role in cancer. 
p53 is vital in the regulation of the cell cycle and functions as a tumour 
suppressor to prevent cancer. In normal cell physiology, p53 levels are low and 
increase when the cell is subjected to stress. Its major functions include growth 
arrest, DNA repair and apoptosis. Unusually high levels of p53 accelerate 
ageing (an established hallmark of cancer) due to excessive apoptosis. SIRT1 
and SIRT7 deacetylate p53 and reduce its influence on cell cycle control during 
stress and in response to DNA damage. Overexpression of SIRT1 deactivates 
p53 which results in a reduction of the cell’s ability to respond to stress and 
DNA damage (Luo et al., 2001, Vaziri et al., 2001). Along with p53, SIRT1 
overexpression can also block FOXO, E2F1, retinoblastoma protein (Rb), B-cell 
lymphoma 6(BCL6) and Ku70 via deacetylation (Bosch-Presegue and Vaquero, 
2011, Heltweg et al., 2006, Wang et al., 2006). Increased levels of SIRT1 have been 
associated with various cancers including prostate (Huffman et al., 2007), acute 
myeloid leukaemia (AML) (Bradbury et al., 2005), primary colon (Stunkel et al., 
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2007) and other non-malignant skin cancers (Hida et al., 2007). Inhibition of 
tumour suppressors by SIRT1 along with its upregulation in various cancers, 
provides evidence supporting the role of SIRT1 in tumour initiation and 
progression via blocking senescence and apoptosis.  
The tumour suppressive function of SIRT1 in cancer is corroborated by its role 
in maintaining genome stability through chromatin regulation and DNA repair 
(Bosch-Presegue and Vaquero, 2011, Saunders and Verdin, 2007, Stunkel et al., 
2007). Decreased SIRT1 levels have been reported in glioblastoma, bladder 
carcinoma, male germ cell tumour prostate carcinoma and ovarian cancers 
(Wang et al., 2008). The role of SIRT1 as a tumour suppressor has been 
substantiated by other studies (Ford et al., 2005, Kojima et al., 2008, Pruitt et al., 
2006). 
Akin to SIRT1, SIRT2 has both pro-and anti-cancer roles. Control of cell-cycle 
progression by SIRT2 is essential for prevention of tumours as it is suppressed 
in gliomas (Hiratsuka et al., 2003) and melanomas (Lennerz et al., 2005). SIRT2 is 
down-regulated in some cancers and its loss is shown to compromise the 
mitotic checkpoint, contributing to genomic instability and tumourigenesis 
(Dryden et al., 2003, Inoue et al., 2007). On the other hand, SIRT2 can promote 
oncogenic phenotypes. SIRT2 is increased in AML in vitro (Dan et al., 2012). 
Knockdown of SIRT2 is shown to induce p53 accumulation and promotes 
apoptosis of cancer cells (Li et al., 2011, Peck et al., 2010). 
Analogous to the bifurcated roles of SIRT1 and SIRT2 in cancer, SIRT3 has roles 
in tumour suppression and progression. Under normal conditions, it has been 
shown to promote apoptosis while under stress conditions it promotes cell 
survival (Allison and Milner, 2007, Kim et al., 2010a).  
More recently, SIRT5 overexpression has been implicated in a study of 
pancreatic cancers (Ouaissi et al., 2008). The tumour suppressive role of SIRT6 is 
supported by its role as a guardian of genome stability (Mahlknecht et al., 2006).  
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Elevated levels of SIRT7 in human breast, thyroid and liver cancers have been 
reported (Ashraf et al., 2006, de Nigris et al., 2002, Kim et al., 2013b). SIRT7 is a 
lysine deacetylase that selectively removes a histone mark, acetylated H3K18 
(H3K18Ac). Deacetylation of H3K18 (which is hypoacetylated in many cancers 
including prostate cancer) by SIRT7 is necessary for maintaining essential 
features of human cancer cells, including anchorage-independent growth and 
escape from contact inhibition (Barber et al., 2012, Seligson et al., 2009). These 
studies direct at SIRT7 providing a growth advantage to cancer cells.  
Further studies are needed to delineate the precise roles of sirtuins in cancer. 
The bifurcated role of sirtuins in cancer can be accredited in part to the nature 
of the genes involved in the cell’s genome maintenance systems (Roth and 
Chen, 2014). Deciphering sirtuin functions would have a significant 
contribution to designing precise modulations of selective sirtuins to help 
cancer prevention and treatment. 
2.5.4. Neurodegenerative diseases 
Sirtuins play an important role in maintaining neuronal health during ageing 
and have been shown to be beneficial in multiple models of neuropathology. 
During neuronal development, SIRT1 promotes axonal elongation, neurite 
outgrowth and dendritic branching. It also plays a role in memory formation by 
modulating synaptic plasticity. It regulates the hypothalamic functions that 
control feeding behaviour, endocrine function and circadian rhythmicity 
(Herskovits and Guarente, 2014).  
The protective role of SIRT1 against neurodegenerative diseases such as 
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotropic 
lateral sclerosis (ALS), spinal and bulbar muscular atropy (SBMA), prion 
disease, multiple sclerosis and psychiatric disorders have been reported 
(Herskovits and Guarente, 2014). Brain-specific SIRT1 knockout in mice 
increases β-amyloid plaque formation, a hallmark of Alzheimer’s disease. 
Overexpression of SIRT1 reverses this effect (Donmez et al., 2010). This may be 
due to activation of transcription of the ADAM-10 gene that encodes for α-
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secretase which helps the brain avoid plaque formation. Another hallmark of 
Alzheimer’s is tau proteins which were shown to be destabilized by SIRT1 
deacetylation, thereby preventing protein aggregation (Min et al., 2010). 
Similarly, SIRT1 activates molecular chaperones such as HSP70 by 
deacetylation of HSF1 in response to α-synuclein aggregation-induced stress. α-
synuclein is a key molecule in the pathogenesis of synucleinopathy including 
dementia with Lewy bodies, Parkinson’s disease and multiple system atrophy 
(Donmez et al., 2012). In Huntington’s disease, SIRT1 overexpression improves 
motor function in mice while brain-specific knock-out worsens disease-related 
pathology (Jeong et al., 2012, Jiang et al., 2012). In contrast, SIRT2 inhibition has 
shown to lower toxicity in a striatal neuron model of Huntington’s disease 
(Luthi-Carter et al., 2010).  
Little is known about the role of other sirtuins in the brain. Further 
understanding of these roles and rational drug design that modulate specific 
sirtuins may offer a promising approach to treat neurodegenerative disorders.  
2.5.5. Cardiovascular diseases 
Cardiovascular disease (CVD) is among the leading causes of death globally. It 
is marked by the deterioration of heart and blood vessel function. As calorie 
restriction improves both endothelial and heart function (Weiss and Fontana, 
2011), the functions of sirtuins in CVD have been explored. The role of SIRT1 in 
endothelial function, vessel inflammation, vascularisation and cholesterol 
metabolism has been well established (Haigis and Sinclair, 2010). SIRT1, SIRT3, 
SIRT6 and SIRT7 are key modulators of cardiac hypertrophy.  
Deacetylation and regulation of p53 by SIRT1 and SIRT7 enables them to 
protect against cardiac hypertrophy (Pillai et al., 2005, Vakhrusheva et al., 2008). 
SIRT1 also binds to PPARα favouring the deacetylation of PGC-1α and prevents 
downregulation of fatty acid oxidation genes (Planavila et al., 2011). 
The mitochondrial SIRT3 is an endogenous negative regulator of cardiac 
hypertrophy which protects the heart by suppressing cellular levels of ROS and 
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deactivation of protein kinase B (AKT). SIRT3 dependent deacetylation of 
FOXO3a leads to its nuclear localization and enhances the expression of 
manganese superoxide dismutase (MnSOD) which reduces ROS levels 
(Sundaresan et al., 2009). Moreover, SIRT3 deacetylates and activates liver 
kinase B1 (LKB1) thus augmenting the activity of the LKB1-AMPK pathway 
and supresses AKT phosphorylation (Pillai et al., 2010).  
SIRT6 directly attenuates IGF/AKT signalling by binding to and suppressing 
the promoter of IGF signalling-related genes by interacting with c-Jun and 
deacetylating H3K9 (Sundaresan et al., 2012). Increased levels of SIRT6 suppress 
NF-κB activation and protect cardiomyocytes from hypertropic responses in 
vitro (Yu et al., 2013).  
2.5.6. Inflammation 
Inflammation is one of the hallmarks of many diseases including cancer and 
cardiac diseases. The anti-inflammatory role of sirtuins, especially SIRT1 and 
SIRT3, has been brought to light by recent research. SIRT1 exhibits pronounced 
anti-inflammatory properties. The endotoxin, lipopolysaccharide (LPS) is a 
predominant microbial mediator that activates the pro-inflammatory cascade in 
the human digestive tract and plays a major role in various inflammatory-
related diseases (Alexander and Rietschel, 2001, Miller et al., 2005). Increased 
levels of LPS-stimulated phosphorylation of JNK and c-JUN along with 
enhanced expression of inflammatory cytokines such as TNF-α, IL-1β and IL-6 
in SIRT1 knockdown mice macrophage were observed (Yoshizaki et al., 2009). 
Lung inflammation following exposure to airborne particulate matter may also 
be prevented by SIRT1 (Wu et al., 2012). Deacetylation of residues K310 of the 
NF-κB subunit p65 by SIRT2 results in downregulation of the immune response 
(Rothgiesser et al., 2010). SIRT7 knockout mice had elevated myocardial levels 
of several cytokines demonstrating the role of SIRT7 in inflammation 
(Vakhrusheva et al., 2008).  
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2.6. Therapeutic potential 
The role of sirtuins in cell survival, fatty acid metabolism, glucose homeostasis, 
genomic stability and oxidative stress makes them potential pharmaceutical 
targets. Activators and inhibitors to treat diseases, regulate metabolism and 
extend lifespan have been extensively researched.  
Among members of the sirtuin family, SIRT1 targeting molecule development 
has been in full swing since its early discovery in a variety of human disorders 
such as metabolic diseases, cancer and ageing related diseases. Drug discovery 
work on other sirtuins has been less explored. Inhibition of SIRT1 could be 
useful for cancer treatment while activators have potential use in life extension. 
Over the past decade, a variety of small-molecule SIRT1-activating compounds 
(STACs) or inhibitors have been published [Figure 2.12]. Of these only 
nicotinamide (NAM) is a physiological inhibitor. 
Activators of SIRT1 can be used to treat a variety of conditions such as 
inflammation, neurodegeneration, regulation of glucose metabolism by 
regulating insulin secretion, regulating ageing process and beneficial metabolic 
effects in calorie restriction (as discussed in the Section 2.5). Activators of SIRT1 
can mimic the effects of calorie restriction which provides a new weapon in the 
treatment of obesity and diabetes (Haigis and Sinclair, 2010). Polyphenols such 
as resveratrol and other small molecule compounds have been developed to 
increase the deacetylase activity of SIRT1 (Alcain and Villalba, 2009a, Howitz et 
al., 2003, Milne et al., 2007). Resveratrol is a pleiotropic molecule and has shown 
to activate the AMPK pathway resulting increased cellular NAD+ concentration 
and subsequent stimulation of SIRT1 activity (Baur et al., 2006, Park et al., 2012). 
However, the exact mechanism of SIRT1 activators remains unclear. 
Increased SIRT1 levels in neurodegenerative diseases and many cancers 
including prostate, AML and colon cancer threw light on the importance of 
developing inhibitors of sirtuins (as discussed in the Section 2.5.3) (Alcain and 
Villalba, 2009b). In recent years a number of sirtuin inhibitors have been 
discovered and characterised. In addition to nicotinamide, the physiologic 
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sirtuin inhibitor, specific inhibitors like splitomycin and its analogues, AGK2, 
tenovin, surfactin, sirtinol, suramin and cambinol have been developed 
(Bedalov et al., 2001, Heltweg et al., 2006, Lain et al., 2008, Sanders et al., 2010, 
Trapp et al., 2006). 
Sirtuins have grown as potential therapeutic targets for age-related diseases and 
metabolic dysfunction. Conflicting data supporting the bifurcated role of 
sirtuins means that highly specific modulation of sirtuin activity is required. 
Altering its activity, despite any health benefits, could result in increased health 
risks and compromise safety. Given the complex role of each sirtuin, future 
effort is needed to develop more selective sirtuin modulators for human use to 
treat cancer and other diseases. 
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Figure 2. 12: Chemical activators and inhibitors of sirtuins.   
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2.7. Aims and Objectives 
Sirtuins are an ancient family of proteins found in all life forms. They display a 
high degree of structural and functional conservation from bacteria to humans. 
The founding member of this vital class of histone deacetylases, yeast Sir2 
(silent mating type information regulator 2), was identified as a gene required 
for maintaining silent chromatin (Shore et al., 1984). In a NAD+-dependent 
manner, sirtuins perform deacylation from lysine-modified ε-amino groups or 
NAD+-dependent protein ADP-ribosylation. The presence and enzymatic 
activity of their homologues in other species piqued curiosity (Tanner et al., 
2000). Extensive work to deepen our understanding of the biological function 
and substrates of sirtuins was undertaken. Reports linking sirtuins to longevity 
and their role in ageing and age-related diseases further provoked general 
interest (Houtkooper et al., 2012). Their unique enzymatic functions and 
potential therapeutic role in ageing and health issues including cancer have 
garnered the interest of researchers to unravel the molecular role of sirtuins in 
various physiological pathways. As this area of molecular science consolidates 
and advances, the sirtuin family of proteins is gaining significance in human 
biology and disease. Although a myriad of questions regarding the role of 
sirtuins remain unanswered, there is a growing body of evidence indicating 
that this research should be prioritised.  
Sirtuins show a strong potential to become valuable predictive and prognostic 
markers for disease and as therapeutic targets for the management of a variety 
of cancer types and age-related diseases. However, due to the interplay of 
sirtuins, a detailed molecular understanding of each sirtuin is essential for the 
development of selective sirtuin modulators. This can be explored using a 
powerful structural biology technique such as X-ray crystallography which will 
help in understanding the mechanism of sirtuin activity at the molecular level.  
The crystal structures of some of the human sirtuins have been deduced but 
growing evidence suggests a unique role for each sirtuin and highlights the 
importance of elucidating their native structures and structures in complex with 
various substrates. Their ability to recognise a wide variety of substrate 
79 
sequences indicates a high degree of adaptability of this class of enzymes to the 
substrates. It is thus essential to obtain the structures of different isoforms and 
enzyme states including substrate bound forms for obtaining a reliable picture 
of the dynamics and preferred conformations of their binding pockets for drug 
development. 
To answer specific questions such as the difference in the deacetylation and 
ribosylation activity among mammalian sirtuins, the biological role of regions 
N- and C-terminal to the catalytic core and inhibition mechanism of synthetic 
sirtuin inhibitors the structure determination of sirtuin complexes containing 
reaction intermediates at various stages of the reaction is required.  
This study of sirtuins focuses on understanding the structural biology of SIRT1, 
SIRT2 and SIRT7. Structural studies of SIRT7 would help understand the 
activity of this enzyme and substrate binding. The crystal structure of SIRT2 in 
its native form (Finnin et al., 2001) and in complex with ADPR (Moniot et al., 
2013) as well as in complex with a macrocyclic peptide S2iL5 (Yamagata et al., 
2014) have been elucidated. Crystal structures of SIRT2 in complex with its 
inhibitors and NAD+ analogues would aid in selective modulation of SIRT2 
activity. SIRT1 being the largest member of the sirtuin family was selected for 
structural studies to identify the differences in its structures contributing to the 
high degree of deacetylase activity. 
In order to perform detailed biochemical and structural analyses, pure protein 
is required. The production of pure protein and its subsequent crystallisation 
remain bottlenecks in this field of structural biology. For this study, cloning of 
the gene of interest into appropriate expression vectors and its transformation 
into carefully selected expression cell lines were initially performed. The 
purified proteins, alone and in complex with various substrates and inhibitors, 










Chapter 3. MATERIALS AND METHODS 
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This chapter summarises the experimental procedures used throughout this 
thesis. Further details of each method are given in the relevant chapters.  
3.1. Chemicals and reagents 
All chemicals and reagents used were purchased from Sigma-Aldrich, Kent, 
U.K. unless otherwise mentioned.  
3.2. Bacterial strains and plasmids 
Several vectors and cell lines were employed for the cloning and expression of 
hGal-7 and sirtuins. The expression plasmids were all carefully selected based 
on features such as compatibility, the incorporation of purification/fusion tags, 
the presence of cleavage sites, and antibiotic resistance. A range of different E. 
coli cell lines were chosen as hosts for protein expression. The advantages of fast 
growth at a high density in an inexpensive medium, as well as the ease of 
genetic manipulation make E. coli a valuable tool in recombinant protein 
expression. The bacterial strains and plasmids used in this thesis are 
highlighted below.  
Competent cells 
E. coli One Shot TOP 10 chemically competent cells (Invitrogen, CA, USA) were 
used for cloning and propagation. 
Expression strains 
Several strains of E. coli were used for protein expression which included BL21-
CodonPlus (DE3)-RIPL competent cells (initially purchased from Stratagene, 
CA, USA) prepared in house, Rosetta-gammiTM 2(DE3)pLysS competent cells 
(Novagen, Darmstadt, Germany) and ArcticExpress (DE3) RIL competent cells 
(Agilent, CA, USA).  
Expression plasmids 
Ligation independent cloning (LIC), shown in Figure 3.1, was developed in the 
1990’s as an alternative to the more traditional restriction method of 
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enzyme/ligase cloning. The number of vector choices, ease of cloning and low 
cost of this method often makes it favourable compared to other techniques. 
Many of the commercially available LIC vectors have been designed to include 
a protease cleavage site, most commonly enterokinase (Ek) or Factor Xa (Xa). 
The Ek/LIC method was employed where possible in this thesis, although 
restriction enzyme/ligase cloning was also used. A summary of the vectors 
used is given in table 3.1, while further details on construct design can be found 
in the relevant results chapter. All vectors were purchased from Novagen, 
Darmstadt, Germany except pGEx-6p-1 which was purchased from GE 
Healthcare, U.K. 
The vector maps for the expression plasmids used are provided in appendix A. 
 
Figure 3. 1: Ligation independent cloning (LIC). 
Inserts are PCR amplified and vectors are made liner either by restriction 
digestion or by PCR. T4 polymerase is then used to create overhangs with 
complementarity between the vector and insert. This technique allows the 
efficient creation of seamless recombinant plasmids.  
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Table 3. 1: Expression plasmids used for hGal-7 and sirtuin expression.  
Vector Promoter Antibiotic 
Resistance 
Tags and Fusion  
Partners 
Protease Cleavage  
Site 
Plasmid Type 
pET-22b T7-lac Ampicillin Signal Sequence 
C-terminal His-Tag 
None Bacterial Expression 





T7-lac (E. coli),  













Bacterial, Insect  
and Mammalian 
Expression 








pET-41 Ek/LIC T7-lac Kanamycin N-terminal His-Tag 
C-terminal S-Tag 
Enterokinase Bacterial Expression 
84 
3.3. Media and supplements 
Several different types of media were used for bacterial growth depending on 
the requirements of the specific cell line. For example, the competent cells used 
in subcloning procedures were grown in Miller Luria Bertani (LB) medium 
(Sigma-Aldrich Co., Kent, U.K.). For the growth of bacterial colonies in petri 
dishes LB media was supplemented with Agar (15 g/L).  
For protein expression, bacterial cell growth was tested in a wide range of 
media including Luria Bertani (LB), Terrific Broth (TB) and Auto-Induction 
(AI). Additional specialised media including modified TB, HIS, ZXY7, SOC 
media, glucose M9Y, superbroth, TYGPN and NZCYM media were also 
employed. The composition for each medium is given in appendix B.  
Prior to inoculation all media was autoclaved at 120 ºC for 15 min and 
supplemented with the appropriate antibiotics. Stock solutions of ampicillin 
(100 mg/mL, chloramphenicol (34 mg/mL), gentamycin (20 mg/mL) and 
kanamycin (30 mg/mL) were prepared and stored at -20 °C, such that a 1/1000 
dilution could be used when required.  
3.4. Molecular biology 
Introduction of a foreign DNA molecule into a replicating cell permits the 
cloning or amplification (production of many identical copies) of that DNA. To 
clone a nucleotide sequence of interest, the cellular DNA is cleaved with a 
specific restriction enzyme and the cleaved DNA fragment is joined to a cloning 
vector to form a recombinant DNA plasmid. The plasmid is then transformed 
into a single host cell where it is replicated. The process of introducing foreign 
DNA into a cell is called transformation (bacteria and yeast) or transfection 
(higher eukaryotes). The multiplication of the host cell with each new cell 
carrying the recombinant plasmid is called cloning. The cloned DNA is 
eventually released from its vector by cleavage (using an appropriate restriction 
endonuclease) and is isolated. This fragment is then ligated to an expression 
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vector and transformed into an expression host cell. This section gives details of 
the methods used for cloning and transformation of the gene of interest.  
3.4.1. Agarose gel electrophoresis 
Agarose gel electrophoresis was utilized to analyse DNA samples. Gels of 1% 
[w/v] agarose were prepared by dissolving agarose in Tris acetate EDTA (TAE) 
buffer (40 mM Tris pH 8.0, 20 mM acetic acid, 1 mM EDTA). SYBR Safe DNA 
Gel Stain (Invitrogen, CA, USA) was added to the molten agarose, using a ratio 
of 1:10,000, before the solution was poured into the cast to set. Samples were 
loaded onto the agarose gel with Blue/Orange 6x Loading Dye (Promega, WI, 
USA). For comparison either a 1 kb DNA Ladder or the 100 bp DNA Ladder 
[(New England Biolabs (NEB, MA, USA)] was loaded alongside the DNA 
samples. These ladders contain molecular weight standards ranging from 0.5-10 
kb and 100-1,500 bp, respectively. Electrophoresis was carried out using Bio-
Rad apparatus and visualisation was performed under UV light on an InGenius 
system (Syngene, U.K.). 
3.4.2. Cloning 
Synthetic genes 
cDNA was available for all the constructs discussed in the following chapters.  
Plasmid isolation 
For plasmid DNA propagation, 10 mL cultures of LB supplemented with the 
appropriate antibiotic were inoculated from a glycerol stock. The cultures were 
grown overnight at 37 oC in a shaking incubator at 200 rpm. Cells were 
harvested and the plasmid DNA was isolated using the Wizard Plus SV 
Minipreps DNA Purification System (Promega, WI, USA).  
Polymerase chain reaction  
Polymerase chain reaction (PCR) consists of the amplification of a specific DNA 
fragment from a template DNA molecule (Saiki et al., 1988, Saiki et al., 1985). 
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Modifications of the basic PCR reaction permit the introduction of mutations 
(deletions, insertions and site-directed mutagenesis) of the gene of interest. The 
targeted fragment is amplified by a thermostable DNA polymerase, which 
extends the fragment delimited by two specific oligonucleotides of 20-40 bp, the 
PCR primers, which anneal to the 5’ and 3’ ends of the fragment.  
The DNA polymerase KOD Hot Start polymerase (EMD Millipore, MA, USA) 
was used. All primers were purchased from Eurofins MWG, (Munich, 
Germany). PCR reaction contained a combination of PCR primers, template 
DNA, PCR buffer, dNTP and Magnesium sulfate (MgSO4) was used. Reactions 
with and without betaine and DMSO were set up. A typical PCR thermal cycle 
would consist of an initial denaturation phase, denaturation phase (first step of 
the cycle), annealing phase (temperature determined by the base composition of 
the PCR primers) and an extension phase (last step of the cycle). A number of 
cycles between the first and the final step are carried out. The final extension 
ensures the completion of those fragments not fully polymerised at the end of 
the last cycle. The specific reaction mixtures and the thermal cycles used for 
PCR amplifications of the insert are given in the respective chapters. A machine, 
PTC-100 Thermal cycler (MJ Research, MN, USA) was used for setting up PCR 
amplification reactions. The samples are analysed by analysing them on an 
agarose gel as described above. The Wizard SV Gel and PCR Clean-up System 
(Promega, WI, USA) was used for PCR clean up and to prepare samples for 
annealing with the cloning or expression vector.  
Transformation 
The heat-shock method was used to transform ligated DNA into TOP10 
competent cells (Invitrogen, CA, USA) according to the manufacturer’s 
instructions. The reactions were plated on LB agar with appropriate 
antibiotic(s) and incubated overnight at 37 ºC. 
Purified and sequence verified (Eurofins MWG Operon, Ebersberg, Germany) 
DNA plasmids were used to transform expression cell lines according to the 
manufacturer’s instructions, again using the heat-shock method. As before the 
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reactions were plated on LB agar with appropriate antibiotic(s) and incubated 
overnight at 37 ºC. 
Screening for positive clones 
After ligation and transformation into cloning competent cells, such as E. coli 
TOP10 cells, resulting transformants were tested for the presence of the desired 
insert. Individual colonies of transformants were used to inoculate 10 mL LB 
cultures [containing appropriate antibiotic(s)] and their plasmid DNA was 
extracted as described previously. These extracts were then sent for sequencing 
(Eurofins MWG Operon, Ebersberg, Germany). A test digest was performed on 
the resulting DNA for non–Ek/LIC clones prior to sending for sequenicng. Each 
test reaction contained 7 µL DNA, 1 µL FastDigest buffer (10x) and 1 µL each of 
the FastDigest restriction enzymes. (Invitrogen, CA, USA). The reaction mixture 
was incubated for one hour and 37 ºC. The digest was analysed by gel 
electrophoresis. 
Glycerol stock preparation 
After being transformed with the sequence-verified plasmid DNA, protein 
expression competent cells were plated on LB agar with appropriate antibiotics 
and incubated overnight at 37 ºC. A single colony was picked and used to 
inoculate 10 mL LB with appropriate antibiotic(s) and the culture was grown 
overnight at 37 ºC with shaking. For each glycerol stock, 500 µL of culture was 
added to 500 µL of 50% [w/v] glycerol in a cryovial and flash frozen in liquid 
nitrogen followed by storage at -80 ºC. 
3.5. Protein methods 
Buffer Preparation 
The buffer solutions were prepared by solublisation of the appropriate 
quantities of the buffer and other required reagents to a small quantity of water. 
After the reagents were dissolved, the pH of the buffer solution was adjusted 
using the appropriate acid or base and analysed using the 3510 Jenway pH 
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meter (Staffordshire, U. K.). Sufficient quatity water was then added to make up 
to the expected volume. The buffers were filtered using Nalgene Rapid flow 
filter units (Thermo Fisher Scientific, MA, USA). 
3.5.1. Protein expression 
Primary cultures (50 mL LB cultures in 250 mL conical flasks) with appropriate 
antibiotic(s) were inoculated from glycerol stock and grown overnight at 37 ºC 
in a shaking incubator at 200 rpm. 10 mL of these seed cultures were used to 
inoculate 1 L secondary cultures, also containing antibiotics, and these were 
then grown at 37 ºC in a shaking incubator (200 rpm) until optical density 
(O.D.) reached 0.6-0.9 at 600 nm. Protein expression was then induced by the 
addition of isopropyl-1-thio-β-D-1-thiogalactopyranoside (IPTG) to a final 
concentration of 1 mM. The incubation temperature was varied if required for 
expression and induction with IPTG. Cells were grown overnight and 
harvested by centrifugation. For storage, cell pellets were resuspended in their 
respective purification buffers and frozen at -80 ºC until the day of use.  
Expression trials 
Primary cultures (10 mL LB cultures in 50 mL falcon tubes) with appropriate 
antibiotic(s) were inoculated with glycerol stocks and grown overnight at 37 ºC 
in a shaking incubator. 1 mL of these seed cultures were used to inoculate 50 
mL media in 250 mL conical flasks containing the respective antibiotics. 
Expression trials in LB and TB media were grown at 37 ºC to an O.D. of 0.6–0.9 
and then induced with 1 mM IPTG. Depending on the design of the expression 
trial, induction was performed at either 37 ºC or 16 ºC. Samples were collected 
at regular intervals and expression was assessed by SDS-PAGE. Expression 
trials in AI media were performed by inoculation of the AI media followed by 
its incubation for 24 h at appropriate temperatures (37 ºC or 16 ºC). All 
expression trials were carried out in a shaking incubator at 200 rpm. Cells were 
harvested after induction by centrifugation (4 ºC at 12,000 g, 10 min). 
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3.5.2. Protein purification 
Specific details of the purification process are given in each chapter for each of 
the proteins purified. A general summary of the experimental procedures used 
is given below. 
Cell preparation 
Frozen cell suspensions were thawed and cell lysis was carried out using a cell 
disruptor (TS Series, Constant System) at 20,000 PSI at 4 ºC.  
For soluble protein, the cell lysate was centrifuged at 30,000g for 30 min at 4 ºC 
to separate the clear fraction. The supernatant was then purified using a range 
of chromatographic methods.  
For insoluble protein, the cell lysate was centrifuged at 10,000g for 30 min at 4 
ºC. The resulting inclusion body pellet was then washed in lysis buffer and 
solubilised before being refolded in respective refolding buffers. The refolded 
protein was purified using appropriate chromatographic techniques. 
Protein Purification 
The proteins were purified on the basis of their biochemical properties and the 
presence of affinity tags. The commonly used purification techniques were 
immobilized metal ion affinity chromatography (IMAC), ion exchange 
chromatography (IEX) and size exclusion chromatography (SEC). Carefully 
designed buffers were filtered prior to use. Details of the chromatographic 
techniques, columns and media used are given in the following chapters. 
Purifications were performed as per the manufacturer’s instructions for each 
column and media. All proteins were purified using ÄKTA systems (GE 
Healthcare, U.K.). 
 Solvent exchange/ Dialysis 
Solvents were fully exchanged by dialysis or gel filtration chromatography 
using a desalting column between purification stages when required. The 
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protein was dialysed in Medicell membranes (U.K.) tubing with an appropriate 
molecular weight cut-off and was dialysed overnight at 4°C against the buffer 
(100x the sample volume) to be used for the following purification step. The 
buffers were replaced 2-3 times to ensure full exchange. When large sample 
volumes were to be solvent exchanged, multiple rounds of desalting using a 
HiPrep 26/10 desalting column (GE Healthcare, Uppsala, Sweden) pre-
equilibrated with the final buffer was used.  
Protein solubilisation strategies 
For insoluble protein expression, cell lysis and clarification of the cell cultures 
after expression yielded inclusion bodies. Four solubilisation conditions with 
guanidine HCl or urea as the chaotrope were used for solubilisation trials 
[Table 3.2] by stirring the pellet overnight at 4 ºC. The degree of solubilisation 
was analysed by SDS-PAGE and the appropriate condition was then used for 
large scale experiments.  
Table 3. 2: Trial solubilisation conditions.  
Buffer Condition 
A 100 mM Tris HCl pH 8, 500 mM NaCl, 7 M guanidine HCl 
B 100 mM Tris HCl pH 8, 500 mM NaCl, 8 M urea 
C 
100 mM Tris HCl pH 8, 500 mM NaCl, 7 M guanidine HCl, 0.15 M 
glutathione reduced 
D 
100 mM Tris HCl pH 8, 500 mM NaCl, 8 M urea, 0.15 M glutathione 
reduced 
 
Protein refolding strategies 
The aim of refolding is to favour protein refolding over aggregation. This is 
done by keeping the protein concentration at or below 0.1 mg/mL. The 
denatured protein was refolded using the drop wise dialysis method at 4 oC. 
This method ensures the instantaneous elimination of the chaotrope upon 20-
fold (or larger) dilution. The dilution buffer was carefully selected by screening 
conditions provided in the refolding screen, iFOLD refolding system (EMD 
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Millipore, MA, USA). The degree of solubilisation was determined by SDS-
PAGE.  
The solubilised protein was dropped into a the selected refolding buffer 
(volume 20x larger than the solubilised protein) at a speed of 0.1 mL/min with 
gentle stirring at 4 ºC. The refolded protein was left undisturbed overnight at 4 
ºC and purified the following day using appropriate chromatographic 
techniques. 
Protein concentration determination 
The final concentration of the purified protein was determined using a 
NanoDrop 2000c (Thermo Fisher Scientific, MA, USA) by A280 measurements 
using an extinction coefficient calculated from the protein sequence by 
ProtParam (Gasteiger et al., 2005). The average of three sample readings was 
used for the final concentration determination.  
3.5.3. Protein identification 
3.5.3.1. SDS-PAGE 
Protein expression and the subsequent purification steps were analysed by 
sodium dodecyl sulfhate polyacrylamide gel electrophoresis (SDS-PAGE). 
Fractions of interest (uninduced samples, induced samples, column load, 
column wash and elution peaks) were prepared by dilution with SDS-PAGE 
sample loading buffer 5x (0.25M Tris-HCl, pH 6.8, 15% [w/v] SDS, 50% [w/v]  
glycerol, 0.01% [w/v] bromophenol blue) with or without 25% v/v  β-
mercaptoethanol. Samples were denatured by heating for 10 min at 95 ºC before 
being loaded onto an 8%, 10%, 12% or 15% [w/v]  BIS-TRIS gel (selected based 
on the molecular weight of protein). Depending on sample, 10 to 20 µL was 
loaded. Protein molecular weight markers (2-212 kDa; NEB, U.K.) were used as 
standards. Gels were run for 60 min at 160 volts in MOPS running buffer (50 
mM MOPS, 50 mM Tris base pH 7.7, 0.1% [w/v] SDS, 1mM EDTA) using a 
Mini-PROTEAN tetra cell (Bio-Rad, CA, USA). 
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3.5.3.2. Western blotting 
Samples were prepared as per SDS-PAGE analysis with the PageRuler 
prestained protein ladder (Thermo Scientific, MA, USA) for molecular weight 
standards. After electrophoresis, gels were set up in a blotting cassette with 
filter papers and with either a nitrocellulose or a PVDF membrane (Millipore, 
MA, USA). Blotting was carried out in SDS running buffer (24mM Trizma, 0.19 
M glycine, 0.1% [w/v] SDS) with 20% v/v methanol for one hour at 60 volts. 
The blots were blocked in 5% [w/v] milk powder in 1x Tris Buffer system (TBS) 
with 0.01% [v/v] Tween (TBST). Stock solution of 10x TBS (200 mM Tris HCl pH 
7.6, 1.5 M NaCl) was prepared and diluted as per required. Following a wash 
step using TBST, primary antibodies, some of which were conjugated with 
HRP, were diluted appropriately in 5% [w/v] milk powder in TBST and added 
to the blots. After incubation for one hour at room temperature, with rocking, 
the blots were washed five times for 10 min each in TBST. HRP conjugated 
secondary antibodies (if required) were diluted appropriately in 5% [w/v] milk 
powder in TBST and incubated for one hour with shaking at room temperature. 
After five washes, blots were revealed using the 3,3’-diaminobenzidine (DAB) 
colorimetric detection method. The antibodies (Ab) used in this thesis include 
monoclonal anti-ploy-His Ab conjugated with HRP (referred to as anti-His Ab) , 
unconjugated anti-GST Ab raised in goat for which anti-goat IgG-peroxidase 
Ab produced in goat was used as the 2º Ab (referred to as anti-GST Ab), 
unconjugated anti-SIRT2 Ab produced in rabbit and anti-SIRT1 Ab produced in 
rabbit for which anti-rabbit IgG-peroxidase Ab produced in goat was used as 
the 2º Ab (referred to as anti-SIRT2 Ab and anti-SIRT1 Ab, respectively). All 
antibodies were purchased from Sigma-Aldrich Co., Kent, U.K. 
3.5.3.3. Mass spectrometry 
Intact protein 
The purified protein was dialysed in water at 4 ºC overnight. The protein was 
then concentrated to between 3 and 10 mg/mL and sent for mass spectrometric 
analysis. Before analysis, 0.1% v/v acetic acid was added to the sample to 
facilitate the ionisation of the protein for mass spectrometry. Samples for intact 
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protein mass spectrometry were performed at the Chemical Characterisation 
and Analysis Facility, University of Bath. 
In-gel tryptic digest mass spectrometry 
The purified protein sample was analysed by SDS-PAGE. The protein band of 
interest was excised and sent to the Proteomics Facility, University of Bristol for 
in-gel trypsin digest mass spectrometry. The protein samples were trypsin 
digested using ProGest automated digestion unit which minimises sample 
handling and keratin contamination. The resulting peptides were then analysed 
by MALDI-TOF/TOF mass spectrometry to generate peptide mass fingerprints 
and peptide sequence information, which was then searched against various 
databases using a Mascot server to identify the protein. Proteins were verified 
based on a match with the top candidate from the search. 
3.6. Biochemical assays 
Biochemical assays were used to confirm the identity of the purified proteins 
and ensure they were biologically active. These included the Fluor-de-Lys SIRT2 
fluorometric drug discovery assay (Enzo Life Sciences, NY, USA), used to 
measure the lysyl deacetylase activity of recombinant sirtuins and the 
isothermal titration calorimetry assay, which was used to measure the binding 
affinity of galectins to the dendrons used in the study.  
These assays have been discussed further in the following chapters. 
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3.7. Protein crystallography 
Protein crystallography has had a profound influence on structural biology. The 
ability of X-ray crystallography to provide accurate structural details at the 
atomic resolution has had a huge impact on biological research. The 
information it provides has become a prerequisite for biological studies such as 
deciphering mechanisms, understanding activity of proteins, identifying 
substrates, rational based drug design and many others.  
To date, 28 Nobel prizes have been awarded for research towards 
macromolecular X-ray crystallography. The contribution of X-ray diffraction to 
biology took off with Rosalind Franklin’s and Maurice Wilkin’s experiments on 
the genetic blueprint for life, DNA, which lead to the work of Francis Crick and 
James Watson in the early 1950’s for which they won the Nobel prize. In the 
same year, the pioneering work by Nobel laureates Max Perutz and John 
Kendrew on haem-containing proteins, including the structure of myoglobin, 
was also recognised. Since then X-ray crystallography has contributed 
significantly to the field of structural biology which is evident in the number of 
structures deposited in the Protein Data Bank (PDB). Of the 103,354 structures 
deposited (as of 23rd September, 2014) 91,655 structures have been solved by X-
ray crystallography. This technique has now become a gold standard in 
understanding the function and regulation of biological macromolecules and 
assemblies. Complemented by the high resolution structural data obtained by 
Nuclear Magnetic Resonance (NMR) and electron diffraction, this wealth of 
knowledge provides a fundamental basis for current thinking in structural 
biology.  
The appropriate wavelength of X-rays (in the Ångström range, ~10-10 m) makes 
it suitable for scattering by the electron cloud of an atom. Often, X-rays at a 
wavelength of 1.54 Å (Cu-Kα, rotating anode home sources) are used for 
macromolecular crystallography which is very similar to the distance between 
bonded carbon atoms. Crystals of proteins behave as an amplifier to increase 
the intensity of diffraction due to their periodicity, i.e. repeated unit cells 
[Figure 3.5]. Thus scattered waves can add up in signal and raise the signal to a 
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measurable level. As the waves add up in phase in some directions, they cancel 
out in a lot of other directions. This results in the diffraction pattern of a crystal 
being an array of spots [Figure 3.3]. The structure of the protein (electron 
density) is back calculated for many such diffraction patterns collected from the 
crystal. The typical process is outlined in figure 3.2. 
 
Figure 3. 2: Outline of the steps involved in protein crystallography. 
 
The process of determining macromolecular crystal structures has remained 
largely unchanged over the years. However, the continued advancement of 
underlying crystallographic technology and methodology, complemented by 
the revolution in molecular biology, has driven the significant increase of 
successes in this field. This development extends to the kind of problems that 
can be tackled, the time involved and the accuracy and efficiency with which 
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protein structures can be determined. In spite of this progress, growing crystals 
that diffract to high resolution still remains one of the major bottlenecks in this 
field.  
As all steps after crystal mounting are now routinely performed by a robot and 
then on a computer, the advancement in computational resources and 
performance available has had a huge influence on protein crystallography. The 
availability of inexpensive computing power has contributed to radical changes 
in data collection, processing and refinement approaches. 
 
 
Figure 3. 3: Representative image of a diffraction pattern.  
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3.7.1. Theory 
3.7.1.1. Principle of X-ray crystallography 
The wave nature of X-rays was established when W. L. Bragg in 1913, first 
elucidated the crystal structures of sodium chloride, potassium chloride, 
potassium bromide and potassium iodide, using X-ray analysis (Bragg, 1913). 
Crystallography relies on the basic theory of X-ray scattering from a crystal, 
which is a well understood phenomenon. Crystals can be thought of as a three-
dimensional array of identical unit cells. This periodicity leads to Laue 
equations and Bragg’s law. 
The three Laue equations give the conditions to be satisfied by an incident wave 
to be diffracted by a crystal. The Laue diffraction conditions are as follows: 
 
Bragg’s Law (Figure 3.4) provides the condition for a plane wave to be 





Figure 3. 4: Schematic representation of Bragg’s Law. 
Two beams (1 and 2) with identical wavelength (λ) and phase approach a 
crystalline solid which gets scattered off two different atoms (O and B) within 
it. The lower beam traverses an extra length of 2dsinθ. The diffracted X-rays 
exhibit constructive interference when the extra distance traversed by beam 2 
(ABC) differs by an integral (n) multiple of the wavelength. 
 
 
A crystal is a regular arrangement of molecules(s), repeated translationally, on a 
three-dimensional lattice. The asymmetric unit is the smallest portion of a 
crystal structure to which symmetry operations can be applied in order to 
generate the complete unit cell [Figure 3.5]. The application of symmetry 
operations (a combination of rotation and translations for biological 
macromolecules) to an asymmetric unit yields one unit cell which when 
translated in three dimensions, makes up the entire crystal. The asymmetric 
unit contains the unique part of the crystal structure which is related to all other 
identical motifs in the unit cell governed by symmetry. The unit cell can be 
described by the lengths of three edges (a, b and c) and the angles between 




Figure 3. 5: Fundamental parts of crystal structures.  
The asymmetric unit (red upward arrow) is rotated 180º about a two-fold 
crystallographic symmetry axis (black oval) to produce a second copy (blue 
downwards arrow). The asymmetric unit may contain several protein 
molecules or just one. Together, the arrows comprise the unit cell. The unit cell 





Figure 3. 6: Measurable parameters of a unit cell. 
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The four basic types of symmetry operations possible for a crystal lattice are 
rotation, reflection, inversion and translation. Based in the highest symmetry 
element present, crystals can be grouped into 7 crystal systems and these can be 
further divided into 14 space lattices called the ‘Bravais Lattices’ (Blundell and 
Johnson, 1976), depending on the type of lattice (primitive or non-primitive) 
chosen to describe the unit cell [Table 3.3]. A combination of these symmetry 
elements gives rise to 230 space groups, of which only 65 are permitted for 
proteins.  
Table 3. 3: Bravais Lattices 
Name Bravais Lattice types Lattice Restrictions 
Triclinic P a≠b≠c  ;  α≠β≠γ 
Monoclinic P, C a≠b≠c  ;  α=γ=90º ≠β 
Orthorhombic P, C, I, F a≠b≠c  ;  α=β=γ=90º 
Tetragonal P, I a=b≠c  ;  α=β=γ=90º 
Trigonal 
P a=b≠c  ;  α=β=90º, γ=120º 
or R a=b=c  ;  α=β=γ<120º, ≠ 90º 
Hexagonal P a=b≠c  ;  α=β=90º, γ=120º 
Cubic P, I, F a=b=c  ;  α=β=γ=90º 
Lattice types: Primitive (P), Base-centred(C), Face-centred(F), Body-centred (I). 
 
The resolution of a crystal refers to the minimum interplanar spacing of the 
reflections included in structure determination. The unit of resolution is the 
Angstrom (Å = 10-10 m). It describes the ability to distinguish between 
neighbouring features in an electron density map.  
 
3.7.1.2. Structure factors 
Crystals only diffract X-ray beams constructively in certain discrete directions. 
The intensity of the diffracted beam (hkl) is proportional to the square of the 
amplitude of the Structure Factor F(hkl). 
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The structure factor is a function of the electron density distribution in the unit 
cell :  
 
Electron density distribution in the unit cell can be calculated by an inverse 
Fourier transform of this function and by virtue of its periodicity expressed in a 
summation as : 
 
The structure factor in equation (3) is a complex quantity: 
 
The amplitudes of  can be derived from the experimentally measured 
intensities of the diffracted beam (hkl). However, the phase angles φ(hkl) cannot 
be obtained directly from the diffraction pattern. Without this information, 
equation (4) cannot be solved. This is known as the ‘phase problem’ in 
crystallography. Several methods can be used to determine the phases 
indirectly (Rupp, 2010). These include the direct and the indirect methods. 
Direct methods  
Direct methods were developed by Hebert Hauptman and Jerome Karle for 
which they were awarded the Nobel prize in 1985 (Karle and Hauptman, 1956). 
In this method, the relationship among phases, based on prior knowledge about 
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crystal structures like atomicity and non-negativity of ρ(xyz) can be used to 
evaluate the phases from the measured intensities. If it is assumed that the 
crystal is made-up of similarly shaped atoms and that all atoms have positive 
electron density, then statistical relationships between sets of structure factors 
can be established. These relationships can be used to deduce possible values 
for phases. Direct methods exploit such relationships and can be used to solve 
the structures of small molecules. However, the statistical relationships become 
weaker as the number of atoms increases, and direct methods are limited to 
structures, with at most a few hundred atoms in the unit cell. Although there 
are developments that push these limits, particularly for crystals that diffract to 
very high resolution (1.2 Å or better), direct methods are not used frequently in 
macromolecular crystallography.  
3.7.1.3. Indirect methods: 
Molecular replacement (MR) 
When a homology model is available, molecular replacement can be successful 
using methods first described by Michael Rossmann and David Blow 
(Rossmann and Blow, 1962). In MR, a model structure is generated from a 
crystal structure or solution structure for a homolog of the unknown structure. 
The method works mainly by computing the three rotation angles to correctly 
orient the model and then by searching for the translation vector, to place the 
search model in the unit cell of the unknown protein. Once the search model is 
correctly oriented, it needs to be placed within the unit cell relative to the 
symmetry of the crystal. Doing a rigid body refinement can optimise the 
solution so obtained and R-factor or the Reliability index can be used to gauge the 
validity of the structure solution. The R-factor is an estimate of error between 
the observed and the calculated structure factors. The correct solution will give 
the lowest R-factor. With the increasing knowledge of three dimensional 




Multiple isomorphous replacement (MIR) 
Max Perutz and his co-workers pioneered the use of isomorphous replacement 
(Green et al., 1954). This method was the first phasing technique which became 
available to macromolecular crystallographers and is widely used for initial 
phasing when a close structural homologue of the protein in question is 
unavailable. This method involves the isomorphous attachment of heavy atoms 
to protein molecules in the crystal, generally by soaking the crystal in a solution 
containing the heavy atom of choice. In this way, a few heavy atoms replace 
some water molecules without changing the unit cell dimensions or the 
structure of the protein itself. On comparing the data collected and intensity 
differences from the native crystal and the heavy atom labelled crystal, 
positions of the heavy atoms and in turn the phase angels can be calculated to 
overcome the phase problem. However, isomorphous replacement has several 
problems including non-isomorphism between crystals (changes in unit-cell, 
reorientation of the protein, conformational changes, changes in salt and 
solvent ions), locating of heavy atoms, problems in refining heavy atom 
positions, occupancies and thermal parameters as well as errors in intensity 
measurement. 
Multiple wavelength anomalous dispersion (MAD) 
Like isomorphous replacement, this technique also exploits the abrupt changes 
to the scattering power of heavy atoms near their absorption edges 
(Hendrickson et al., 1985). MAD overcomes the problem of non-isomorphism 
observed in isomorphous replacement. Data are collected at several 
wavelengths, typically three, in order to maximise the absorption and 
dispersive effects. At certain wavelengths, tightly bound electrons in an atom 
do not scatter as free electrons do and thus cause an anomalous scattering 
effect. This effect depends on the wavelength and is generally stronger for 
heavy atoms. This anomaly results in unequal intensities of otherwise 
equivalent reflections, called Bijvoet pairs. This can be used to calculate the 
phase angle and facilitates phase determination from a single crystal.   
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3.7.1.4. Phase improvement 
The degree of success of the phasing experiment is affected by the quality of the 
diffraction data and the model for molecular replacement, or heavy atom model 
for isomorphous replacement or anomalous dispersion. This in turn can result 
in large errors in the phases and electron density maps. Several methods have 
been developed to improve the phases. These methods result from our prior 
knowledge of a good electron density map and include methods such as 
density modification by solvent flattening, averaging and histogram matching 
or by automated fitting and refinement.  
In a protein crystal, roughly half the volume is occupied by well-ordered 
protein molecules and the other half by disordered solvent which have flat 
featureless electron density. However, this disordered solvent region may 
contribute to features which will result in phase errors. Solvent flattening will 
lead to modification of the density making the corresponding phases more 
accurate. The programmes written for solvent flattening, have algorithms 
written for automatically defining boundaries between the ordered protein and 
disordered solvent regions. 
As more than one copy of the protein molecule can crystallise in one 
asymmetric unit of the unit cell and because the same protein appears in 
different parts of the electron density map, averaging the density will result in 
elimination of random errors and increase the accuracy of the corresponding 
phases.  
Histogram matching takes advantage of the fact that proteins are made up of 
similar atoms and relative distances which result in similarity in the density 
values in the electron density maps of different proteins. Phase errors may be 
observed due to incorrect distribution of high and low densities which can be 
altered to the expected distribution based on the prior knowledge of density 
values of similar atoms in different proteins using a programme for histogram 
matching. This method would also contribute to increasing the accuracy of the 
phases.  
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Similarly, automated fitting and refinement can be done by utilising prior 
knowledge of bond lengths, bond angles and chemical connectivity defined by 
the amino acid sequence to build an atomic modelling and iterative refinement.  
With the phase problem solved and improved, the initial model can be built in 
the electron density maps. The model can then be refined against observed X-
ray intensity data and standard protein geometrical information. The quality of 
the final model is assessed through cross validation of the X-ray data and 
extensive validation of the geometry of the protein model. The resolution of the 
diffracted data collected, which is determined by the quality of the crystal, 
plays a key role in the accuracy of the structure determination process.  
 
3.7.2. Crystallisation 
Proteins, like many other molecules, can form crystals when the solution in 
which they are dissolved becomes supersaturated. Under such conditions, 
protein molecules get packed in a repeating array with non-covalent 
interactions holding them in place (Russo Krauss et al., 2013). The techniques 
used for setting up crystallisation experiments of the proteins discussed in this 
thesis include vapour diffusion (hanging and sitting drop) and microbatch 
under oil.  
The crystallisation of a protein requires a specific environment which is 
empirically determined for each protein. During crystallisation, the soluble state 
is slowly transformed towards precipitation and eventually when all conditions 
are met, the protein molecules arrange themselves in regular orientations to 
form repeating unit cells. Figure 3.7 illustrates the conditions required for 




Figure 3. 7: Schematic representation of a protein crystallisation phase 
diagram.  
The horizontal axis can be any crystallising parameter being varied (usually 
precipitant concentration). The supersolubility curve is the line separating 
conditions under which spontaneous nucleation (or phase separation or 
precipitation) occurs from the condition under which the crystallisation 
solution remains clear if left undisturbed. Theoretically, the more 
supersaturated the protein solution in the drop, the greater the likelihood that a 
critical nucleus will form and the smaller the nucleus needed to induce crystal 
formation. This is represented in the phase diagram by dividing the 




Vapour diffusion is the most common method employed for protein 
crystallisation. In this method, a droplet containing purified protein and the 
reservoir solution, which consists of salt(s), buffer(s) and/or precipitant(s), are 
allowed to equilibrate with a large reservoir containing similar salt(s), buffer(s) 
and/or precipitant(s) in higher concentrations. This allows the water to 
vaporise from the drop into the reservoir, thus gradually increasing the protein 
and precipitant concentration in the drop. If the appropriate crystallisation 
solutions are used for a given protein, crystal growth will occur in the drop on 
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reaching equilibrium. Vapour diffusion can be performed in either a hanging-
drop, a sitting-drop format or by modified microbatch screening under oil 
[Figure 3.8]. 
 
Figure 3. 8: Vapour diffusion method.  
(A) Hanging-drop method: A drop of protein and reservoir solution is placed 
on an inverted cover slip, which is then suspended above the reservoir. (B) 
Sitting-drop method: A drop of protein and reservoir solution is placed on a 
pedestal that is separated from the reservoir. Both methods require sealing of 
the environment for equilibration to occur between the drop and the reservoir. 
(C) Modified microbatch crystallisation or crystallisation under oil: A drop of 
protein and reservoir solution is pipetted into the drop and layered with oil. 
Alcohol is added to the periphery. Oil acts as barrier between alcohol and the 
drop resulting in gradual diffusion of alcohol into the drop. Vapour batch 
plates were designed and provided by Douglas Instruments, U.K. 
 
Pre-crystallisation test 
A pre-crystallisation test (PCT) was carried out to determine the optimum 
protein concentration for crystallisation. Table 3.3 gives the details of 
crystallisation conditions prepared, as recommended in the PCT User Guide 
(Hampton Research, CA, USA). The hanging drop vapour diffusion method 
was used to set up a 4-well crystallisation plate. A drop size of 2 µL was used, 
in which the ratio of protein to reservoir was 1:1. Various protein concentrations 
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were tested. The PCT plates were incubated overnight at 16 ºC before the degree 
of precipitation was analysed using a light microscope. The PCT User Guide 
was followed to determine the initial protein concentration for setting up 
automated screening.  
Table 3.3: Pre-crystallisation test reagents 
Reagent Condition 
1 0.1 M Tris-HCl pH 8.5, 2.0 M Ammonium sulfate 
2 0.1 M Tris-HCl pH 8.5, 1.0 M Ammonium sulfate 
3 
0.1 M Tris-HCl pH 8.5, 0.2 M Magnesium chloride hexahydrate, 
30% [w/v] PEG 4000 
4 
0.1 M Tris-HCl pH 8.5, 0.2 M Magnesium chloride hexahydrate, 
15% [w/v] PEG 4000 
 
Automated preliminary crystallisation screen : Pheonix 
Automated crystallisation screening was used to identify suitable crystallisation 
conditions for all purified protein. An automated nano-dispenser (Crystal 
Phoenix, Art Robbins Instruments) was used to set up plates, quickly and 
accurately. 96-well INTELLI-plates (Art Robbins Instruments) were set up 
following a sitting-drop vapour diffusion method.  
For this set up, 40 µL mother liquor in the reservoir and 200 nl drop size with 
2:1, 1:1 and 0:1 (blank drop) protein to mother liquor ratios were used. Several 
commercially available screens from Molecular Dimensions, U.K. were used: 
Structure Screen I+II HT-96; Clear Strategy I HT-96; Clear Strategy II HT-96; 
PACT premier HT-96; JCSG-plus HT-96; Morpheus HT-96; PGA Screen HT-96; 
Heavy + Light twin pack HT-96; ProPlex HT-96; The Stura Footprint 
Combination HT-96; MIDAS HT-96; MemGold HT-96.  
Automated preliminary crystallisation screen : Oryx4 
An automated nano-dispenser was employed to set up modified microbatch 
plates (Oryx 4, Douglas Instruments, U.K.). 96-well vapour batch plates 
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(Douglas Instruments, U.K.) were set up following a modified microbatch 
vapour diffusion method. Commercial screens, PACT premier HT-96, JCSG-plus 
HT-96, Morpheus HT-96, PGA Screen HT-96 and Heavy + Light twin pack HT-
96 screens were used for this purpose. 
All plates (set up using Oryx and Pheonix) were incubated at 16 ºC. 
Crystallisation plates were checked immediately after set up followed by 
regular monitoring after 24 h, 1 week, 2 weeks and then regularly until the 
drops dried. When nucleation or potential crystallisation hits were observed 
further optimisation trials were performed. This involved either manually 
setting up 24-well plates or using automated set ups on the robot. 
Manual crystallisation optimisation trials 
Any signs of nucleation or crystallisation were used as a starting point for 
optimisation trials. Trials by hanging drop method using 24-well plates (XRL 
plates, Molecular dimensions) were performed. Various parameters were used 
for optimisation trials which included a broad range of precipitant 
concentrations (0–200% of the initial concentration), buffer systems for pH 
optimisation and protein to mother liquor ratios ( 1:1, 1:2, 2:1, 3:1), drop size (1 – 
4 µL) and reservoir volume (400-1000 µL).  
Seeding 
Tiny crystals or part of a crystal or crystalline material, known as the crystal 
seed, can act as a template for the assembly of macromolecules. Seeds can be 
used to initiate nucleation and also reduce the time for random molecular 
collision or interaction which results in nucleation. Modifying the seed quantity 
and selecting a suitable method can help yield larger crystals with better 
morphology and diffracting capability. Seeding methods such as streak seeding, 
microseeding and random microseed matrix seeding were used to optimise 
crystals (D'Arcy et al., 2007). The methods are described below. 
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Streak seeding: A probe, usually a cat’s or rabbit’s whisker, is used to touch an 
existing crystal to dislodge small fragments, known as crystal seeds, from it. 
These seeds are then transferred into a pre-equilibrated drop containing the 
same conditions the seed were taken from, by rapidly running the whisker in a 
line through the drop. This method should provide seed nucleated crystal 
growth along the line in the drop. 
Microseeding: In this method, pre-existing crystals are crushed by vortexing the 
crystals with a small glass bead in an Eppendorf to create a seed stock. This 
stock is then diluted in series and re-introduced back into a pre-equilibrated 
droplet. The crushed crystals aid nucleation and crystal growth.  
Random microseed matrix screening: The seed stock is prepared in a similar 
way to microseeding. However, this seed stock is then introduced into random 
commercial screens using the robot. Many salt crystals grow by this method but 
a few cases of protein crystal growth have been reported (D'Arcy et al., 2007). 
Macroseeding: A suitable crystal of good morphology is removed from a well 
and is washed repeatedly in stabilizing solution. The crystal is then transferred 
to a pre-equilibrated drop where in this case the crystal is expected to grow in 
size rather than stimulate in new crystal growth. 
Epitaxial nucleation: Impurities like cellulose fibres sometimes provide 
surfaces that are suitable for macromolecular crystal growth.  
Details for the crystallisation screening and optimisation set up are given in 
each chapter. 
3.7.3. X-ray diffraction data collection and processing 
X-ray sources 
X-ray sources are of two types: Laboratory sources and synchrotron sources. 
The X-rays are produced in laboratories either by sealed tube sources or by 
copper-rotating anode (fixed wavelength of 1.5418 Å for Cu-Kα radiation). 
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Although they are convenient and less expensive, they produce about 100-1000 
times less flux than a synchrotron. A synchrotron is a source of electromagnetic 
radiation usually produced using bending magnets, undulators and/or 
wigglers. The advantage of a synchrotron source is that it generates tuneable 
and intense X-rays. Special beam-lines for macromolecular crystallography are 
available in synchrotrons such as Diamond Light Source (DLS), Oxfordshire, 
U.K. All diffraction data discussed in this thesis, were collected at DLS 
macromolecular crystallography beam-lines I02, I03, I04, I24 or I04-1. 
Data collection  
Crystals were mounted on cryoloops (Molecular Dimensions, U.K.) and flash 
frozen in liquid nitrogen prior to data collection. The crystal loops were 
mounted on the goniometer by a robot, centred and tested for X-ray diffraction. 
When diffraction spots were observed, appropriate settings were applied for 
data collection (wavelength, exposure time, resolution, oscillation range, beam 
transmission, detector distance) and images were collected. Depending on the 
unit cell dimensions and radiation damage of the crystals, images were 
collected. Beamlines I02, I03, I04 and I04-1 are presently equipped with 
PILATUS 6M, 6M-F, 6M-F and 2M detectors (Dectris), respectively. The 
microfocus, beam-line I24 was equipped with PILATUS 3 6M detector (Dectris).  
Data processing 
X-ray diffraction data processing proceeds through indexing, pre-refinement of 
crystal orientation, intensity integration, post refinement and scaling. Data were 
processed using auto-indexing and data reduction programs, MOSFLM (Battye 
et al., 2011, Leslie, 2006) or XDS (Kabsch, 2010) followed by Xia2 (Winter, 2010) 
and scaled using AIMLESS (Evans and Murshudov, 2013). Details on data 
collection and processing are given in the following chapters. 
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3.7.4. Structure determination, refinement and validation 
Molecular replacement 
Molecular replacement was used to determine the structures discussed in this 
thesis. The details are given in the respective sections. Initial phases were 
obtained using PHASER (McCoy et al., 2007) and the co-ordinates were 
obtained from the appropriate native PDB files. 
Refinement and validation 
Crystallographic refinement is carried out to improve parameters of the model 
structure such that the structure factors calculated from the built model gets 
closer to the observed amplitudes. Iterative cycles of refinement optimise the 
atomic model, allow for improved phases and help compute electron density 
maps that show finer details of the molecular structure.  
Refinement of the crystal structures discussed in this thesis were carried out 
with PHENIX (Adams et al., 2010) and manually with COOT (Emsley et al., 
2010) version 0.7. PHENIX, a refinement program, can perform rigid body, and 
restrained or unrestrained refinement against X-ray data. It minimises the 
coordinate parameters to satisfy either a maximum likelihood or least square 
residual. After initial rigid body refinement on the molecular replacement 
solution, several rounds of restrained refinement were carried out. Between 
refinement rounds, manual adjustments and model fitting were performed with 
COOT using real space refinement and regularisation options. COOT was used 
to add ligand molecules where appropriate and PHENIX was used to 
automatically refine water molecules. The water molecules were checked using 
COOT.  
Quality of the final structures was assessed by the figure of merit, R factors, 
plotting of Ramachandran plots and geometric statistics. All structures were 
checked using MOLPROBITY (Chen et al., 2010) for validation of the structure. 
Bond lengths and bond angels of the main chain and side chains, planarity, 
chirality, solvent content and torsion angles of the main chain (φ, ψ), were 
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monitored by this programme. Any distorted geometry was corrected manually 
using COOT followed by a round refinement and validation using 
MOLPROBITY.  
The primary measure of refining structure is given by the residual factor or 
reliability factor or Rwork. It is a measure of the agreement between the 
crystallographic model and experimental diffraction data. It is defined by the 
following equation: 
 
Another parameter which states the quality of a structure and helps avoid over-
fitting of the model is Rfree (Brunger, 1992). 5-10% of the total reflections are set 
apart during scaling. Refinement is carried out against the remaining data. Rfree 
is calculated against this subset of reflections that is not used for refinement. 
This helps to reduce model bias and over fitting of data. Iterative model fitting 
and refinement cycles results in model improvement and both Rwork and Rfree 
values dropping. Decreasing R-factor values are complimented by another 
parameter called Figure of Merit (FOM) which is indicative of how well the 
model represents true structure factors.  
Another vital parameter that helps assess the quality of the model is the 
Ramachandran plot which underline the stereochemistry, conformation 
(planarity of the peptide bond, bond angels, bond length, etc.) and the backbone 
of the conformational angles (φ, ψ) of the current model based on the expected 
values for simple organic molecules (Ramachandran et al., 1963).  
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3.7.5. Structure analysis and PDB deposition 
On completion of structure refinement and validation, the structure co-
ordinates are deposited with the Protein Data Bank (PDB) (Bernstein et al., 
1977). The PDB is a vast global repository of all three-dimensional structures 
elucidates so far. 
Analysis of the three-dimensional structure of the proteins and its complexes 
provides understanding of its functional aspects. The final refined structure 
reveals the architecture of the protein and its salient features such as its 
evolution, mechanism of action, basis of interactions among others. Several 
software packages including PYMOL (The PyMOL Molecular Graphics System, 
Version 1.5.0.4, Schrödinger, LLC) for drawing figures and analysis, 
SUPERPOSE (Krissinel and Henrick, 2004) for RMS calculations and LIGPLOT+ 








Chapter 4. MULTIVALENT GALACTOSE BASED 





Human Galectin–7 (hGal-7), is expressed with the first onset of epidermal 
stratification (Magnaldo et al., 1998) and thus marks the differentiation levels of 
keratinocyte. It is involved in the migration of epithelial cells and re-
epithelisation of corneal and/or epidermal wounds (Cao et al., 2003). Presence 
of hGal-7 in the areas of cell-cell contact, especially in the upper layers of the 
epidermis and their down regulation in transformed keratinocytes, suggests its 
therapeutic value due to its involvement in physiological cell growth through 
modulation of cell-cell and cell-matrix interactions. Due to its bridging function, 
the formation of galectin oligomers through supramolecular assembly is an 
essential element of galectin function, which relies on the multivalence of 
galectins or ligands (Nagae and Yamaguchi, 2014). 
Galectin-7 is a prototype galectin and is known to dimerise in solution. In 1998, 
Leonidas et al. (1998) reported the first crystal structure of hGal-7 in which 
dimerisation was observed. Morris et al. (2004) later confirmed the relevance of 
the dimer complex using ultracentrifugation techniques and the dimer was also 
observed in the NMR structure reported by Nesmelova et al., 2012 (Nesmelova 
et al., 2012). Recent analysis by NMR, circular dichroism and molecular 
dynamic simulations showed that ligand binding to galectin-7 caused long-
range effects resulting in the stabilization of the dimer and exposed positive 
cooperativity (Ermakova et al., 2013).  
To date, the crystal structures of hGal-7 in complex with galactose (PDB: 
2GAL), galactosamine (PDB: 3GAL), lactose (PDB: 4GAL), N-acetyl lactosamine 
(PDB: 5GAL) (Leonidas et al., 1998) and with a galactose-benzyl phosphate 
inhibitor (PDB: 3ZXE) (Masuyer et al., 2012) have been reported which provide 
a comprehensive understanding of the carbohydrate recognition mechanism. 
Furthermore, with its inherent self-assembling capability, hGal-7 represents an 
ideal prototype lectin to study the formation of ligand-associated 
supramolecular assemblies. 
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Dendrimers are synthetic, monodisperse macromolecules consisting of three 
distinguishing structural features: the core, the branches or arms of the 
molecule and the termini which can all harbour a variety of chemical functions 
(Newkome et al., 2001, Villalonga-Barber et al., 2008, Vögtle et al., 2009). The 
polyvalent nature of dendrimers and their flexibility make them unique 
nanodevices for biochemical applications (Boas et al., 2006, Gardikis et al., 2012).  
In this study, synthetic galactose-based dendrimeric units, or dendrons, of 
varying size and composition are empolyed to investigate the cross-linking of 
hGal-7 through carbohydrate recognition to form supramolecular assemblies. 
The routes for the preparation of these compounds were based on a modular 
approach, making use of “click chemistry” protocols, whereby various cores, 
branching units and terminal groups could be combined in different ways to 
provide a library of dendrimeric structures. The six compounds used in this 
study therefore constitute a part of this library (Figure 4.1 and 4.2).  
This chapter gives details about the expression, purification, crystallisation and 
isothermal titration calorimetry studies of hGal-7. Diverse crystallisation 
screens were set up for the dendrons and further optimisation of these 
conditions was required. These optimisation set ups are discussed in (Section 
4.3.2). Crystallisation with all six ligands was attempted. However, X-ray data 
were collected for only three complexes; viz. D1, D2, D3 (Figure 4.1). This data 
has been analysed (Section 4.3.3) and the results are  discussed (Section 4.4). 
Isothermal titration calorimetry studies were performed to understand the 
binding affinity of the multivalent dendrons to hGal-7. Various controls, 
followed by D1 and D2 were used as the first set of ligands to be tested by this 
method. The preliminary results obtained from these experiments are presented 
(Section 4.3.4). 
The aim of this chapter is to understand the ligand-associated 
supramolecular assembly formation of hGal-7 using galactose based 
multivalent dendrimers.  
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Figure 4. 1 Structures of dendrimers D1, D2 and D3.  




Figure 4. 2: Structures of dendrimers D4, D5 and D6.  
The chemical structures of dendrimers with the distinguishing structural features (i.e. core, arms and termini) indicated. (A) D4 (B) D5 
(C) D6  
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4.2. Methods 
4.2.1. Cloning, expression and purification of hGal-7 
The gene coding for hGal-7 was obtained from RZPD (#IRAKp961G19141Q2, 
Berlin, Germany) and cloned into a modified pET-22 vector (Novagen, 
Darmstadt, Germany) with a cleavable N-terminal poly-histidine tag. This 
recombinant plasmid was already available in the laboratory. The plasmid was 
transformed into E. coli BL21 (DE3) cells. Cells were grown in LB media 
containing ampicillin at 37 °C to an O.D. of 0.6–0.7 and were then induced with 
1 mM IPTG at 18 °C. Cells were harvested after 18 h of induction by 
centrifugation (4 °C at 12,000 g, 10 min). Induction of protein expression was 
analysed by SDS-PAGE.  
Cell pellets were resuspended in wash buffer (50 mM sodium phosphate pH 8.0, 
200 mM NaCl, 10 mM imidazole) and lysed in an One shot  model. The 
preparation was then clarified by centrifugation (4 °C at 75,000 g, 25 min ). The 
supernatant was loaded on a 5 mL HisTrap FF column (GE Healthcare, 
Uppsala, Sweden) pre-equilibrated with wash buffer. The column was washed 
extensively and a single step elution (50 mM sodium phosphate pH 8.0, 200 mM 
NaCl, 300 mM imidazole) was carried out. 
The eluted fraction was dialysed overnight in wash buffer at 4 °C and loaded on 
a gel filtration column (Superdex 200; GE Healthcare, Uppsala, Sweden) pre-
equilibrated with final buffer (50 mM sodium phosphate pH 8.0, 200 mM NaCl).  
4.2.2. Synthesis of the dendrimers 
Ligands were synthesised and provided by Dr. Barry Steele’s group, National 
Hellenic Research Foundation, Institute of Biology, Medicinal Chemistry and 
Biotechnology, Athens, Greece.  
The detailed atom labelling for the ligands are shown in appendix C. 
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Table 4. 1: Chemical formulae and molecular weights of the dendrons. 
Dendrons Chemical Formula Molecular weight 
D1 C31H49N10O18 849.78 
D2 C49H80N10O33 1337.21 
D3 C71H102N20O39 1861.7 
D4 C10H150N30O57 2708.45 
D5 C107H164N20O69 2834.54 
D6 C156H240N30O102 4167.71 
 
4.2.3. Crystallisation 
Pre-crystallisation tests were performed to determine the initial protein 
concentration for each batch of hGal-7 purified. Automated crystallisation 
screens of hGal-7 in complex with dendrons were then set up as described in 
Section 3.6.2. For this purpose, hGal-7 (at a concentration of 10 mg/mL) was 
pre-incubated at room temperature with the dendron, at protein to dendron 
ratios of 1:1, 1:2 and 1:3. Different conditions gave crystallisation hits for hGal-7 
in complex with the dendremeric molecules. As discussed in Section 3.6.2, the 
crystallisation screens normally vary in buffer type and pH, salt type and 
concentration, as well as precipitant type and concentration. The conditions 
were then optimised by setting up sparse matrix screens around the conditions 
in which hits were observed. Temperature, protein concentration and various 
crystallisation techniques are also known to effect crystal growth. The manual 
optimisation techniques have been previously discussed in Section 3.6.2 and 
further specific details have been discussed in the results in Section 4.3.2.  
4.2.4. Data collection and structure determination 
Data were collected at the Diamond Light Source (Oxford, U.K.) on beam-lines 
I04, I04-1 and I03 which were equipped with a Pilatus 6M detector, Pilatus 1.2M 
detector and Pilatus 6M detector respectively.  
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The data were processed using either MOSFLM (Battye et al., 2011, Leslie, 2006) 
or XDS (Kabsch, 2010) followed by Xia2 (Winter, 2010) and scaled using 
AIMLESS (Evans and Murshudov, 2013). Initial phases were obtained by the 
molecular replacement method using PHASER (McCoy et al., 2007) with the co-
ordinates of hGal-7 (PDB: 1BKZ) (Leonidas et al., 1998). Crystallographic 
refinement was carried out using PHENIX (Adams et al., 2010). Model fitting 
was done using COOT (Emsley et al., 2010) version 0.7. The programme 
MOLPROBITY (Chen et al., 2010) was used for validation of the structure. 
Detailed statistics for the refined structure of hGal-7 complexes are given in 
tables 4.2 and 4.3. Figures were drawn with PYMOL (The PyMOL Molecular 
Graphics System, Version 1.5.0.4, Schrödinger, LLC). RMS calculations were 
performed using SUPERPOSE (Krissinel and Henrick, 2004). Ligand protein 
interactions were analysed using LIGPLOT+ (Laskowski and Swindells, 2011).  
The atomic co-ordinates and structure factors (codes 4UW3, 4UW4, 4UW5 and 
4UW6) have been deposited in the Protein Data Bank, Research Collaboratory 
for structural Bioinformatics, Rutgers University, New Brunswick, NJ 
(http://www.rcsb.org/). 
4.2.5. Isothermal titration calorimetry: 
Isothermal titration calorimetry (ITC) is a physical technique used to determine 
the thermodynamic parameters of interactions in solution. In this study ITC 
was employed ITC to determine binding affinity of dendrons to hGal-7.  
Principle of ITC 
Formation of unique spatial structures of biological macromolecules are in 
principle reversible, thermodynamically driven reactions. Thus, direct 
measurement of heat effects associated with intra- and inter-macromolecular 
processes can be performed using ITC. The reaction occurs in the sample pool 
whose temperature will be different from the reference pool, and this difference 
will be detected by an ITC instrument. Exothermic reaction activates negative 
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feedback of constant temperature power, while decalescence reaction activates 
positive feedback which can make the temperature constant. 
Experimental design 
Purified hGal-7 was dialysed overnight against 50 mM Na phosphate, 150 mM 
NaCl and 10 mM β-mercaptoethanol at 4 ºC. The dialysed protein was then 
concentrated to several concentrations (1 mg/mL, 2 mg/mL, 5 mg/mL) to 
optimise the concentration of protein required to perform ITC experiments. 
Dendrons (D1 and D2), D-galactose (GAL) and N-acetyl galactosamine 
(GALNAc), were dissolved into the dialysis buffer at varying concentrations (10 
mM, 20 mM, 25 mM). Both, the protein and ligand samples were degassed. The 
dendrons were placed in the injection syringe while the protein was placed in 
the nanocalorimeter cell of a Low Volume Nano ITC 60102 (TA Instruments). 
The complete reaction chamber was maintained at 15 ºC. 190 µL of the protein 
was titrated with the dendrons (15 injections of 3 µL at an interval of 180 s). 
Control experiments were performed by injecting dendrons in the buffer. 
Commercial GAL and GALNAc, prepared as in the same manner as the 
dendrons, were used as standards for binding affinity comparison. Data were 
fitted with NanoAnalyze software (TA Instruments) according to standard 
procedures. Fitted data yielded the stoichiometry (n), the dissociation constant 
(Kd), the association constant (Ka), the enthalpy of binding (ΔH) and entropy, ΔS. 
The changes in free energy, ΔG) were calculated from the equation ΔG = ΔH – 
TΔS, where T is the absolute temperature. Two independent titrations were 
performed for each ligand tested.  
4.2.6. Dynamic light scattering  
Dynamic light scattering (DLS) is a technique used to determine the size 
distribution profile of proteins nucleic acids, and complexes, to detect the state 




Particles move in a solution by Brownian motion. Particles of different size 
move in solution at different speeds, the larger the molecule, the slower the 
movement in solution (Lorber et al., 2012). On exposure of the protein solution 
to monochromatic coherent laser, the particles in solution scatter a small 
fraction of the light. The intensity of this scattered light is recorded by the 
detector. Due to the Brownian motion of particles, the intensity of scattered 
light detected fluctuates with a constant change in distances between particles. 
This constant movement of particles causes the scattered light to undergo either 
constructive or destructive interference. The measured intensity fluctuations 
provides information about how fast the particles move in solution from which 
its size can be predicted. For example, smaller particles have higher intensity 
fluctuations than larger particles as they move faster in solution.  
The size of the particle in solution (RH) is calculated using the Stokes-Einstein 
equation. 
 
The Zetasizer software autocorrelates the intensities of the scattered light for the 
duration of the experiment. The time autocorrelation function of scattered light 
is used to determine the distribution of size across a molecule.  
Experimental details 
The final purified hGal-7 (0.5 mg/mL) was used for DLS measurements. Prior 
to adding dendrimers, the protein was filtered with 0.22 µm Millipore Millex ® 
(EMD Millipore, MA, USA) filter units to eliminate dust interferences. 
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Dendrons were prepared by dissolving in the final buffer used for hGal-7. The 
protein, hGal-7 was pre-incubated with the dendrons for 4 h at room 
temperature at varying protein: ligand ratios of 6:1, 3:1 and 1:2. The readings 
were taken in triplicate. DLS measurements were acquired with Zetasizer Nano 
S (Malvern Instruments, U.K.) which uses a 4 mW He-Ne laser with wavelength 
(λ0) = 633 nm, and a scattering angle of 173º. A low volume 12 µL quartz cuvette 
(QS 3.00 mm) was equilibrated by rinsing with the final buffer. 50 µL of the 
sample was loaded into the cuvette and the external surfaces of the cuvette 
were wiped with soft lens cleaning tissue to ensure no particles were present 
that could lead to false reading. The cuvette was placed in the sample holder 
and allowed to equilibrate to 16 ºC for 10 min. A series of three scans were 
performed and subsequent intensity fluctuations were recorded which contain 
information about the time scale movement of the scattering particles. 




4.3. Results  
4.3.1. Cloning, expression and purification of hGal-7 
hGal-7 was expressed in E. coli BL21 (DE3) cells and purified using IMAC 
[Figure 4.3] followed by size exclusion chromatography [Figure 4.4]. The 16 kDa 
purified protein [Figure 4.5] was then used to set up crystallisation screens in 
complex with the multivalent dendrons and for isothermal calorimetry 
experiments to study the binding affinity of hGal-7 to the dendrons.  
 
Figure 4. 3: hGal-7 purification step 1. 
Example chromatogram of IMAC utilising the HisTrap FF column for 
purification of His-tagged hGal-7. Blue line represents the absorbance at A280 




Figure 4. 4: hGal-7 purification step 2.  
Example chromatogram of purification of hGal-7 by SEC using superdex 200 
column. Blue line represents the absorbance at A280. 
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Figure 4. 5: Example of hGal-7 purification analysed by SDS-PAGE. 
hGAl-7 purification analysed by SDS-PAGE using IMAC (lane 2) followed by 
SEC (lanes 3-8). The final purified sample is shown in lane 9. The molecular 
weights of the SDS-PAGE marker (M) are labelled. 
 
4.3.2. Crystallisation of hGal-7 with dendrimers  
Several crystallisation hits were observed for preliminary crystallisation 
screening of hGal-7 in complex with the dendremeric molecules. Of the 12 
commercial screens, PACT premier HT-96, JCSG-plus HT-96, Morpheus HT-96 
and PGA Screen HT-96 gave the most number of hits.  
hGal-7 in complex with dendrons yielded crystallisation hits within 4 - 7 days 
of set up. The crystals were either small needles or microcrystalline powder 
which required further optimisation trials. It was observed that a protein to 
dendron ratio of 3:1 and an incubation temperature of 16 ºC was favourable for 
crystal growth. Two different morphologies of the crystals for hGal-7 in 
complex with D2 were observed. They were either needle like crystals or small 
rod-like crystals.  
It was also observed that poly(ethylene glycol) 3350 (PEG 3350) and BisTris 
propane pH 7 yielded more crystals than other conditions. To optimise the 
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protein concentration required for crystallisation, PACT premier HT-96 and 
JCSG-plus HT-96 screens were set up using the robot. Using these screens, 
protein concentration optimisation trials were set up with a protein 
concentration of 12mg/mL, 10 mg/mL, 8 mg/mL, 6 mg/mL and 4 mg/mL. 
The hits obtained from these screens were then used to set up manual 
optimisation trials. To reduce the rate of equilibration and to slow down the 
process of crystallisation, paraffin oil and silicone oil were added to the 
reservoir prior to sealing. This helped yield larger crystals that were suitable for 
X-ray data collection. The final conditions for crystallisation of hGal-7 in 
complex with the D1, D2 and D3 for which x-ray diffraction data were collected 
are listed below.  
hGal-7 in complex with D1 was crystallised in 0.05 M BisTris Propane (pH 7), 
and 17% [w/v] PEG 3350, at a protein concentration of 12 mg/mL and protein 
to ligand ratio of 3:1. Paraffin oil was used to slow down the rate of 
equilibration. 
hGal-7 in complex with D2 crystallised in two different conditions. Crystal 
form, D2-1 crystallised in 0.05 M BisTris Propane (pH 7), and 17% [w/v] PEG 
3350, at a protein concentration of 12 mg/mL and protein to ligand ratio of 3:1. 
Crystal form, D2-2 crystallised in 0.05 M BisTris Propane (pH 7), and 14% [w/v] 
PEG 3350, at a protein concentration of 10 mg/mL and protein to ligand ratio of 
3:1. Paraffin oil was used for D2-2 to slow down the rate of equilibration. 
hGal-7 in complex with D3 was crystallised in 0.05 M BisTris Propane (pH 7), 
and 17% [w/v] PEG 3350, at a protein concentration of 6 mg/mL and protein to 
ligand ratio of 3:1. Paraffin oil was used to slow down the rate of equilibration.  
Despite varying various conditions for crystallisation of hGal-7 in complex with 
dendrons D4, D5 and D6, no diffractable crystals were observed. 
Figure 4.11, 4.12, 4.13 and 4.14 show the crystals shot for data collection at the 
Diamond Light Source (DLS). 
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Figure 4. 6: Examples of initial hits observed for hGal-7 in complex with 
dendrons D1 and D3 
(A-B) hGal-7 in complex with D1. (C-D) hGal-7 in complex with D3. Conditions: 
(A) C3 of JCSG-plus HT-96, (B) E6 of PACT premier HT-96, (C) F7 of PACT 




Figure 4. 7: Examples of initial hits observed for hGal-7 in complex with D2  
(A-B) Crystal morphology 1 (C-D) Crystal morphology 2. Conditions: (A) C3 of 
JCSG-plus HT-96, (B) A8 of JCSG-plus HT-96, (C) G3 of PACT premier HT-96 (D) 




Figure 4. 8: Examples of initial hits observed. hGal-7 in complex with (A) D4 
(B) D5 and (C) D6 with different morphology.  
Conditions: (A) G3 of PACT premier HT-96, (B) G4 of PACT premier HT-96, (C) 





Figure 4. 9: Example of optimisation hits for hGal-7 in complex with D1.  




Figure 4. 10: Examples of optimisation hits for hGal-7 in complex with D2.  
(A) morphology 1 observed under polarised light (B) Crystal morphology 1 
observed under white light (C) Crystal morphology 2–no biorefringence 
observed.   
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4.3.3. Crystallographic results for hGal-7 in complex dendrimers. 
Of the numerous crystals taken for data collection to the synchrotron, only a 
few diffracted to high resolution (>2.5Å). On processing these data sets, the 
structures revealed that on many occasions the proteins crystallised in their 
native form with no dendrimer bound at the CRD. 
However, four datasets were collected for dendron bound hGal-7. 
A complete dataset for hGal-7 in complex with D1 to 1.48 Å were collected on 
beam-line I04 from a crystal in the space group P212121 with unit cell 
dimensions a = 30.4, b = 65.3, c = 114.1 Å and two molecules per asymmetric 
unit [Figure 4.11].  
Data were collected from two forms of hGal-7 in complex with D2 in the space 
group P212121. The first crystal form (D2-1) was collected on beam-line I04 to 
1.86 Å with unit cell dimensions a = 38.91, b = 58.42, c = 114.84 Å and two 
molecules in the asymmetric unit [Figure 4.11]. The second crystal form (D2-2) 
was collected on the beam-line I03 to 2.0 Å with unit cell dimensions a = 63.4, b 
= 115.65, c = 116.25Å and six molecules per asymmetric unit [Figure 4.11].  
Data from the co-crystal of hGal-7 in complex with D3 was collected on the 
beam-line I04-1 to 1.79 Å in the space group C2 with unit cell dimensions a = 
58.93, b = 53.38, c = 89.21 Å, and β=102.8o, and two molecules in the asymmetric 
unit [Figure 4.11].  
Table 4.2 gives details of the data collection and refinement statistics. Figure 
4.12 shows the representative electron density of hGal-7 in complex with the 





Figure 4. 11: Crystals and X-ray diffraction of hGal-7 in complex with 
dendrons. 
(A) Example of the diffraction image collected at DLS beam-line I04 where the 
crystals of hGal-7 in complex with D1 diffracted to 1.48. Å. (B-E) Crystals 
mounted in a loop for data collection. (B) hGal-7 in complex with D1, (C) hGal-7 
in complex with D2-1, (D) hGal-7 in complex with D2-2 and (E) hGal-7 in 
complex with D2-3. 
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Table 4. 2: X-ray data collection and refinement statistics for hGal-7 in 
complex with D1 and D2-1. 
 hGal-7 – D1 hGal-7– D2-1 
Data Collection Statistics 
Space group P212121 P212121 
Number of molecules 
/ asymmetric unit 
2 2 
Cell dimensions 
a = 30.4, b = 65.4, 
c = 114.1 Å 
a = 39, b = 58.5, 
c = 115.9 Å 
Resolution range 
(outer shell), Å 
29.38 – 1.48 
(1.56 – 1.48) 
57.5 – 1.77 
(1.83 – 1.77) 
Rsymma (outer shell), % 7.5 (48.6) 5.3 (7.5) 
I/σI (outer shell) 16.5 (4.3) 17.0 (9.5) 
Completeness  
(outer shell), % 
99.8 (98.34) 96.6 (91.5) 
Redundancy  
(outer shell) 
8.4 (6.9) 3.4 (2.4) 
Total number of reflections 328115 87011 
Unique no. of reflections 38926 25666 
Wilson B-factor (Å2) 13.59 12.72 
Refinement Statistics 
Rcrystb (%) 17.6 18.2 
Rfreec (%) 19.8 23.6 




























Bond length (Å) 



















RCSB PDB Code 4UW3 4UW4 
a Rsymm = ΣhΣi|I(h) − Ii(h)|/ΣhΣiIi(h), where Ii(h) and I(h) are the ith reflection and the 
mean measurements of the intensity of reflection h, 
respectively. b Rcryst = Σh|Fo − Fc|/ΣhFo where Fo and Fc are the observed and 
calculated structure factor amplitudes of reflection h, respectively. c Rfree is equal 
to Rcryst for a randomly selected subset of reflections not used in the refinement.  
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Table 4. 3: X-ray data collection and refinement statistics for hGal-7 in 
complex with D2-2 and D3. 
 hGal-7– D2-2 hGal-7–D3 
Data Collection Statistics 
Space group P212121 C2 
Number of molecules 
/ asymmetric unit 
6 2 
Cell dimensions 
a = 63.4, b = 115.6,  
c = 116.2 Å 
a = 58.9, b = 53.4,  
c = 89.2 Å and =102.9o 
Resolution range 
(outer shell), Å 
55.69 – 2.04 
(2.11 – 2.04) 
45.49 – 1.79 
(1.85 – 1.79) 
Rsymma (outer shell), % 7.3 (59.8) 5.6 (20.9) 
I/σI (outer shell) 9.1 (2.1) 8.2 (3.4) 
Completeness  
(outer shell), % 
98.7 (99.3) 95.2 (91.5) 
Redundancy  
(outer shell) 
3.3 (3.3) 2.6 (2.5) 
Total number of reflections 178525 62672 
Unique no. of reflections 54509 24387 
Wilson B-factor (Å2) 32.06 17.93 
Refinement Statistics 
Rcrystb (%) 23.6 20.0 
Rfreec (%) 31.5 25.1 




























Bond length (Å) 



















RCSB PDB Code 4UW5 4UW6 
a Rsymm = ΣhΣi|I(h) − Ii(h)|/ΣhΣiIi(h), where Ii(h) and I(h) are the ith reflection and the 
mean measurements of the intensity of reflection h, 
respectively. b Rcryst = Σh|Fo − Fc|/ΣhFo where Fo and Fc are the observed and 
calculated structure factor amplitudes of reflection h, respectively. c Rfree is equal 
to Rcryst for a randomly selected subset of reflections not used in the refinement. 
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Figure 4. 12: Representative electron densities of hGal-7 in complex with 
dendrons. 
 The CRD is formed by residues of the β- sheets (C1-C5) and the adjoining loop 
residues. Residues are shown as sticks and the electron density maps contoured 




4.3.2.1. Overall structure of hGal-7 
The crystal structure of hGal-7 in complex with dendrons D1, D2 (in two crystal 
forms -1 and -2), and D3 were determined at 1.48, 1.86, 2.00 and 1.79 Å 
resolution, respectively. The overall structure of hGal-7 [Figure 4.13] remains 
unchanged upon ligand binding and appears as a dimer comparable to that 
previously described (Leonidas et al., 1998). The ‘jelly-roll’ fold of galectin is 
completely observed in the electron density maps except for residues 1-3 at the 
N-terminal end.  
Various parts of the carbohydrate ligands are visible in all of the structures with 
a common feature being at least one galactose moiety of each ligand bound at 
the CRD. Interaction between the protein and ligand resulted in cross-linking of 
hGal-7 thus forming a continuous sequence of ‘dimer–ligand–dimer’ repeats, 
with binding of the ligand also impacting on the hGal-7 dimeric interface.  
The characteristic Π-Π stacking interaction between W69 and the terminal 
galactosyl ring is observed in the hGal-7 complex structure. The dendron 
binding is strengthened by additional hydrogen bonds and non-bonded 
interactions between various parts of the dendron and the CRD. Water 
molecules strengthen ligand binding through water mediated interactions. 
Ligand binding at the CRD also has a long range effect on the dimerisation 
interface. All these interactions have been discussed below.  
Due to the subtle differences in the mode of ligand binding and dimerisation in 
each complex, the resultant monomers adopt significantly different crystal-
packing contacts in each structure. This results in the formation of different 




Figure 4. 13: Cartoon structure of hGal-7. (A) hGal-7 monomer, (B) Superposition of hGal-7 complexes. 
(A) The β-strands forming the jelly-roll fold of hGal-7 have been labelled. (B) The structures of hGal-7 in complex with D1(light pink), 
D2-1(violet), D2-2(green), D3(light orange) and galactose (cyan) are superposed using the C atoms of Chain A (monomer on the right).  
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4.3.2.2. Dimeric Interface  
The dimeric interface is based on the -strand (B1-B5 interaction) [Figure 4.13] 
of two monomeric hGal-7 molecules and has been described extensively for the 
native structure (Leonidas et al., 1998). The two monomers are associated by a 
two-fold rotational symmetry axis forming an extended -sheet. Ligand binding 
does not appear to disrupt the dimeric state of hGal-7 but slightly alters the 
interface of dimerisation. PISA analysis (Krissinel and Henrick, 2007) of this 
dimeric interface shows ~795 Å2 interface area in the native structure (PDB: 
3ZXF) (Masuyer et al., 2012) associated with 14 hydrogen bonds and 21 salt 
bridges. 
Ligand binding at the CRD results in a long range impact at the dimeric 
interface which has been analysed by calculating the RMS deviation for the 
main chain, C and the side chains of the A and B chains of hGal7 in complex 
with each ligand with respect to the native hGal-7 chain A [Table 4.4]. Chain B 
in each complex shows a higher RMS deviation for the main chain and Cα 
atoms than chain A. However the RMS deviation for the side chains is 
comparably higher for chains A and B. Table 4.5 shows a comparison of the 
RMS deviation of the side chains involved in the dimerisation of hGal7 in each 
complex. Figure 4.14 shows the dimerisation surface of hGal-7 and Figure 4.15 
shows the residues involved in the dimerisation of hGal-7. 
Table 4. 4: RMS deviations for chains A and B in the complexes with respect 















Main Chain - 
Chain A 0.54 0.74 0.60 0.44 0.63 
Chain B 0.77 0.82 1.10 1.07 1.15 
C - 
Chain A 0.50 0.75 058 0.44 0.53 
Chain B 0.79 0.82 1.11 1.07 1.13 
Side Chain - 
Chain A 1.18 1.61 1.48 1.47 1.65 
Chain B 1.66 1.66 1.90 1.90 1.87 
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Residue Chain A Chain B Chain A Chain B Chain A Chain B Chain A Chain B Chain A Chain B 
R14 1.21 2.59 3.53 4.36 2.64 2.00 1.94 2.26 1.55 2.88 
T17 0.33 0.28 0.51 0.20 0.51 0.48 0.79 0.51 0.56 0.28 
R20 0.47 1.46 1.45 0.53 0.51 0.62 2.17 1.55 2.21 1.60 
R22 0.53 1.33 0.39 1.39 0.30 1.63 0.65 1.87 0.36 1.25 
E87 0.46 1.53 0.50 0.86 0.36 1.61 0.64 1.61 0.41 1.57 
S93 1.93 0.26 0.23 0.54 0.07 0.32 0.41 1.12 0.23 0.60 
D94 0.86 0.59 0.46 3.02 2.92 0.39 2.96 1.25 0.33 2.35 
D95 2.55 0.98 1.60 0.46 1.01 1.46 1.45 1.28 2.58 1.27 
K98 0.61 1.02 2.01 0.81 0.88 1.08 0.92 1.49 0.58 0.86 





Figure 4. 14: Surface of the dimeric interface of hGal-7.  
A) Surface of the monomer that interacts with the second molecule of hGal-7 to 





Figure 4. 15: The dimeric interface of hGal-7 in the crystal structure.  
The structures of hGal-7 in complex with D1 (light pink), D2-1 (violet), D2-2 
(smudge), D3 (light orange) and galactose (cyan) are superposed using the C 
atoms of Chain A. The inset highlights the residues (shown as sticks) that are 
involved in hydrogen bond formation at the dimeric interface. 
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PISA analysis of the hGal-7 dimer in complex with D1 shows a dimeric interface 
of 758 Å2 associated with 13 hydrogen bonds and 14 salt bridges (Krissinel and 
Henrick, 2007). The hydrogen bonds between residues R14-D95, R20-D103 and 
D103-R133, which are observed in the native hGal-7 structures, dissociate in this 
complex and additional bonds between residues R22-D103 and R14-S93 are 
formed [Table 4.6]. Salt bridges between R14-D95, R20-D103, and D103-R133 
dissociate while an additional salt bridge between R22–D103 is observed [Table 
4.7]. 
hGal-7 in complex with D2-1 shows a dimeric interface of 774 Å2 associated 
with 17 hydrogen bonds and 16 salt bridges on PISA analysis (Krissinel and 
Henrick, 2007). As compared to the dimeric interface of the native dimer, most 
hydrogen bonds are retained in this the hGal-7 complex with D2-1, with the 
exception of those between R14-D95 and D103-R133 [Table 4.6]. The salt bridges 
between R20-E87 and R133-D103 that are observed in the native hGal-7 
structure, dissociate at the dimeric interface in this complex [Table 4.7]. 
However, an overall decrease in the bond distance between residues forming 
the non-bonded contacts at the dimeric interface is observed.  
hGal-7 in complex with D2-2 shows a dimeric interface of 772 Å2 associated 
with 16 hydrogen bonds and 20 salt bridges. As compared to native hGal-7, 
additional hydrogen bonds between R14-D94, R22-E87 and D103-R133 are 
formed in this complex [Table 4.6]. Further, the non-bonded contacts between 
D103-R133 dissociate, while between R14-D94 they are formed [Table 4.7]. 
The crystal structure of hGal-7 in complex with D3 shows a dimeric interface of 
766 Å2 associated with 15 hydrogen bonds and 16 salt bridges. Hydrogen bonds 
at the dimeric interface between R22-D103 and R14-D94 are formed additional 
to those observed in the native structure [Table 4.6]. It is also observed that the 
hydrogen bonds between R14-D95, R22-E87 and R133-D103 dissociate in the 
structure of this complex. The non-bonded contacts at the dimeric interface 
between R14-D95, R20-E87, R20-D103, R22-E87 and R133-D103 dissociate in this 
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structure and additional hydrogen bonds between R14-D94 and R22-D103 are 
formed [Table 4.7]. 
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Table 4. 6: Hydrogen bond distances between residues forming the dimeric interface in the complexes of hGal-7 with the dendrons.  
All contacts shorter than 3.3 Å are listed. 
 Distances (Å) 
Residue(A) Residue (B) hGal-7-D1 hGal-7-D2-1 hGal-7-D2-2 hGal-7-D3 Native hGal-7 
S93 – OG R14 – NH2 3.2 - - - - 
D94 – OD2 R14 – NH2 - - 2.2 - - 
D95 – OD1 R14 – NH2 - - 2.9 - - 
G102 – O R20 – NH2 2.8 2.8 3.1 2.9 3.1 
D103 – OD1 R20 – NH2 - - 3.0 - 2.7 
E87 – OE1 R22 – NH2 2.8 2.5 2.5 - - 
D103 – OD1 R22 – NH1 2.7 - - 2.2 - 
R20 – NH1 E87 – OE2 3.0 - - - - 
R22 – NH2 E87 – OE1 3.3 2.7 2.8 - 3.4 
R14 – NH1 D94 – OD2 - 3.3 - 2.7 - 
R14 – NH2 D95 – OD1 - - - - 2.3 
F135 – O K98 – NZ 3.3 - - 3.1 2.9 
F135 – OXT K98 – NZ - 2.8 - 2.6 - 
R20 – NH2 G102 – O 2.7 - 3.2 2.8 3.0 
R20 – NH2 D103 – OD1 - 2.7 - 2.9 2.8 
R22 – NH1 D103 – OD1 3.2 - - 2.5 - 
R133 – NE D103 – O 2.9 2.8 - - - 
R133 – NH1 D103 – O - - 2.7 - - 
D103 – O R133 – NH1 - - - - 2.7 
D103 - OD2 R133 – NH2 - - - - 2.9 
D103 – O R133 – NE - 3.0 2.8 - - 
K98 – NZ F135 – O - - - 2.9 - 
K98 – NZ F135 – OXT - 2.9 3.1 2.9 2.8 
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Table 4. 7: Distances between the residues involved in the formation of salt bridges at the dimeric interface.  
Contact distances with the maximum allowed values of C-C, 4.1 Å ; C-N, 3.8 Å, C-O, 3.7 Å; O-O, 3.3 Å; O-N, 3.4 Å; and N-N, 3.4 Å are 
listed. 
 Distances (Å) 
Residue(A) Residue (B) hGal-7-D1 hGal-7-D2-1 hGal-7-D2-2 hGal-7-D3 Native hGal-7 
D94 – OD2 R14 – NE - - 3.2 - - 
D94 – OD2 R14 – NH2 - - 2.2 - - 
D95 – OD1 R14 – NH2 - - 2.9 - - 
E87 – OE1 R20 – NH1 - - - - 3.4 
D103 – OD1 R20 – NH2 - - 3.0  2.7 
E87 – OE1 R22 – NH2 2.8 2.5 2.5 - - 
E87 – OE2 R22 – NH2 - - 3.1 - - 
D103 – OD1 R22 – NH2 - - - 3.8 - 
D103 – OD1 R22 – NH1 2.7 - - 2.2 - 
R20 – NH1 E87 – OE2 3.0 - 3.3 - - 
R22 – NH2 E87 – OE1 3.3 2.7 2.8 - - 
R22 – NH2 E87 – OE2 - 3.3 - - 3.4 
R14 – NH1 D94 – OD2 - - - 2.7 - 
R14 – NH1 D95 – OD1 - 3.3 - - - 
R14 – NH2 D95 – OD2 - - - - 2.3 
F135 – O K98 – NZ 3.3 - - 3.1 2.9 
F135 – OXT K98 – NZ - 2.8 - 2.6 - 
R20 – NH1 D103 – OD1 - - - - 3.7 
R20 – NH2 D103 – OD1 - 2.7 - 2.9 2.8 
R22 – NH1 D103 – OD1 3.2 - - 2.5 - 
R133 – NH2 D103 – OD2 - - - 3.3 - 
D103 – OD2 R133 – NH2 - - - - 2.9 
K98 – NZ F135 – O - 3.4 3.4 2.9 - 
K98 – NZ F135 – OXT - 2.9 3.1 2.9 2.8 
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4.3.2.3. Complex formation of hGal-7 with dendrons: 
The CRD is highly conserved in hGal-7 (Leonidas et al., 1998) and consists of 
residues H49, N51, R53, N62, W69, E72 and R74 on C4, C5 and the adjoining 
loop regions, which form a concave surface on the exposed surfaces of the 
dimer. The characteristic Π-Π stacking interaction of the galactosyl group with 
W69 is observed in all complexes. Additional hydrogen bonds and non-bonded 
contacts between the galactosyl termini of the dendrons and the residues at the 
CRD are also observed. Water molecules play an important role in the binding 
of dendrons to hGal-7 at the CRD. In addition to direct hydrogen bonding 
between the residues at the CRD and the ligands, a number of water molecules 
facilitate these interactions. 
The electron density omit maps for the ligands in each complex are presented in 
figure 4.16. Electron density for two of the three arms for D1, two of the three 
arms for D2 (D2-1), all three arms of D2 (D2-2) and four of the six arms for D3 
are observed in their respective complex structures with hGal-7.  
 The superposition of the terminal galactosyl ring of each of the dendrons with 
galactose is presented in figure 4.17. With the varying size, length and flexibility 
of the dendrons, the spatial orientation of the ligands in each complex is 
different. A comparison of this change in orientation is presented in figure 4.17.  
Table 4.8 and 4.9 give details of the hydrogen bonds and non-bonded contacts 




Figure 4. 16: Omit maps for hGal-7 in complex with dendrons.  
(A) hGal-7 in complex with D1 (B) hGal-7 in complex with D2-1 (C) hGal-7 in complex with D2-2 and (D) hGal-7 in complex with D3. The 
omit maps are contoured at 1σ. Residues involved in the recognition and binding of the ligands are shown as sticks. 
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Figure 4. 17: CRD for hGal-7 in complex with dendrons. 
(A) Superpose of hGal-7 in complex with D1 (light pink), D2-1 (pale cyan), D2-2 
(smudge), D3 (light orange) and GAL (cyan). (B-E) All complex structures are 
shown in a similar spacial orientation. hGal-7 in complex with (B) D1 (C) D2-1 
(D) D2-2 (E-1 and E-2) D3.E-1 and E-2 are symmetry related ligands bound to 
two different CRDs of the dimer. Residues involved in the recognition and 
binding of the ligands are shown as sticks. Water molecules that contribute to 
the bonding are shown as spheres. 
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Table 4. 8: Hydrogen bond distances between the ligand atoms and the atoms 
of the residues at the CRD in the complex structures. 












OED - OG S30 - - - 3.3 - 
O8 – NE2 H49 2.7 - - - - 
O4 – NE2 H49 - - - 2.9 - 
OCV – NE2 H49 - - 2.9 - - 
OW3 – NE2 H49 2.7 2.9 2.8 2.9 2.7 
OW1 – NH2 R53 2.9 3.0 3.1 3.1 - 
OW2 – NH2 R53 3.0 - - - - 
OW3 – NH2 R53 2.9 2.9 2.9 2.9 3.2 
OX4 – NH2 R53 - 3.0 2.9 - - 
OX4 – NH1 R53 - 2.9 2.6 - - 
O8 – NH2 R53 2.9 - - - - 
O5 – NH2 R53 3.0 - - 2.9 - 
OCV – NH2 R53 - - 2.8 - - 
OCM – NH2 R53 - - 3.1 - - 
ODG – NH2 R53 - - 3.2 - - 
ODC – NH1 R53 - - 2.4 - - 
O4 – NH2 R53 - - - 2.9 - 
OCU – ND2 N62 - - 2.8 - - 
O12 – ND2 N62 3.0 - - - - 
OW2 – ND2 N62 - 2.9 2.8 3.1 2.6 
O6 – ND2 N62 - - - 2.9 - 
OCF – NH2 R71 - - 3.2 - - 
OCF – NE R71 - - 3.1 - - 
ODG – NH1 R71 - - - 3.1 - 
OZ3 – N E72 - - - 3.2 - 
OX3 – NH2 R74 - 3.2 - - - 
ODH – NH2 R74 - - 3.2 - - 
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Table 4. 9: Distances between the atoms of the residues at the CRD forming 
non-bonded interactions with the ligand in the complexes. 
Contact distances with the maximum allowed values of C-C, 4.1 Å ; C-N, 3.8 Å, 











 - GAL 
CAS - CB S30 - - - 3.8 - 
OED - CB S30 - - - 3.6 - 
CEV - NH2 R31 - - - 3.4 - 
CEV - CZ R31 - - - 3.5 - 
CBO - CZ R31 - - - 3.8 - 
CEV - NE R31 - - - 3.8 - 
CBO - NE R31 - - - 3.8 - 
CAT - CD R31 - - - 3.8 - 
CAC - CD R31 - - - 3.9 - 
OAU - CD R31 - - - 3.2 - 
CAC - CG R31 - - - 3.6 - 
OAU - CG R21 - - - 3.4 - 
CW3 – CD2 H49 3.9 - - - 3.8 
CW3 – NE2 H49 - 3.5 3.3 3.7 3.3 
CW1 – CD2 H49 - 3.8 3.8 3.7 3.6 
OW3 – CD2 H49 3.5 - 3.6 3.4 3.5 
OW3 – CE1 H49 3.7 - - - - 
OW3 – NE2 H49 3.3 - - - - 
NX6 – CZ R53 3.4 - - - - 
CX4 – NH1 R53 - 3.7 - - - 
OX4 – CZ R53 - 3.4 3.2 - - 
CW2 – NH2 R53 3.7 3.8 - - - 
CW1 – NH2 R53 3.7 - - - - 
CW5 – NH2 R53 - 3.7 3.8 - - 
CW6 – NH2 R53 3.7 3.6 3.7 - - 
CEV - OD2 D55 - - - 3.2 - 
CAT - OD2 D55 - - - 3.6 - 
OW2 – CG N62 - - - - 3.5 
OW2 – CB N62 - - - - 3.6 
CW1 – ND2 N62 - - 3.7 - 3.7 
CW1 – CB N62 - - 3.9 - - 
CL1 – O G67 - - - 3.2 - 
CL1 – CA S68 - - - 3.6 - 
CL3 – CA S68 - - - 3.8 - 
CL3 – CB S68 - - - 3.5 - 
OL3 – CB S68 - - - 3.6 - 
CW1 – CD2 W69 - 3.9 - 3.9 - 
CW2 – CD2 W69 3.8 - 3.8 3.8 - 
CW2 – CE2 W69 3.7 - 3.7 3.7 - 
CW3 – CE2 W69 3.7 - 3.7 3.8 - 
CW3 – CZ2 W69 3.6 - 3.6 3.7 3.8 
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CW4 – CZ2 W69 - - 3.7 - - 
CW4 – CE2 W69 - - 3.8 - - 
CM9 – CB W69 - - - 3.7 - 
OL1 – CD1 W69 - - - 3.5 - 
CW3 – CH2 W69 - - - - 3.9 
CW3 – CZ2 W69 - - - - 3.8 
CW1 – CE3 W69 - - - - 3.9 
CL1 – CD1 W69 - - - 3.8 - 
CCP - CZ2 W69 - 3.8 - - - 
CCO - CZ2 W69 - 3.7 - - - 
CCP - CE2 W69 - 3.9 - - - 
CCO - CE2 W69 - 3.7 - - - 
CCN - CE2 W69 - 3.7 - - - 
CN2 – O G70 - - - 3.6 - 
CB2 – O G70 - - - 3.5 - 
OZ3 – CD R71 - - - 3.4 - 
ODG – CD R71 - - - 3.2 - 
CA3 – CZ R71 - - - 3.8 - 
CA3 – NH1 R71 - - - 3.2 - 
CZ1 – NH1 R71 - - - 3.4 - 
CZ3 – NH1 R71 - - - 3.0 - 
CDF – NH1 R71 - - - 3.6 - 
CBY - NH2 R71 - - 3.8 - - 
OW2 – CG E72 3.4 3.3 3.1 3.4 3.2 
OW2 – CD E72 3.4 3.4 3.2 3.3 3.5 
CW1 – OE2 E72 - 3.6 3.5 - 3.7 
CW8 – OE2 E72 - 3.6 - - - 
CX4 – OE2 E72 - 3.3 3.1 - - 
CX3 – OE2 E72 - 3.6 - - - 
CX3 – OE1 E72 - 3.6 - - - 
OX4 – CD E72 - 3.2 - - - 
CY6 – OE1 E72 - - - 3.6 - 
CZ2 – OE1 E72 - - - 3.7 - 
CA3 – CB E72 - - - 3.7 - 
CDU – NH2 R74 - - - 3.6 - 
CY9 – NH1 R74 - - - 3.7 - 
CY8 – NH1 R74 - - - 3.5 - 
CY7 – NH1 R74 - - - 3.3 - 
CY7 – CZ R74 - - - 3.9 - 
CAS - OD2 D126 - - - 3.0 - 
CAS - OD1 D126 - - - 3.5 - 




The terminal monosaccharide (galactosyl ring) of D1 forms Π-Π stacking 
interactions with W69. Three hydrogen bonds between R53 and OW1, OW2 and 
OW3 of D1 and a hydrogen bond between H49 and OW3 of D1 contribute to 
the binding of the galactosyl ring [Table 4.8]. Residues N51 and R31 interact 
with OW4 and NX7 of D1, respectively, through water molecules [Figure 4.17B, 
4.18]. Non-bonded contacts between H49, R53, W69 and E72 with D1 are also 
observed [Table 4.9]. No significant changes in the ligand binding are observed 
between chain A and chain B of the hGal-7 dimer [Figure 4.18].  
 
Figure 4. 18: CRD of hGal-7 in complex with D1.  
Hydrogen bond interactions with both the chains of the dimer are shown. D1 is 
shown as sticks in light pink. Water molecules are shown as grey spheres. 
Distances are given in Å. 
 
The terminal monosaccharide (galactosyl ring) of D2 forms Π-Π stacking 
interactions with W69 and hydrogen bonds with other amino acids of the CRD. 
Additional hydrogen bonds and other non-bonded contacts between the 
penultimate galactosyl ring and the CRD strengthens dendrimer recognition 
and interaction with hGal-7.  
In the first crystal form, D2-1, residues H49, R53, N62 and R74 are involved in 
hydrogen bonding with the ligand [Table 4.8]. Most of these bonds are 
observed in the second crystal form, in addition to interaction with R71 [Table 
4.8]. Both crystal forms show non-bonded interactions between residues H49, 
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R53, W69 and E72 with the ligands [Table 4.9]. In addition to this, hGal-7 in 
complex with D2-2 interacts with N62 and R71 through non-bonded contacts. 
The interactions between the ligand and residues N51, R31, W69 that are 
mediated through a water molecule are observed in both crystal forms [Fig. 
4.17C, 4.17D, 4.19, 4.20].  
In hGal-7 complexed with D2-1, the hydrogen bond observed between D2-1 
and N51 at the CRD of chain A is not observed at the CRD of chain B [Figure 
4.22]. This could be due to subtle changes at the CRD observed in both the 
chains. No significant changes in the ligand binding are observed between 
chain A and chain B of the hGal-7 dimer [Figure 4.23]. 
 
Figure 4. 19: CRD of hGal-7 in complex with D2-1.  
Hydrogen bond interactions with both the chains of the dimer are shown. D2-1 
is shown as sticks in pale blue and water molecules shown are as grey spheres. 
Distances are given in Å. 
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Figure 4. 20: CRD of hGal-7 in complex with D2-2.  
Hydrogen bond interactions with both the chains of the dimer are shown. D2-2 
is shown as sticks in smudge and water molecules are shown as grey spheres. 
Distances are given in Å. 
 
The terminal galactosyl ring of D3 forms Π-Π stacking interactions with W69 
and hydrogen bonds with other amino acids of the CRD. In addition to the 
hydrogen bonds [Table 4.8] observed between the terminal galactosyl ring of 
the dendrons and the CRD residues (H49, R53, N62, R71), a hydrogen bond 
between OZ3 and OGD of the diamido phenyl group forming the core of D3, is 
also observed [Figure 4.21]. This interaction along with the other non-bonded 
contacts that have been listed in Table 4.9, contribute to strengthening the 
binding of D3 to hGal-7.  
In addition to the main arm of the ligand described above, a second arm with 
weak electron density was observed to interact with hGal-7 away from the 
CRD. This pseudo secondary binding site was slightly different between the 
two interacting hGal-7 dimers. With one of the partners, the ligand arm forms 
hydrogen bonds with S30 and non-bonded contacts bonds with S30, R31, D55 
and D126 of hGal-7, while the symmetry related molecule of the ligand forms 
non-bonded contacts with G67 and R74 of a second hGal-7 partner [Figure 4.22]. 
These interactions occur at a pseudo-secondary binding site. In both the 
molecules of the dimeric hGal-7, D3 interacts with the hydrophobic pockets and 
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thus enables a ‘tweezer-like’ clinging of the protein by the ligand [Figure 4.22]. 
Hydrogen bonds mediated through water molecules are observed between N51 
and R31 of hGal-7 and the ligand [Figures 4.17E-1, 4.17E-2, 4.22, 4.23]. 
 
Figure 4. 21: CRD of hGal-7 in complex with D3.  
OZ3 and ODG of the diamido phenyl group forming the core of the dendron 
D3 (shown as sticks in light orange), interacts with R71 of hGal-7. Water 




Figure 4. 22: CRD of hGal-7 in complex with D3. 
 H-bond interactions with both the chains of the dimer are shown. D3 is shown 
as sticks in light orange and water molecules are shown as grey spheres. 





Figure 4. 23: Secondary binding site of D3 with hGal-7.  
Two conformations of ligand binding are observed in the crystal structure of 
hGal-7 in complex with D3 (shown as sticks in pink and blue). The two arms of 
D3 bind to hydrophobic pockets of hGal-7 which results in ‘tweezer-like’ 
clinging of the protein by the ligand. hGal-7 is shown as surface and is coloured 
as per its hydrophobicity as described by Eisenberg et al. (1984) where red-
through-white indicates hydrophobicity-through-hydrophilicity. 
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4.3.2.4. Cross-linking by the dendron 
The recognition of dendrimeric compounds by hGal-7 results in cross-linking 
with the protein in each of the complexes described here. Complexes of hGal-7 
with D1, D2-1 and D3 result in the cross-linking of two molecules of hGal-7. 
Interestingly the crystal form of D2-2 in complex with hGal-7 reveals that the 
dendron links three protein molecules [Figures 4.24 - 4.27]. The dimer partner of 
these hGal-7 molecules binds to another dendron thus, the dendrimeric units in 
each of these supramolecular assemblies act as a bridge between hGal-7 
molecules.  
The similarities in the electron density observed for the ligands D1 and D2-1 are 
also reflected in the similarity in the crystal packing of hGal-7 in complex with 
D1 and D2-1 [Figure 4.28, 4.29]. However, the crystal packing of the complex 
structures show some distinct differences [Figure 4.28 - 4.31]. It is observed that 
the distance between W69 at the CRD of adjacent hGal-7 molecules connected 
by the dendron increases with an increase in the dendron size. In the crystal 
structures of the dendron complexes, where electron density for the dendron 
connecting two molecules of hGal-7 (D1, D2-1 and D3) was observed, the 
distance between W69 at the CRD of adjacent hGal-7 is 16.3, 9.6 and 20 Å, 
respectively. However, in the hGal-7 ˗ D2-2 structure, an increase in this 
distance to an average of 27.4 Å is observed. Thus the crystal packing in this 
crystal form provides sufficient volume for the ligand to bind to three different 




Figure 4. 24: Polymerisation forms of hGal-7 by D1.  
(A) Chemical structure of D1 (The flexible arm of the ligand for which electron density is not observed is coloured in yellow). (B) Cartoon 
representation of polymerisation oh hGal-7 by D1. (C) Ribbon diagram of the hGal-7 dimer with D1 shown as sticks and surface. 
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Figure 4. 25: Polymerisation forms of hGal-7 by D2-1. 
(A) Chemical structure of D2-1 (The flexible arm of the ligand for which electron density is not observed is coloured in yellow). (B) 




Figure 4. 26: Polymerisation forms of hGal-7 by D2-2.  
(A) Chemical structure of D2. (B) Cartoon representation of polymerisation of hGal-7 by D2-2. (C) Ribbon diagram of the hGal-7 dimer 
with D2-2 shown as sticks and surface. 
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Figure 4. 27: Polymerisation forms of hGal-7 by D3. 
(A) Chemical structure of D3 (The flexible arms of the ligand for which electron density is not observed is coloured in yellow). (B) 




Figure 4. 28: Crystal packing of hGal-7 in complex with D1. 
Molecules of the hGal-7 dimer are shown in red. Symmetry related molecules 





Figure 4. 29: Crystal packing of hGal-7 in complex with D2-1.  
Molecules of the hGal-7 dimer are shown in red. Symmetry related molecules 




Figure 4. 30: Crystal packing of hGal-7 in complex with D2-2.  
Molecules of the hGal-7 dimer are shown in red. Symmetry related molecules 





Figure 4. 31: Crystal packing of hGal-7 in complex with D3.  
Molecules of the hGal-7 dimer are shown in red. Symmetry related molecules 
are shown in cyan and D3 is shown as sticks in orange.  
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4.3.4. Isothermal titration calorimetry studies 
ITC studies were carried out to investigate the binding affinity of hGal-7 with 
the different dendrons used for crystallographic studies. A ligand concentration 
of 20 mM and a protein concentration of 5 mg/mL (0.33 mM) were determined 
as the optimum concentrations for the ITC experiments. Preliminary isothermal 
calorimetry data for D2 (Kd = 0.26 mM) interacting with hGal-7 gave an affinity 
constant several fold higher than that of GalNAc (Kd = 1.04 mM) and GAL (Kd = 
2.17 mM) while the affinity for D1 (Kd = 3.12 mM) is comparable to GalNAc GAL 
(Kd = 1.04 mM) [Table 4.10 and figures 4.32, 4.33].  
Table 4. 10: ITC data for GalNAc, GAL, D1 and D2 binding to hGal-7.  













































































β-Mercaptoethanol was used as a reducing agent in the buffer to ensure the 
presence of monomeric hGal-7 and to prevent its continuous cross-linking. 
However, the binding stoichiometry is ambiguous in this data [Table 4.10]. This 
could be due to the varying ratios of simple cross-linking of ‘n’ number of hGal-
7 molecules (where n = number of arms of the ligand) and continuous cross-
linking resulting in the formation of supramolecular assemblies.  
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Figure 4. 32: ITC data for GALNAc and GAL in complex with hGal-7.  
Bottom: thermograms obtained by injections of the compound. Top: 
corresponding integrated titration curves. 
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Figure 4. 33: ITC data for D1 and D2 in complex with hGal-7.  
Bottom: thermograms obtained by injections of the compound. Top: 
corresponding integrated titration curves.  
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4.3.5. Dynamic light scattering experiments 
DLS measurements were used to observe cross-linking of hGal-7 in solution by 
dendrons [Figure 4.34]. A single intensity peak was observed for native hGal-7. 
Upon ligand binding the intensity of this peak decreased from 100% for native 
hGal-7 to 12% for D1, 5.1% for D2, 46.9% for D3 and additional peaks for higher 
order structures (with diameters of D1: 1013 nm, 80% and 5560 nm, 7.4%; D2: 6733 
nm, 95%; D3: 675 nm, 44.6% and 5292 nm, 8.4%) were observed [Table 4.11 and 
Figure 4.34]. The formation of these supramolecular assemblies in solution 
corroborate the crystallographic findings discussed in section 4.3.3. 
In addition, a slight change in the size of the main hGal-7 peak in the presence 
of the ligands which appear to indicate changes in dimer size (Native: 7.82 nm; 
D1: 5.78 nm; D2: 8.99 nm; D3: 6.15 nm) upon ligand binding is observed [Table 
4.11]. These fluctuations are reflected in the crystal structures of the complexes 
and are the result of changes in the dimeric interface induced by ligand binding 
at the CRD. 
Table 4. 11: Representative dynamic light scattering measurements. 
Sample Peak 
Size 
( diameter, nm) 
Percentage 
(%) 
Native hGal-7 1 7.82 100 
hGal-7 – D1 1 5.79 12 
 2 1013 80 
 3 5560 7.4 
hGal-7 – D2 1 8.99 5.1 
 2 6733 95 
hGal-7 – D3 1 6.15 49.9 
 2 675 44.6 




Figure 4. 34: Dynamic light scattering measurements.  
Representative DLS data for native hGal-7 and hGal-7 in complex with 
dendrons D1, D2 and D3. Left panel: The autocorrelation function showing the 
exponential decay of the scattering signal. Right panel: The intensity graph 




4.4. Discussion  
Galectin–7, an important member of the -galactoside-binding animal lectin 
family, has been widely implicated in cancer. The structural data of native 
hGal-7 and its known ligands have aided the development of synthetic 
carbohydrate based ligands. These enable us to study their activity through 
structure activity based relations. This wealth of knowledge has led to the 
development of specially designed dendrimers with terminal groups that are 
specific for their recognition by the CRD of hGal-7. The binding of dendrimers 
to galectins results in their polymerisation and helps us understand the 
implications and structural features of the formation of native supramolecular 
assemblies seen in other lectins. Galectins with a single CRD (prototype 
galectins) are known to dimerise and in some cases oligomerise upon binding 
to polysaccharides, which results in cell-cell interactions and signal 
transduction.  
The different morphology [Figures 4.11] of the crystals observed in the 
crystallisation experiments can be attributed to the different crystal packing and 
supramolecular formation of hGal-7 in complex with dendrons of varying size 
and flexibility. Ligand flexibility, which could have resulted in disordered 
crystal formation, may help explain why the higher order dendrons (i.e. D4, D5 
and D6) did not yield diffraction quality crystals. 
Crystallographic results show that ligand binding at the CRD has a long range 
effect at the dimerisation interface. The binding of D2 and D3 to hGal-7 results 
in a higher RMS deviation of chain B compared to that of the native hGal-7 
dimer [Tables 4.4, 4.5 and Figure 4.15]. The hydrogen bonds between residues 
R20–G102 and K98-F135 of the two monomers at the interface of the dimer are 
conserved in all the complex structures as well as in the native structure. 
Several additional hydrogen bonds are formed at the dimeric interface as a 
result of ligand binding at the CRD [Table 4.6]. Overall, the number of 
interactions between the residues at the dimeric interface in the complex 
structures remains comparable to that of the native structure, and even present 
slightly decreased surface contact areas. Therefore, although variations in the 
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dimer interface were observed upon ligand binding, they do not seem to offer 
additional stability to the dimer, in contrast to the observations made by 
Ermakova et al. (2013). While an effect of the crystallographic packing may not 
be excluded, the disparities seen at the dimeric interface more likely result from 
the flexibility within the supramolecular assemblies provided by the dendrons’ 
extended arms. 
The dendrimeric compounds are recognised by residues H49, N51, R53, N62, 
W69, E72 and R74 of the CRD of hGal-7. The interaction of the terminal 
galactosyl rings of the dendrons with the CRD are similar to that observed in 
the crystal structure of hGal-7 in complex with galactose. In addition to the 
recognition of the terminal galactosyl rings, the triazole ring (in D1 and D3) and 
the penultimate galactosyl ring (in D2), provide additional binding sites and 
further stabilise the complexes with hGal-7.  
The pseudo secondary binding site observed in hGal-7 in complex with D3 
appears to be a unique feature [Figure 4.35] compared to other structures of 
galectins bound to complex carbohydrates. Bourne et al. (1994) for example 
presented the first oligosaccharide structures of bovine Gal-1 cross-linked by N-
acetyllactosamine units where the interactions occurred solely at the CRD. The 
rigidity of the glycosidic linkages in multi saccharide structures may prevent 
secondary interactions from taking place. Long and flexible dendrimers may 
enhance binding through cumulative interactions by interacting at the other 
hydrophobic pockets as observed in the case of D3 [Figure 4.23]. Additionally, 
the specific interaction of D3 with moderately conserved S30, R31, S68 and non-
conserved D55 could be exploited to obtain specificity towards hGal-7 or other 
galectin sub-types [Figure 4.36]. The pseudo secondary site appears to only play 
a minimal role in the assembly of the supramolecules. It however indicates that 
better selectivity between lectins may be achieved by designing ligands able to 




 Figure 4. 35: Residues of the galectin CRD involved in cross-linking. 
The pseudo- secondary binding site observed in the hGal-7-D3 complex is 
shown (hGal-7 in cyan and Gal-1 in grey). (A) hGAl-7 in complex with D3 
(orange) (B) hGal-1 in complex with thiodigalactoside (yellow) (PDB code: 
3OYW) (C-E) Bovine Gal-1 in complex with biantennary complex type 
saccharides (C) PDB code: 1SLA (violet) (D) PDB code: 1SLB (pale blue) (E) PDB 
code: 1SLC (pale green). Residues involved in the recognition and binding of 
the ligands are shown as sticks.   
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Figure 4. 36: ConSurf analysis of hGal-7 in complex with D3. 
D3 is shown as stick in orange bound at the CRD. The amino-acids are coloured 
by their conservation grades using the colour-coding bar, with turquoise-
through-maroon indicating variable-through-conserved. 
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The binding of multivalent carbohydrate based dendrons to hGal-7 promotes 
‘cross-linking’ and results in the formation of large hetero-oligomers of hGal-7 
and the multivalent dendrons. Depending on the size, flexibility of the 
dendrimeric ligand and the crystal packing of the complex, different modes of 
binding are observed. These results corroborate the glycoprotein clustering of 
hGal-3 by multivalent glycodendrimers studied using mass spectrometry and 
dynamic light scattering (Goodman et al., 2014). The binding of the terminal 
dissacharide of D2 is analogous to the interaction of the disaccharide in the 
structure of hGal-1 in complex with thiodigalactoside (Stannard et al., 2010) 
[Figure 4.35]. This similarity in the mode of binding highlights the potential use 
of dendrons and larger dendrimers for studying other members of the lectin 
family. Thiodigalactoside was suggested to have potential use as an adjuvant to 
promote vaccine stimulated immune responses against tumours (Stannard et al., 
2010). 
On analysis of the ITC data, it is observed that the binding affinities of hGal-7 to 
GAL (Kd = 2.17 mM) and GALNAc (Kd = 1.04 mM) are much higher than that 
reported for lactose (Kd = 4.54 mM) and N-acetyl lactosamine (Kd = 5.88 mM) 
(Brewer, 2004). On comparison with monosaccharides, an enhancement of 
binding affinity of glycodendrimers with lectins ascribed to a “cluster glycoside 
effect” has been reported (Dimick et al., 1999, Mouline et al., 2014, Varki, 1993). 
This enhancement is observed in the binding affinity studies of D2 (Kd = 0.26 
mM) with hGal-7. However, the binding affinity of D1 (Kd = 3.12 mM) is 
comparable to that of monosaccharides lactose, GAL and GALNAc. 
The binding affinity data in conjuncture with the crystallographic results 
suggest that multivalent dendrons with additional galactosyl molecules at the 
termini (as seen in D2) may help enhance ligand binding. Future ITC and 
crystallographic studies with the higher-order dendrimers, will help further the 
understanding of supramolecular assembly formation of galectins. It will also 
be interesting to see the effect of the pseudo secondary site observed in the 
crystallographic results of hGal-7 in complex with D3 on the binding affinity of 
this dendron. Additionally, analytical ultracentrifugation studies or mass 
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spectrometric analysis to determine the exact size and polydispersity of higher 
order polymers in the hGal-7–dendron mixture may help in determining the 
stoichiometry of these reaction mixtures.  
Dynamic light scattering was employed as a qualitative method to indicate the 
formation of supramolecular assemblies in solution. This showed that dendron-
induced cross-linking of hGal-7, results in the formation of multiple species of 
varying sizes in solution. This polydispersity observed using DLS 
measurements, corroborate our crystallographic results in which two forms of 
cross-linking of hGal-7 by D2 and involvement of only parts of the dendrons, 
D1 and D3, are observed. Similar polydispersity in cross-linking of hGal-3 by 
glycodendrimers has been reported (Goodman et al., 2014). Further analysis 
using techniques such as analytical ultracentrifugation or size exclusion 
chromatography with multi-angle light scattering may be required to further 
characterise the state of higher-order structures in solution. 
In conclusion, hGal-7 polymerisation can be regulated by nucleating polymers 
such as the multivalent glycodendrimers used here. The crystal structures of the 
hGal-7 in complex with the dendrimeric compounds discussed will provide 
new tools to investigate the recognition of carbohydrates by galectins. The 
ability of these compounds to polymerise galectins will provide insights that 
will improve the general understating of their role in the formation of 
supramolecular assemblies and more generally, the lattice formation by lectins 
in cell signalling and signal transduction. The possibility of designing and 
synthesising dendrimers with specific functions, and their ability to be used in 
conjunction with nano-devices and liposomes make them ideal tools for such 






















Sirtuins, also known as the Sir2 family of proteins (silent mating type 
information regulator 2) were first identified in yeast where Sir2 came out on 
top in a screen for modulators of yeast lifespan (Kaeberlein et al., 1999). They 
are NAD+ dependent deacetylases, but may have other related activities and 
are highly conserved in all organisms. The knowledge of their involvement in 
biological processes is steadily growing along with their implication as 
potential therapeutic target in various conditions such as ageing and age-
related diseases including cancer. Due to their role in ageing and ageing related 
diseases, sirtuins have garnered the attention of the general public and 
researchers alike. Their unique enzymatic function, ability to modulate 
physiological processes on their own and by interplay with other members of 
the sirtuin family, and their diverse substrate recognition properties make them 
a fascinating family of enzymes. Work towards uncovering how their molecular 
activities explain their physiological outcomes in sirtuin influenced pathways 
has generated a great wealth of knowledge. However, further research aimed at 
understanding their dynamic molecular role in order to help design molecules 
to modulate their function is required. 
Sequence alignment of all seven human sirtuins, reveals a 2.5% identity which 
includes 21 identical residue positions. Differences in the primary sequences 
which would be translated into the secondary structure, will provide insight 
into their varied affinity to diverse substrates and their role in normal cellular 
physiology.  
The study of SIRT1, SIRT2 and SIRT7 was carried out to aid in understanding 
the structural implications on the dynamic role of sirtuins. This chapter 
describes the work carried out towards the structural studies of sirtuins. The 
cloning, expression, purification and crystallisation experiments carried out for 
each sirtuin (SIRT2, SIRT7 and SIRT1) are discussed separately in sections 5.1-
5.3. The discussion of the results from these experiments is presented in section 
5.4.   
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5.1. Sirtuin 2 
5.1.1. Introduction 
The human Sir2 ortholog, SIRT2, is the only main cytoplasmic isoform 
(Michishita et al., 2005, Vaziri et al., 2001) but its presence in the nucleus has also 
been reported (Bae et al., 2004, Inoue et al., 2007) and it appears to contain a 
nuclear export motif [Figure 5.1.1] (Cen et al., 2011, Wilson et al., 2006). SIRT2 
deacetylates various substrates including α-tubulin and the histone H4, thereby 
regulating functions in cell cycle progression, cellular motility and 
differentiation (Cen et al., 2011, North et al., 2003, Vaquero et al., 2006). Five 
splice variants of SIRT2 have been reported, Isoforms 1-5 have 389, 352, 369, 271 
and 319 residues, respectively (UniProt, 2014). Isoform 1 is the canonical 
sequence and is expressed in the heart, liver and skeletal muscle. Isoform 2 is 
dominant in the brain and lacks an N-terminal extension to the catalytic domain 
(Afshar and Murnane, 1999, Frye, 1999). SIRT2 expression in the brain is 
indicative of its central role in this tissue and its contribution to pathologies of 
neurodegenerative diseases such as Parkinson’s and Huntington’s disease (de 
Oliveira et al., 2012).  
 
Figure 5.1. 1: Key features of the structure of SIRT2.  
A schematic representation of the structure of SIRT2. The structurally important 
cysteine (C) residues involved in zinc binding are indicated along with the 
histidine (H) residue that behaves as a proton acceptor.  
 
SIRT2 shows typical sirtuin architecture, in which a conserved catalytic core 
that is involved in substrate binding is flanked by N- and C-terminal extensions 
(discussed in section 2.5). SIRT3 is the closest homologue of SIRT2 while SIRT4 
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is the least similar [Table 5.1.1]. The N- and C-terminal regions appear to 
control sub-cellular localisation and play a role in catalytic activity (Flick and 
Luscher, 2012). SIRT2 activity can be modulated by C-terminal phosphorylation 
of residues S368 and S372 or by acetylation of lysines residues (Han et al., 2008).  
Table 5.1. 1: Overview of the results of a sequence comparison of SIRT2 with 
other human sirtuins. 
ClustalO was used for sequence comparison (UniProt, 2014). 
  Identity (%) Identical positions 
SIRT2 SIRT1 17.806 138 
SIRT2 SIRT3 34.87 158 
SIRT2 SIRT4 14.20 75 
SIRT2 SIRT5 17.66 74 
SIRT2 SIRT6 20.23 87 
SIRT2 SIRT7 18.49 83 
 
The first crystal structure of the catalytic core of SIRT2 revealed a typical oval 
shaped architecture as observed in other sirtuins composed of two globular 
subdomains, a Rossmann fold domain and a zinc-binding domain (Finnin et al., 
2001). The crystal structure of the catalytic core in complex with ADPR 
highlighted its differences from the apoform which included a 25º rotation of 
the zinc-binding domain towards the Rossmann-fold domain which closed the 
co-substrate binding site around its ligand (Moniot et al., 2013). The crystal 
structure of SIRT2 in complex with a macrocyclic peptide inhibitor S2iL5 
showed the inhibitor induced open and closed domain movement of SIRT2 
brought about by the movement of loop comprised of residues 289-304 
(Yamagata et al., 2014). The structural studies to date have mainly explored the 
catalytic core domain however little is known about the role and structure of 
the N- and C-terminal SIRT2 extensions. 
Pharmacological inhibition of SIRT2 is an attractive approach for the treatment 
of neurological diseases and various cancers (discussed in section 2.5 and 2.6). 
Several inhibitors of sirtuins have been developed but have shown limited 
specificity to SIRT2 and have not yet been tested on other sirtuins and their 
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isoforms. The molecular details of ligand binding and the associated 
conformational changes are therefore of great interest (Moniot et al., 2012).  
The structural studies of SIRT2 presented here were aimed at understanding 
ligand recognition and binding to SIRT2. This would provide insights in 
SIRT2-specific and general sirtuin features that could be exploited for 
rational drug design. 
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5.1.2. Methods 
5.1.2.1. Cloning, Expression and Purification 
Table 5.1.2 summarises the constructs of SIRT2 that were designed for its 
expression with covalently linked affinity tags to help both expression and 
purification of the protein. The vector maps are provided in appendix A. The 
final optimised cloning, expression and protein purification protocols for each 
construct are given below. 








SIRT2.1 34-356 pTriEx-4 Ek/LIC N-term His and S-tag 41.5 
SIRT2.4 34-356 pET22b C-term His tag 37.6 
SIRT2.6 34-389 pET-46 Ek/LIC N-term His tag 41.5 
SIRT2.7 34-356 pGEx-6P1 N-term GST tag 62.9 
 
5.1.2.1.1. SIRT2.6 
The gene coding SIRT2 (residues 34-389) was previously cloned into pET-46 
Ek/LIC (Novagen, Darmstadt, Germany) with a cleavable N-terminal poly-
histidine tag. This recombinant plasmid, named SIRT2.6, was then transformed 
into E. coli Rosetta-gamiTM 2(DE3)pLysS cells. For protein expression, cells were 
grown in autoinduction (AI) media with ampicillin at 37 °C for 6 h and then 
incubated at 16 ºC for 16 h. Cells were harvested after 22 h after inoculation by 
centrifugation (4 °C at 12,000 g, 10 min).  
The expressed protein was purified using immobilised metal ion affinity 
chromatography (IMAC) followed by size exclusion chromatography (SEC). 
Cell pellets were resuspended in wash buffer (50 mM HEPES pH 7.3, 
200 mM NaCl, 15 mM imidazole) and lysed in an One shot  model (Constant 
systems, U.K.). The preparation was then clarified by centrifugation (4 °C at 
75,000 g, 25 min). The supernatant was loaded on a 5 mL HisTrap FF column 
(GE Healthcare, Uppsala, Sweden) pre-equilibrated with wash buffer. The 
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column was washed extensively and a gradient elution of 1-100 % over 50 mL 
(50 mM HEPES pH 7.3, 200 mM NaCl, 500 mM imidazole) was carried out. The 
eluted fraction was dialysed overnight in wash buffer at 4 °C and loaded on a 
gel filtration column (16/600 Superdex 200 pg; GE Healthcare, Uppsala, 
Sweden) pre-equilibrated with final buffer (50 mM HEPES pH 7.3, 
200 mM NaCl). Fractions were analysed by SDS-PAGE.  
5.1.2.1.2. SIRT2.6a 
The protein purified from the initial SIRT2.6 glycerol stocks was shown not to 
be the desired SIRT2 protein. The recombinant plasmid for SIRT2.6 was 
transformed into E. coli TOP10 cells and the DNA was extracted for sequencing 
as described in section 3.4.2. Upon verification that the DNA sequence was 
correct, it was transformed into E. coli Rosetta-gamiTM 2(DE3)pLysS cells and 
fresh glycerol stocks were prepared as described in Section 3.4.2. DNA was 
sequenced at Eurofins MWG Operon, Ebersberg, Germany using the T7 primer 
for forward sequencing and the TriExDOWN primer for reverse sequencing.  
Expression trials were carried out by inoculating AI, LB and TB media with 
ampicillin and chloramphenicol (as described in Section 3.4.1) followed by 
induction with 1 mM IPTG. Samples were collected at regular intervals and 
protein expression was analysed using SDS-PAGE.  
For large scale expression, cells were grown in TB media with ampicillin and 
chloramphenicol at 37 ºC to an O.D. of 0.6–0.7. The cultures were then induced 
with 1 mm IPTG. Cells were harvested after 8 h of induction by centrifugation 
(4 °C at 12,000 g, 10 min). Induction of protein expression was analysed by SDS-
PAGE. 
SIRT2.6a was purified using IMAC followed by anion exchange (AIEX) 
chromatography. Cell pellets were resuspended in wash buffer 1 
(50 mM HEPES pH 7.4, 200 mM NaCl, 15 mM imidazole) and lysed in an One 
shot model (Constant systems, U.K.). The preparation was then clarified by 
centrifugation (4 °C at 75,000 g, 25 min). The supernatant was loaded on a 5 mL 
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HisTrap FF column (GE Healthcare, Uppsala, Sweden) pre-equilibrated with 
wash buffer 1. The column was washed extensively with wash buffer 1 before a 
wash with ~100 mL of 10 % elution buffer. The protein was eluted by gradient 
elution using 0-100% gradient over 50 mL with elution buffer 1 (50 mM HEPES 
pH 7.4, 200 mM NaCl, 500 mM imidazole) and the eluted fraction was dialysed 
overnight in wash buffer 2 (50 mM HEPES pH 7.4) at 4 °C. The dialysed sample 
SIRT2.6a (pI 5.84) was loaded on a manually packed 10 mL anion exchange 
column using quaternary amine (Q) sepharose beads (Sigma-Aldrich Co., Kent, 
U.K.) pre-equilibrated with wash buffer 2. The column was washed extensively 
and a gradient elution of 0-100 % over 100 mL using elution buffer 2 (50 mM 
Tris HCl pH 7.4, 500 mM NaCl) was carried out. The eluted fractions were 
analysed by SDS-PAGE and the desired fraction were dialysed overnight in 
final buffer (50 mM HEPES pH 7.3, 200 mM NaCl). Mass spectrometric analysis 
and western blot analysis, using anti-His antibody (Ab) and anti-SIRT2 Ab, 
were carried out as described in section 3.5.3. Antibodies were purchased from 
Sigma-Aldrich Co., Kent, U.K. 
5.1.2.1.3. SIRT2.1 
The gene coding SIRT2 (residues 34-356) was cloned into the pTriEx-4 Ek/LIC 
vector (Novagen, Darmstadt, Germany) with a cleavable N-terminal poly-
histidine and S-tag. This recombinant plasmid was named SIRT2.1. 
Plasmid DNA was transformed into E. coli TOP10 cells and the DNA was 
extracted for sequencing as described in section 3.4.2. Following DNA 
sequencing, the plasmid was transformed into E. coli Rosetta-gamiTM 
2(DE3)pLysS cells and fresh glycerol stocks were prepared as described in 
Section 3.3.2. DNA was sent for sequencing at Eurofins MWG Operon, 
Ebersberg, Germany using the T7 primer for forward sequencing and the 
TriExDOWN primer for reverse sequencing. 
Expression trials were carried out by inoculating LB and TB media with 
ampicillin and chloramphenicol as described in Section 3.4.1 followed by 
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induction with 1 mM IPTG. Samples were collected at regular intervals and 
protein expression was analysed using SDS-PAGE.  
For large scale expression, cells were grown in LB media with ampicillin and 
chloramphenicol at 37 ºC to an O.D. of 0.6–0.7 and were then induced with 
1 mM IPTG. Cells were harvested after 16 h of induction by centrifugation (4 °C 
at 12,000 g, 10 min). Induction of protein expression was analysed by SDS-
PAGE. 
SIRT2.1 was purified using IMAC followed by SEC. Cell pellets were 
resuspended in wash buffer (50 mM Tris HCl pH 7.4, 200 mM NaCl, 
10 mM imidazole) and lysed in an One shot model (Constant systems, U.K.). 
The preparation was then clarified by centrifugation (4 °C at 75,000 g, 25 min). 
The supernatant was loaded on a 5 mL HisTrap FF column (GE Healthcare, 
Uppsala, Sweden) pre-equilibrated with wash buffer. The column was washed 
extensively and a gradient elution of 0-100 % over 50 mL (50 mM Tris HCl pH 
7.4, 200 mM NaCl, 500 mM imidazole) was carried out. The eluted fraction was 
dialysed overnight in wash buffer at 4 °C and loaded on a gel filtration column 
(16/600 Superdex 200 Prep grade; GE Healthcare, Uppsala, Sweden) pre-
equilibrated with final buffer (50 Tris HCl pH 7.4, 200 mM NaCl). The eluted 
samples were analysed by SDS-PAGE. Tryptic digest of in-gel protein for mass 
spectrometric analysis and western blot analysis using anti-His Ab and anti-
SIRT2 Ab were carried out as described in section 3.5.3. Antibodies were 
purchased from Sigma-Aldrich Co., Kent, U.K. 
5.1.2.1.4. SIRT2.4 
The gene coding SIRT2 (residues 34-356) was cloned into pET-22b (Novagen, 
Darmstadt, Germany) with a C-terminal poly-histidine. This recombinant 
plasmid was named SIRT2.4. 
This plasmid was transformed into E. coli TOP10 cells and the DNA was 
extracted for sequencing as described in section 3.4.2. Upon verification of the 
DNA sequence, the plasmid was transformed into E. coli BL21-CodonPlus 
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(DE3)-RIPL cells and glycerol stocks was prepared as described in section 3.3.2. 
DNA was sequenced at Eurofins MWG Operon, Ebersberg, Germany using the 
T7 primer for forward sequencing and the T7 term primer for reverse 
sequencing. 
Expression trials were carried out by inoculating LB and TB media with 
ampicillin as described in Section 3.4.1 followed by induction with 1mM IPTG. 
Samples were collected at regular intervals and protein expression was 
analysed using SDS-PAGE.  
For large scale expression, cells were grown in TB media with ampicillin at 37 
ºC to an O.D. of 0.6–0.7 and were then induced with 1 mM IPTG. Cells were 
harvested after 16 h of induction by centrifugation (4 ºC at 12,000 g, 10min). 
Induction of the protein expression was analysed by SDS-PAGE. 
Purification of SIRT2.4 was carried out using IMAC followed by SEC as 
described for SIRT2.1 in section 5.1.2.1.4. Tryptic digest of in-gel protein for 
mass spectrometric analysis and western blot analysis using anti-His Ab and 
anti-SIRT2 Ab were carried out as described in section 3.5.3. Antibodies were 
purchased from Sigma-Aldrich Co., Kent, U.K. 
5.1.2.1.5. SIRT2.7 
The gene coding SIRT2 (residues 34-356) was cloned into pGEx-6P-1 vector (GE 
Healthcare, U.K.) with a cleavable N-terminal GST-tag. This recombinant 
plasmid was named SIRT2.7. 
The recombinant plasmid SIRT2.6 was used for PCR amplification as described 
in section 3.4.2. Primers were designed such that a BamH1 restriction site was 
incorporated into the DNA using the forward primer and an EcoR1 restriction 
site was incorporated using the reverse primer. The primers used for PCR 
amplification are given in table 5.1.3, while the components of the reaction 
mixtures and the parameters for thermal cycling are given in tables 5.1.4 and 
5.1.5, respectively. 
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Table 5.1. 3: Primers used for PCR amplification of SIRT2.7 
Primer Sequence (5’-3’) 
SIRT2.7fwd GAA TTC ATG GCA GCC GGG GGT CTG 
SIRT2.7rev CTC GAG TTA CGT CAC TTT CTT CCT 
 
 Table 5.1. 4: PCR reaction for SIRT2.7 
Reaction Tube 1 (µL) Tube 2 (µL) Tube 3 (µL) Tube 4 (µL) 
DNA template  
(SIRT2.6)(100ng/µL) 
2 2 2 2 
Primer (100 µM) 
SIRT2.7fwd) 
1.5 1.5 1.5 1.5 
Primer (100 µM) 
(SIRT2.7rev) 
1.5 1.5 1.5 1.5 
KOD polymerase 
(1U/µL) 
1 1 1 1 
10x Buffer 5 5 5 5 
dNTPs (2mM each) 5 5 5 5 
MgSO4 (25 mM) 5 5 2 2 
DMSO 2 - 2 - 
Water (q.s. 50 µL) 27 29 30 32 
 
Table 5.1. 5: PCR thermal cycling parameters for SIRT2.7 
Cycle Temperature (ºC) 
Time (min) 
Initial denaturation 5 1 
Denaturation 95 1 
Annealing 57 1 
Extension 72 2.5 
Back to step 2 
(Denaturation) for 35x 
  
Final extension 72 10 
Hold at 4oC   
 
The PCR products were analysed by running the samples on an agarose gel as 
described in section 3.4.1. The final purified product was ligated with a pCR™-
Blunt vector (Zero Blunt® PCR Cloning Kit, Invitrogen, CA, USA). The 
recombinant vector was transformed into E. coli TOP10 cells and the DNA was 
extracted as described in section 3.4.2. Double digestion experiments to test for 
the presence of an insert were performed by incubating the reaction mixture 
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[Table 5.1.6] for 1 h at 37 ºC. FastDigest BamHI and EcoRI (Thermo scientific, 
MA, USA) were used for double digestion of the recombinant blunt vector 
(RBV) and pGEx-6P-1 vector (GE Healthcare, Uppsala, Sweden). 
 
Table 5.1. 6: Double digestion set up for SIRT2.7. 






BamH1 1 4 4 
EcoR1 1 4 4 
RBV / (pGEx-6P-1 
vector) 
6 25 25 
10x FastDigest 
Green buffer 
1 5 5 
Water  1 (q.s. 10 µL) 12 (q.s. 50 µL) 12 (q.s. 50 µL) 
 
Once a dropout of the correct molecular weight was observed following test 
double digestions the blunt vector was sequenced using the M13(-21) primer. 
On verification of sequence, final double digestion of the RBV and pGEx-6P-1 
vector was carried out [Table 5.1.6]. The Rapid DNA Ligation Kit (Thermo 
Scientific, MA, USA) was used for ligation of the insert and vector DNA. 
Ligation of the drop out (~1200 bp) from the RBV and the treated pGEx-6P-1 
was carried out by incubating the ligation reaction (1 µL T4 DNA ligase, 1 µL 
treated pGEx-6P-1, 6 µL RBV drop out, 2 µL 5x rapid ligation buffer) for one 
hour at 21 ºC. The recombinant plasmid was transformed into E. coli TOP10 
cells and the DNA was extracted for sequence analysis as described in Section 
3.4.2. On verification of the sequence, the final recombinant plasmid was 
transformed into E. coli ArcticExpress (DE3) RIL cells (Agilent Technologies, 
CA, USA) and glycerol stocks were prepared as described in Section 3.4.2. 
Expression trials in LB media were carried out as per the manufacturer’s 
instructions for E. coli ArcticExpress (DE3) RIL competent cells. 
For large scale expressions, overnight cultures were grown in LB media with 
gentamycin and ampicillin. Large cultures were grown by inoculating modified 
LB media (+10 mM glucose) with overnight cultures containing no antibiotics. 
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These cultures were grown for 6 h at 30 ºC and induced with 1 mM IPTG at 10 
oC. Cells were harvested after 18 h of induction by centrifugation (4 °C at 
12,000 g, 10 min). Induction of the protein expression was analysed by SDS-
PAGE.  
SIRT2.7 was purified using GST-tagged affinity chromatography (GST-AC) 
followed by GST-tag cleavage and SEC. Cell pellets were resuspended in PBS 
pH 7.3 ( 140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.3) 
buffer and lysed in an One shot model (Constant systems, U.K.). The 
preparation was then clarified by centrifugation (4 °C at 30,000 g, 30 min). The 
supernatant was loaded on a 5 mL GSTrap FF column (GE Healthcare, Uppsala, 
Sweden) pre-equilibrated with wash PBS pH 7.3 buffer. The column was 
washed extensively and a single step elution (50 mM Tris HCl pH 8.0, 10 mM 
reduced glutathione) was carried out. Western blot analysis using anti-GST Ab 
and anti-SIRT2 Ab was performed to confirm the identity of the purified 
protein. Antibodies were purchased from Sigma-Aldrich Co., Kent, U.K. 
PreScission protease (GE Healthcare, Uppsala, Sweden) was added to the 
eluted protein (one unit protease cleaves 90% 100 µg of GST fusion protein) and 
dialysed overnight in 50 mM Tris HCl pH 8.0, 10 mM reduced glutathione at 4 
ºC. The GST cleaved protein was loaded on a gel filtration column (16/600 
Superdex 200 pg; GE Healthcare, Uppsala, Sweden) pre-equilibrated with final 
buffer (50 mM Tris HCl pH 7.4, 200 mM NaCl). The eluted samples were 
analysed by SDS-PAGE and by tryptic in-gel digest mass spectrometric analysis 
as described in section 3.5.3.3. 
5.1.2.2. SIRT2 activity assay 
The Fluor-de-lys®-SIRT2 fluorometric drug discovery assay kit (Enzo Life 
Sciences, NY, USA) was employed to measure the activity of purified SIRT2 
protein. This assay was also used to determine the inhibitory capacity of sirtuin 
inhibitors used in the crystallisation experiments.  
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Principle of Fluor-de-lys®-SIRT2 assay 
The assay involves the incubation of Fluor-de-lys® substrate with SIRT2 resulting 
in its NAD+-dependent deacetylation. The deactylated Fluor-de-lys® substrate 
can then react with the Fluor-de-lys® developer II to produce a fluorophore 
[Figure 5.1.2]. The fluorophore is excited at 360 nm and the emitted light is 
detected on a fluorometric plate reader. NAD+ is consumed in the reaction to 
produce nicotinamide (NAM) and O-acetyl-ADP-ribose (AADPR). 
 




The experiments were performed as per manufacturer’s instructions in a 96-
well NUNC microplates (Thermo Fisher Scientific, MA, USA). Human 
recombinant SIRT2 provided in the kit was used as a control. The FLUOstar 
Omega Multi-Mode Microplate Reader with a CCD-based Spectrometer (BMG 
LABTECH, Germany) was used for reading the plate. Excitation at a 
wavelength of 360 nm and detection of the emitted light at 460 nm was used for 
reading the plate. 
SIRT2 activity assay 
Test samples (SIRT2.1, SIRT2.4, SIRT2.6 and SIRT2.7) were dialysed in protein 
buffer (50 mM Tris HCl pH 7.4, 200 mM NaCl) and initial stock solutions of 5 
mg/mL, 2 mg/mL and 1 mg/mL were prepared. The control samples were 
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prepared at similar concentrations to the test samples. The substrate mix and 
developer mix were prepared as per manufacturer’s instructions. The test 
samples/control and NAD+-substrate mix [Table 5.1.7] were mixed and 
incubated at 37 ºC. After 1 h, the developer and the nicotinamide stop solution 
(Developer mix) were added to the reaction mixture [Table 5.1.7]. The plate was 
read using the fluorescence spectrometer after 30-45 min of incubation.  
 
Table 5.1. 7: SIRT2 activity assay 










Blank 5 - 5 10 20 
Test sample 5 5 - 10 20 
Control 5 5 - 10 20 
 
SIRT2 inhibitor assay  
The SIRT2 inhibition assay was performed similar to the SIRT2 activity assay. 
The inhibitors AGK2, cambinol (CAM), salermide (SEL) and suramin at initial 
concentrations of 200, 20, 2 and 0.2 mg/mL were prepared in assay buffer. All 
compounds were purchased from Calbiochem, U.K. and dissolved in DMSO 
(except suramin which was dissolved in water) to prepare 10 mM stock 
solutions. A DMSO control was assayed along with the inhibitors. SIRT2.6 at 0.5 
mg/mL was incubated with the inhibitors for 1 h at 37 ºC. The test sample 
(SIRT2.6 + inhibitor mix) and the NAD+ - substrate mix [Table 5.1.8] were 
incubated at 37 ºC. After 1 h, the developer and the nicotinamide stop solution 
(Developer mix) were added [Table 5.1.8] and incubated at 37 ºC. The plate was 

































- 10 20 
Test 
sample 
- 5 5 - 10 20 
 
5.1.2.2. Crystallisation of SIRT2 
Crystallisation trials for SIRT2 started with screening of sparse-matrix 
commercial conditions (Section 3.7.2). The vapour diffusion sitting drop method 
was the preferred crystallisation technique. A variety of conditions were tested 
at different temperatures (4 ºC, 16 ºC and 21 ºC), with drops containing protein 
and reservoir solution in ratios of 1:1, 1:2 and 1:3.  
The protein obtained from constructs SIRT2.1, 2.4, 2.6 and 2.7 were used for 
setting up crystallisation trials as described in section 3.7.2. Initial crystallisation 
trials of native SIRT 2 were set up in their respective final purification buffers. 
Protein concentrations of 2 mg/mL, 6 mg/mL, 8 mg/mL, 10 mg/mL and 12 
mg/mL were used for these experiments.  
In addition to the commercial screens available, optimisation screens based on 
the crystallisation conditions from the reported SIRT2 structures were also used 
(Finnin et al., 2001, Moniot et al., 2013). These included 96-well screens designed 
based on varying concentrations of PEG10000, ammonium acetate and NaCl. 
Additional conditions varying the ionic strength of the crystallisation 
conditions by altering the pH and concentration of bis-tris propane and bis-tris 
methane were employed.  
A similar sparse matrix screening of SIRT2.6 and SIRT2.7 in complex with the 
substrates NAD+ and ADPR (Sigma-Aldrich Co., Kent, U.K.) as well as the 
inhibitors CAM, SEL, AGK2 and surmain were also set up. Protein 
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concentrations of 2 mg/mL, 6 mg/mL and 8 mg/mL were used and protein to 
ligand ratio was either 1:2 or 1:4.   
In addition to the sitting drop method, modified microbatch or crystallisation 
under oil, were attempted to crystallise native SIRT2.6. The crystallisation robot 
Oryx8 (Douglas Instruments, U.K.) was used to set up 96-well plates using 
PACT premier HT-96, JCSG-plus HT-96, Morpheus HT-96, PGA Screen HT-96 




5.1.3.1. SIRT2 construct SIRT 2.6 
SIRT2.6 is truncated at the N-terminus compared to native SIRT2 and comprises 
residues 34-389. The recombinant gene was cloned into the pET-46 Ek/LIC 
vector to enable protein expression with a covalently linked His-tag. The 
expressed protein is expected to have a theoretical mass of 41.5 kDa. 
Initial expression in TB media followed by IMAC and SEC of SIRT2.6 resulted 
in two proteins being observed by SDS-PAGE at ~55 kDa and ~66 kDa [Figure 
5.1.3 and 5.1.4]. Western blot analysis using anti-His Ab and anti-SIRT2 Ab 
failed to detect any protein, which confirmed neither the purified proteins were 
the desired SIRT2.  
 
Figure 5.1. 3: SIRT2.6 purification.  
Example chromatogram of (A) IMAC utilising the HisTrap FF column for 
purification of His-tagged SIRT2.6 followed by (B) SEC using a superdex 200 
column. The elution peaks are indicated in the figure. Blue line represents the 




Figure 5.1. 4: Example of SIRT2.6 purification analysed by SDS-PAGE. 
SIRT2.6 purification analysed by SDS-PAGE (A) samples from IMAC (lanes 1-7) 
followed by (B) SEC (lanes 8-14). The molecular weights of the SDS-PAGE 
marker (M) are labelled. 
 
The verified plasmid isolated from the E. coli TOP10 cells glycerol stock was 
used for verification of DNA sequence (referred to as SIRT2.6a). Positive results 
for forward and reverse DNA sequencing were obtained. The alignment of the 
translated DNA sequences of SIRT2.6a with SIRT2 is given are in appendix E1.1 
and E1.2. The recombinant plasmid was successfully transformed into Rosetta-
gamiTM 2(DE3)pLysS cells and expression trials were performed in LB, TB and 
AI media. Soluble expression was most favourable in TB and this media was 
selected for large scale expression of SIRT2.6a [Figure 5.1.5].  
Initial IMAC purifications of SIRT2.6a resulted in a 30 kDa impurity being co-
purified with the desired protein. Washing the HisTrap FF column after loading 
with ~100 mL of 10 % elution buffer enabled the removal of this impurity. 
Successful purification of SIRT2.6a was achieved using IMAC followed by AIEX 
[Figure 5.1.6 and 5.1.7]. A yield of 20-25 mg of SIRT2.6a per litre of cultures was 
obtained using this method. The identity of the protein was confirmed by intact 
protein mass spectrometry and western blot analysis using anti-His Ab and 
anti-SIRT2 Ab [Figure 5.1.8 and 5.1.9]. The SIRT2 activity assay and 
crystallisation screening for this protein is discussed in sections 5.1.3.4 and 
5.1.3.5, respectively.  
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Figure 5.1. 5:Example of SIRT2.6a expression analysed by SDS-PAGE. 
(A) Samples from SIRT2.6a expression trials (B) samples from large scale 
expression of SIRT2.6a in TB. The molecular weights of the SDS-PAGE marker 
(M) are labelled. 
 
 
Figure 5.1. 6: SIRT2.6a purification.  
Example chromatogram of (A) IMAC utilising the HisTrap FF column for 
purification of His-tagged SIRT2.6a followed by (B) AIEX using a manually 




Figure 5.1. 7: Example of SIRT2.6a purification analysed by SDS-PAGE. 
SIRT2.6a purification analysed by SDS-PAGE (A) samples from IMAC (lanes 1-
6) followed by (B) SEC (lanes 7-10). The molecular weights of the SDS-PAGE 





Figure 5.1. 8: Western blot analysis of SIRT2.6a. 
Samples of SIRT2.6a analysed by western blotting (WB) (A) samples from 
IMAC (lane 1) followed by (B) SEC (lanes 2-5). The molecular weights of the 
SDS-PAGE marker (M) and western blot marker (M1) are labelled. 
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Figure 5.1. 9: Mass spectrometric analysis of SIRT2.6a. 
Purified sample of SIRT2.6 analysed by mass spectrometric analysis. The peak 
corresponding to SIRT2.6a (41.6 kDa) is indicated. 
 
As crystallisation of SIRT2 using SIRT2.6 was challenging (section 5.2.3.5), 
additional constructs SIRT2.1, SIRT2.4 and SIRT2.7 with variations in covalently 
linked affinity tags and truncations were expressed and purified for further 
crystallisation trials. 
5.1.3.2. SIRT2 constructs SIRT 2.1 and SIRT2.4 
The SIRT2.1 construct is a truncated at the N- and C-terminals compared to 
native SIRT2 and comprises residues 34-356. The recombinant gene was cloned 
into the pTriEx-4 Ek/LIC vector in order to facilitate the expression with a 
covalently linked N-terminal His and S-tag. The expressed protein is expected 
to have a theoretical mass of 41.5 kDa. 
The SIRT2.4 construct is also truncated at the N- and C-terminals and comprises 
residues 34-356. The recombinant plasmid was cloned into pET-22b vector and 
the expressed protein is expected to have a theoretical mass of 37.6 kDa. This 
vector facilitates the expression with a covalently linked C-terminal His-tag.  
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After verification of the DNA sequences for both recombinant plasmids, 
SIRT2.1 was transformed into E. coli Rosetta-gamiTM 2(DE3)pLysS cells while 
SIRT2.4 was successfully transformed into E. coli BL21-CodonPlus (DE3)-RIPL 
cells. Positive results for forward and reverse DNA sequencing were obtained. 
The alignment of the translated DNA sequence of SIRT2.1 and SIRT2.4 with 
SIRT2 are given in appendix E1.3-E1.6. 
Based on the expression trials for SIRT2.1 and SIRT2.4 in LB and TB media at 37 
oC, LB media was selected for the large scale expression of SIRT2.1 and TB 
media was selected for the large scale expression of SIRT2.4 [Figure 5.1.10]. 
Purification of both proteins was succesfully carried out using IMAC followed 
by SEC [Figures 5.1.11-5.1.14]. The identity of the final purified protein was 
confirmed by western blot analysis using anti-His Ab and anti-SIRT2 Ab 
[Figure 5.1.15]. A yield of 10-15 mg of SIRT2.1 and 15-17 mg of SIRT2.4 was 
obtained per litre culture purified using this method. The purified protein were 
used for crystallisation screening (section 5.1.3.4) and SIRT2 activity assays 
(section 5.1.3.4). 
 
Figure 5.1. 10: Example of SIRT2.1 and SIRT2.4 expression trials analysed by 
SDS-PAGE. 
Expression trials for SIRT2.1 and SIRT2.4 analysed by SDS-PAGE. The 
molecular weights of the SDS-PAGE marker (M) are labelled. 
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Figure 5.1. 11: SIRT2.1 purification.  
Example chromatogram of (A) IMAC utilising the HisTrap FF column for 
purification of His-tagged SIRT2.1 followed by (B) SEC using a superdex 200 
column. Blue line represents the absorbance at A280 and the brown line 
represents the percentage of elution buffer. 
 
 
Figure 5.1. 12: Example of SDS-PAGE for SIRT2.1 purification. 
SIRT2.1 purification analysed by SDS-PAGE (A) samples from IMAC (lanes 1-5) 
followed by (B) SEC (lanes 6-8). The molecular weights of the SDS-PAGE 
marker (M) are labelled. 
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Figure 5.1. 13: SIRT2.4 purification.  
Example chromatogram of (A) IMAC utilising the HisTrap FF column for 
purification of His-tagged SIRT2.4 followed by (B) SEC using a superdex 200 
column. Blue line represents the absorbance at A280 and the brown line 
represents the percentage of elution buffer. 
 
 
Figure 5.1. 14: Example of SIRT2.4 purification analysed by SDS-PAGE. 
SIRT2.4 purification analysed by SDS-PAGE (A) samples from IMAC (lanes 1-5) 
followed by (B) SEC (lanes 6-9). The molecular weights of the SDS-PAGE 
marker (M) are labelled. 
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Figure 5.1. 15: Western blot analysis of SIRT2.1 and SIRT2.4. 
Purified samples of SIRT2.1 and SIRT2.4 analysed by western blotting (WB) 
using (A)anti-His Ab (B) anti-SIRT2 Ab. The molecular weights of the western 
blot marker (M1) are labelled. 
 
 
5.1.3.3. SIRT2 construct SIRT 2.7 
The recombinant gene for construct SIRT2.7 was cloned in a pGEx-6P-1 vector 
to facilitate the expression of SIRT2 with a covalently linked GST-tag to aid 
protein expression. The primers SIRT2.7fwd and SIRT2.7rev were used for PCR 
amplification of the desired region of the SIRT2.6 expression vector. A band of 
~1200 bp was observed on analysis of the sample on an agarose gel [Figure 
5.1.16].The resulting gene of interest was used for annealing with the PCR Blunt 
vector and was successfully transformed into E. coli TOP10 cells for DNA 
extraction and sequencing. Positive results for forward DNA sequencing was 
obtained. The alignment of the translated DNA sequence of SIRT2.7 in the 
recombinant bunt vector with SIRT2 is given in appendix E1.7. 
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Figure 5.1. 16: SIRT2.7. cloning.  
(A) Agarose gel of the PCR product for SIRT2.7. (B) Double digestion for 
SIRT2.7. The base pairs of the DNA ladder (M2) are labelled. 
 
On verification of the DNA sequence, successful double digestion of the pGEx-
6P-1 vector and the SIRT2.7 PCR blunt vector with EcoRI and BaHI restriction 
enzymes was carried out [Figure 5.1.16]. A drop out at ~1200 bp for the 
recombinant blunt vector and ~4000 bp for pGEx-6P-1 was observed. These 
bands were extracted and the drop outs were ligated to the double digested 
pEx-6P-1 vector. The ligated recombinant pGEx-6P-1 plasmid was transformed 
into TOP10 cells and the DNA was extracted for sequencing. Positive results for 
forward DNA sequencing was obtained. The alignment of the translated DNA 
sequence of SIRT2.7 with SIRT2 is given in appendix E1.8. Following 
verification of the DNA sequence, the plasmid was transformed into E. coli 
ArcticExpress (DE3) RIL cells to enable soluble expression of the protein at low 
temperatures. Expression of the protein during subsequent expression trails 
were analysed by SDS-PAGE and confirmed using anti-GST Ab for western blot 
analysis [Figure 5.1.17]. To avoid leaky expression, 10 mM glucose was added 
to the LB media during large scale expression trials [Figure 5.1.17].  
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Figure 5.1. 17: Example gel for SDS-PAGE analysis for expression of SIRT2.7. 
(A-B) Samples from SIRT2.7 expression trials in LB (C) samples from large scale 




Initial purification of SIRT2.7 was attained using GST-AC [Figure 5.1.18 and 
5.1.19]. A western blot analysis using anti-GST Ab and anti-SIRT2 Ab confirmed 
the identity of the protein [Figure 5.1.20]. The purified protein was treated with 
PreScission protease for GST-tag cleavage and the untagged SIRT2 was 
separated from GST using SEC [Figure 5.1.18 and 5.1.19]. Tryptic digest of in-
gel protein for mass spectrometric analysis was performed on the final purified 
protein to confirm the identity of the protein (~36kDa). A yield of ~5-7 mg of 
untagged SIRT2 per litre of cell culture was obtained from each purification. 
The purified protein was used in the SIRT2 activity assay and crystallisation 






Figure 5.1. 18: SIRT2.7 purification.  
Example chromatogram of (A) SIRT2.7 purification utilising a GSTrap FF 
column for GST-AC followed by PreScission protease treatment and (B) SEC 




Figure 5.1. 19: Example of purification of SIRT2.7 analysed by SDS-PAGE.  
SIRT2.7 purification analysed by SDS-PAGE (A) samples from GST-AC (lanes 1-
8) followed by (B) PreScission protease (lane BP) and SEC (lanes 9-10). The 




Figure 5.1. 20: Western blot analysis of SIRT2.7 after GST-AC. 
SIRT2.7 analysed by western blotting (WB) using (B) anti-GST Ab (C) anti-
SIRT2 Ab. The molecular weights of the SDS-PAGE marker (M) and western 
blot marker (M1) are labelled. 
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5.2.3.4. SIRT2 activity Assay 
The NAD+ binding activity of purified recombinant SIRT2 constructs SIRT2.1, 
SIRT2.4, SIRT2.6 and SIRT2.7 were confirmed by performing Fluor-de-lys®-
SIRT2 activity assay. The purified protein at three different concentrations were 
tested of which SIRT2.6a showed the highest activity at each concentration 
[Figure 5.1.21]. SIRT2.1 activity was observed to be lower than the control while 
SIRT2.4 and SIRT2.7 along with SIRT2.6s was much higher.  
 
Figure 5.1. 21: Fluor-de-lys®-SIRT2 activity assay on recombinant SIRT2 
constructs. 
SIRT2 activity assay performed using SIRT2.1, SIRT2.4, SIRT2.6a and SIRT2.7. 
Recombinant SIRT2 was used as a control.  
 
As SIRT2.6a showed the highest activity, inhibitor activity assays were 
performed using this protein to confirm that it recognises the inhibitor. 
Inhibitors, AGK2, CAM, SEL and suramin were used for this purpose. A DMSO 
control was also tested as AGK2, CAM and SEL were prepared in DMSO. The 
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control showed minimal contribution to the inhibitory activity of SIRT2.6a. The 
assay revealed that suramin shows the highest inhibitory activity compared to 
other compounds [Figure 5.1.22]. 
 
Figure 5.1. 22: Fluor-de-lys®-SIRT2 inhibition activity assay on recombinant 
SIRT2.6a. 
Inhibition of SIRT2 activity analysed using inhibitors AGK2, CAM, SEL and 




5.2.3.5. Crystallisation trials for SIRT2 
Finding the winning combination that supports crystal growth often begins 
with experiments deigned on a coarse grid aiming to seek important 
experimental variables that can be explored in greater detail. 
Crystallisation trials for SIRT2 started with setting up of sparse-matrix 
commercial conditions (Section 3.7.2). In an attempt to crystallise SIRT2, 
purified protein from constructs SIRT2.1, SIRT2.4, SIRT2.6 and SIRT2.7 were 
used for setting up automated preliminary crystallisation screening. All 12 
commercial crystallisation screens (12 screens x 96 conditions each x 3 ratios x 3 
temperatures x 4 protein constructs x 5 concentrations) were set up to for 
crystallisation of native SIRT2. The vapour diffusion sitting drop method was 
the preferred crystallisation technique.  
A variety of conditions were tried at different temperatures (4 ºC, 16 ºC and 21 
ºC), with drops containing the protein solution and the reservoir solution in a 
ratios of 1:1, 1:2 and 1:3. Protein concentrations of 2 mg/mL, 6 mg/mL, 8 
mg/mL, 10 mg/mL and 12 mg/mL were used for these experiments. It was 
observed that crystallisation of SIRT2 at concentrations above 8 mg/mL 
resulted in precipitation of the protein within 48 h of setting up of the 
crystallisation experiments. However, a mix of precipitation and clear drops 
were observed at other concentrations. It was also observed that incubation at 4 
ºC resulted in a decrease in precipitation of the protein at all concentrations. 
However, no crystals were observed at this temperature.  
As single crystal growth was not observed, randomised microseed matrix 
screening for SIRT2.4, SIRT2.6 and SIRT2.7 was performed. For this, all drops 
from JCSG-plus HT-96 plates after 2 months of incubation were pooled and 
used as seeds to set up additional screening conditions in the hope that any 
crystalline precipitate present in the pool would aid crystal growth. MemGold 
HT-96 and JCSG-plus HT-96 showed potential crystallisation hits for which 
optimisation plates using microseeding were set up [Figure 5.1.23].  
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Among the various constructs used, crystallisation screening showed that 
untagged SIRT2.7 precipitated much faster than 6xHis tagged SIRT2.6. Even 
after 6 months of incubation, many clear drops of SIRT2.6 at 12 mg/mL 
incubated at 4 ºC were observed. However, no signs of nucleation or 
crystallisation were seen.  
As crystallisation of native protein did not yield desirable results, crystallisation 
screening of SIRT2.6 in complex with inhibitors was set up which yielded many 
salt crystals. These were confirmed to be salt crystals on exposure to X-ray 
radiation. However, potential signs of crystallisation were observed in two 
conditions for SIRT2.6 (8-14mg/mL) in complex with suramin (protein to 
ligand ration of 1:3) which was incubated for 45 days at 4 ºC [Figure 5.1.22]. 
Recently, few of these conditions showed crystal like growth on incubation of 
SIRT 2.7 at 16 ºC for 2 months. These included B9 [0.005 M nickel chloride 
hexahydrate, 0.1 M sodium acetate pH 5.5, 20% [w/v] PEG 4000], C4 (0.5 M 
potassium phosphate monobasic, 0.1M sodium cacodylate pH 6.5) and F12 [0.15 
M potassium thiocyanate, 0.1 M Tris-HCl pH 7.5, 15% [w/v] PEG 6000] of the 
Clear Strategy II HT-96 screen. Further optimisation of these conditions have 
been set up.  
 
Figure 5.1. 23: Examples of crystallisation hits observed for SIRT2.  
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(A-C) SIRT2.6 in complex with suramin (8 mg/mL) (D-E) Native SIRT2.6 
microbatch plates (F-H) SIRT2.6 + suramin (14 mg/mL) (I-K) Native SIRT2.4 
(random microseed matrix screening). 
As the crystals for native structure of SIRT2 (PDB: 1J8F) were grown in 24% v/v 
ethanol, 200 mM NaCl and 100 mM bis-tris propane HCl pH 7.0 at 4 ºC, (Finnin 
et al., 2001) crystallisation experiments based on varying these conditions were 
designed. Screens varying crystallisation condition for SIRT2 in complex with 
ADPR (20% [w/v] PEG10,000, 100 mM ammonium acetate, 100 mM bis-tris pH 
5.5) (PDB: 3ZGV) (Moniot et al., 2013) were also designed. However, not much 
success was attained from these experiments. As ethanol was one of the 
constituents in the condition for native SIRT2, modified microbatch plates to 
ensure slow diffusion of ethanol into the crystallisation drop were set up. On 
incubation at 16 ºC for 2 months, many conditions showed crystal like growth 
[Figure 5.1.23]. However, exposure to X-ray radiation confirmed that these 
crystals were unlikely to be protein.  
Although SIRT2 was expressed and purified and was shown to be biologically 
active, its crystallisation to date has been unsuccessful. Possible reasons for this 
are discussed in section 5.4. 
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5.2 Sirtuin 7 
5.2.1. Introduction 
The human Sir2 orthologue, SIRT7, is a class IV sirtuin and is the least 
understood member of the mammalian sirtuin family. However, it has several 
features suggesting its importance in human diseases such as cancer. It has poor 
NAD+ dependent deacetylase activity compared to other sirtuin members. It is 
not yet known whether it requires activation by free fatty acids as observed for 
SIRT6, the closest homolog of SIRT7 and only other member of class IV sirtuin 
(Feldman et al., 2013, Pan et al., 2011) [Table 5.2.1]. Three splice variants of SIRT7 
have been reported, isoforms 1-3 with 400, 183 and 320 residues, respectively 
(UniProt, 2014). Isoform 1 is the canonical SIRT7.  
Table 5.2. 1: Overview of the results of a sequence comparison of SIRT7 with 
other human sirtuins. 
ClustalO was used for sequence comparison (UniProt, 2014). 
  Identity (%) Identical positions 
SIRT7 SIRT1 10.354 82 
SIRT7 SIRT2 18.49 83 
SIRT7 SIRT3 17.36 83 
SIRT7 SIRT4 17.65 78 
SIRT7 SIRT5 14.71 64 
SIRT7 SIRT6 29.79 126 
 
SIRT7 is a highly selective H3K18Ac deacetylase and plays a pivotal role in 
chromatin regulation, cellular transformation programs and tumour formation 
(Barber et al., 2012). This is a result of depletion of the SIRT7 histone mark 
which is associated with highly malignant cancers and poor patient prognosis. 
SIRT7 is localised in the nucleolus, which is the subcellular site of ribosome 
assembly that increases in size and number in aggressive tumours (Hein et al., 
2013, Michishita et al., 2005). As SIRT7 has an impact on ribosome biogenesis 
through multiple mechanisms, it may be playing a role in supporting the high 
biosynthetic and metabolic demands of cancer cells (Paredes et al., 2014). These 
functions of SIRT7 suggest a role as a central coordinator of epigenetic and 
cellular homeostatic programs that support cancer progression.  
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The primary structure of SIRT7 is the least similar to the other member of the 
Sir2 family. The SIRT7 enzymatic domain shows an average similarity of 18% 
similarity to the highly conserved core domain of other sirtuins and 29.79% 
similarity to the closest sirtuin member, SIRT6 [Table 5.2.1]. The non-conserved 
N- and C-terminal flanking regions of SIRT7 may play a role in its relatively 
low deacetylase activity. These regions in other sirtuins have been shown to 
bind to endogenous chemical regulators (Davenport et al., 2014, Sinclair and 
Guarente, 2014, Tennen et al., 2010, Zhao et al., 2003).  
The highly conserved co-factor binding loop observed in other sirtuins, which is 
responsible for structural contacts and enzymatic activity, is replaced by a 
single helix containing several NAD+ binding residues in SIRT6. The structure 
of SIRT7 has not yet been determined, however, predictions made based on its 
primary sequence comparison to other sirtuins indicate that SIRT7 also lacks 
this domain and is likely to adopt the same unique structural feature observed 
in SIRT6 (Pan et al., 2011).  
 
Figure 5.2. 1: Key features of the structure of SIRT7. 
A schematic representation of the structure of SIRT7. The structurally important 
cysteine (C) residues involved in zinc binding are indicated along with the 
histidine (H) residue that behaves as a proton acceptor.  
 
In contrast to other sirtuins, small-molecule modulator screening for SIRT7 has 
not been amenable due to its poor deacetylase activity on the substrates used 
for these screens. The recent identification of SIRT7 substrates has helped 
overcome this barrier and will aid the design of SIRT7-specific modulating 
compounds (Barber et al., 2012, Chen et al., 2013). However, deeper 
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understanding of SIRT7 biology at the molecular and physiological level is 
essential for understanding the potential therapeutic benefits and detrimental 
side effects of SIRT7 modulation.  
To provide a clear picture of the structural contribution of SIRT7 to its 
elusive enzymatic activity, structural and biochemical studies of SIRT7 were 
initiated. In this context, the cloning, expression, purification and 
crystallisation of full length SIRT7 [Figure 5.2.1] was carried out. Structural 
understanding of SIRT7 will provide valuable insight into its physiological 
role.  
 
   
212 
5.2.2. Methods 
5.2.2.1. Cloning, Expression and Purification 
Table 5.2.2 summarises the constructs of SIRT7 that were designed for 
expression with covalently linked affinity tags to help expression and 
purification of the protein. The vector maps are provided in appendix A. The 
final optimised cloning, expression and protein purification protocols for each 
construct are given below. 







7.1 1-400 pTriEx-4 Ek/LIC N-term His and S-tag 49.6 
7.6 1-400 pET-41 Ek/LIC 
N-term GST, His and 
S-tag 
76.2 
7.7 1-400 pGEx-6P-1 N-term GST tag 71.3 
 
SIRT 7.1 
The gene coding for SIRT7 was cloned into the pTriEx-4 Ek/LIC vector 
(Novagen, Darmstadt, Germany) with a cleavable N-terminal poly-histidine 
and S-tag. This recombinant plasmid was named SIRT7.1.  
The plasmid was transformed into E. coli TOP10 cells and the DNA was 
extracted for sequencing and transformation into E. coli Rosetta-gamiTM 
2(DE3)pLysS cells as described in Section 3.4.2. Extracted DNA was sent for 
sequencing to Eurofins MWG Operon, Ebersberg, Germany using T7 primer for 
forward sequencing. Expression trials were carried out by inoculating AI, LB 
and TB media with ampicillin and chloramphenicol as described in Section 
3.4.1. Samples were collected at regular intervals and expression was analysed 
by SDS-PAGE. As insoluble expression was observed, various screens were 
tested to identify appropriate conditions for solubilisation of inclusion bodies 
and protein refolding, as described in section 3.5.2. 
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 For large scale expression, cells were grown in LB media at 37 ºC to an O.D. of 
0.6–0.7 and cultures were then induced with 1 mM IPTG. Cells were harvested 
after 18 h of induction by centrifugation (4 ºC at 12,000 g, 10 min). Induction of 
protein expression was analysed by SDS-PAGE.  
Refolded SIRT7.1 was purified using IMAC followed by SEC. Cell pellets were 
resuspended in lysis buffer (50 mM Tris HCl pH 7.4) and lysed in an One shot 
model (Constant systems, U.K.). The preparation was then clarified by 
centrifugation (4 ºC at 30,000 g, 30 min). The pellet was resuspended in 50 mM 
HEPES pH 7.4, 0.1% v/v Triton x100 and clarified by centrifugation (4 °C at 
10,000 g, 30 min). Following the wash step, inclusion bodies were solubilised in 
the solubilisation buffer (50 mM Tris HCl, 500 mM NaCl, 7 M guanidine HCl, 
0.15 M reduced glutathione) and the sample was left stirring overnight at 4 ºC. 
A drop-wise rapid dilution method was employed for refolding in the refolding 
buffer (50 mM Tris HCl pH 7.4, 0.1 % [w/v] PEG6000, 200 mM NaCl), which was 
subsequently left undisturbed overnight. The preparation was clarified by 
centrifugation (4 °C at 12,000 g, 15 min). The supernatant was loaded on a 5 mL 
HisTrap FF column (GE Healthcare, Uppsala, Sweden) pre-equilibrated with 
wash buffer (50 mM Tris HCl pH 7.4, 200 mM NaCl, 15 mM imidazole). The 
column was washed extensively and a gradient elution of 0-100% buffer B (50 
mM Tris HCl pH 7.4, 200 mM NaCl, 500 mM imidazole) over 50 mL was carried 
out. The eluted fraction was dialysed overnight in wash buffer at 4 °C and 
loaded on a gel filtration column (16/600 Superdex 200 pg; GE Healthcare, 
Uppsala, Sweden) pre-equilibrated with final buffer (50 mM Tris HCl pH 7.4, 
200 mM NaCl). The eluted samples were analysed by SDS-PAGE. Western blot 
analysis using anti-His Ab (Sigma-Aldrich Co., Kent, U.K.) and mass 
spectrometric analysis of the samples were carried out to confirm the identity of 






Alternatively, SIRT7.1 was purified by another method (referred to as 
SIRT7.1a). SIRT7.1a (pI 9.65) was purified by cation exchange chromatography 
(CIEX). The refolded protein was loaded on a manually packed 10 mL 
sulphopropyl (SP) sepharose (Sigma Aldrich, MO, USA) column pre-
equilibrated with wash buffer (50 mM Tris HCl pH 7.4). The column was 
washed extensively and a gradient elution of 0-100% buffer B (50 mM Tris HCl 
pH 7.4, 1 M NaCl) over 100 mL was carried out. The eluted samples were 
analysed by SDS-PAGE. 
SIRT7.6 
The gene coding SIRT7 was cloned into pET-41 Ek/LIC vector (Novagen, 
Darmstadt, Germany) with a cleavable N-terminal GST-tag. This recombinant 
plasmid was named SIRT7.6. 
The recombinant plasmid SIRT7.1 was used for PCR amplification as described 
in Section 3.4.2. The primers used for PCR amplification are given in table 5.2.3, 
while the components of the reaction mixtures and the parameters for thermal 
cycling are given in tables 5.2.4 and 5.2.5, respectively. 
Table 5.2. 3: Primers used for PCR reaction of SIRT7.6 
Primer Sequence (5’-3’) 
SIRT7.6fwd GAC GAC GAC AAG ATG GCA GCC GGG CTG AGC CGC 










Table 5.2. 4: PCR reaction for SIRT7.6 
Reaction Tube 1 (µL) Tube 2 (µL) Tube 3 (µL) 
DNA template  
(SIRT7.1)(100ng/µL) 
2 2 2 
Primer (SIRT7.6fwd)  
(10 µM) 
1.5 1.5 1.5 
Primer (SIRT7.6rev) 
(10 µM) 
1.5 1.5 1.5 
KOD polymerase 
(1U/µL) 
1 1 1 
10x Buffer 5 5 5 
dNTPs (2mM each) 5 5 5 
MgSO4 (25 mM) 3 3 3 
Betaine - 10 - 
DMSO - - 2 
Water (q.s. 50 µL) 31 21 29 
 
Table 5.2. 5: PCR thermal cycle for SIRT7.6 
Cycle Temperature (ºC) 
Time (min) 
Initial denaturation 94 2 
Denaturation 94 0.5 
Annealing 62 1 
Extension 72 1 
Back to step 2 
(Denaturation) for 35x 
  
Final extension 72 10 
Hold at 4oC   
 
The PCR products were analysed by running the samples on an agarose gel as 
described in section 3.4.1. The final purified product was ligated into the pET-
41Ek/LIC vector (Novagen, Darmstadt, Germany) with a cleavable N-terminal 
GST, His and S-tag. The recombinant vector was transformed into E. coli TOP10 
cells and the DNA was extracted as described in section 3.4.2. The sequence 
verified plasmid was then transformed into E. coli Rosetta-gamiTM 2(DE3)pLysS 
cells and glycerol stocks were prepared as described in Section 3.4.2. Expression 
trials were carried out by inoculating in LB, TB, modified TB, HIS, ZXY7, SOC, 
glucose M9Y, superbroth, TYGPN and NZCYM media supplemented with 
kanamycin and chloramphenicol as described in Section 3.4.1. Composition of 
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the various media is given in appendix B. Samples were collected at regular 
intervals and protein expression was analysed by SDS-PAGE. 
SIRT7.6a 
The recombinant plasmid was transformed into E. coli ArcticExpress (DE3) RIL 
cells and glycerol stocks were prepared as described in Section 3.4.2. This 
transformant was named SIRT7.6a. 
Expression trials in LB media were carried out as per manufacturer’s 
instructions for E. coli ArcticExpress (DE3) RIL cells. For large scale expressions, 
overnight cultures were grown in LB media supplemented with gentamycin 
and kanamycin. Large cultures were grown by inoculating modified LB media 
(+10 mM MgCl2 and 10 mM glucose) containing no antibiotics with overnight 
cultures. These large scale cultures were grown for 6 h at 30 ºC before being 
induced with 1 mM IPTG. The cells were then grown at 10 ºC overnight. Cells 
were harvested after 18 h of induction by centrifugation (4 °C at 12,000 g, 10 
min). Induction of protein expression was analysed by SDS-PAGE.  
SIRT7.6a was purified using GST-AC followed by GST-tag cleavage and SEC. 
Cell pellets were resuspended in PBS (140 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.3) and were lysed in an One shot model 
(Constant systems, U.K.). The preparation was then clarified by centrifugation 
(4 °C at 30,000 g, 30 min). The supernatant was loaded on a 5 mL GSTrap FF 
column (GE Healthcare, Uppsala, Sweden) pre-equilibrated with PSB. The 
column was washed extensively with PBS and a single step elution (50 mM Tris 
HCl pH 8.0, 10 mM reduced glutathione) was carried out. The eluted fraction 
was concentrated and desalted using a HiPrep 26/10 desalting column (GE 
Healthcare, Uppsala, Sweden). The eluate was concentrated and loaded on a gel 
filtration column (16/600 Superdex 200 pg; GE Healthcare, Uppsala, Sweden) 
pre-equilibrated with final buffer (50 mM Tris HCl pH 7.4, 200 mM NaCl). The 
eluted samples were analysed by SDS-PAGE. Western blot analysis using anti-
GST Ab (Sigma-Aldrich Co., Kent, U.K.) and in–gel tryptic digest mass 
spectrometric analysis of the samples were carried out to confirm the identity of 
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the protein. GST-tag cleavage trial experiments with enterokinase (Trevigen, 
MD, USA) were carried out as per manufacturer’s protocols. 
 SIRT 7.7 
The gene coding SIRT7 was cloned into the pGEx-6P-1 vector (GE Healthcare, 
U.K.) with a cleavable N-terminal GST-tag. The recombinant plasmid SIRT7.1 
was used for PCR amplification as described in section 3.4.2. Primers were 
designed such that a EcoR1 restriction site was incorporated into the DNA using 
the forward primer and an Xho1 restriction site was incorporated using the 
reverse primer. The primers used for PCR amplification are given in table 5.2.6, 
while the components of the reaction mixtures and the parameters for thermal 
cycling are given in tables 5.2.7 and 5.2.8, respectively. 
Table 5.2. 6: Primers used for PCR reaction of SIRT7.7 
Primer Sequence (5’-3’) 
SIRT7.7fwd GAA TTC ATG GCA GCC GGG GGT CTG 
SIRT7.7rev CTC GAG TTA CGT CAC TTT CTT CCT 
 
Table 5.2. 7: PCR reaction for SIRT7.7 
Reaction Tube 1 (µL) Tube 2 (µL) 
DNA template  
(SIRT7.1) (100ng/µL) 
2 2 






KOD polymerase  
(1U /µL) 
1 1 
10x Buffer 5 5 
dNTPs (2 mM each) 5 5 
MgSO4 (25 mM) 2 2 
Betaine 10 10 
DMSO 2 - 
Water (q.s. 50 µL) 20 22 
 
 
Table 5.2. 8: PCR thermal cycle for SIRT7.7 
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Cycle Temperature (ºC) 
Time (min) 
Initial denaturation 95 2 
Denaturation 95 0.5 
Annealing 50 1 
Extension 72 1 
Back to step 2 
(Denaturation) for 35x 
  
Final extension 72 10 
Hold at 4oC   
 
The PCR products were analysed by running the samples on an agarose gel as 
described in section 3.4.1. The final purified product was ligated with a pCR™-
Blunt vector (Zero Blunt® PCR Cloning Kit, Invitrogen, CA, USA). The 
recombinant vector was transformed into E. coli TOP10 cells and the DNA was 
extracted as described in section 3.4.2. Double digestion experiments to test for 
the presence of an insert were performed by incubating the reaction mixture 
[Table 5.2.9] for 1 h at 37 ºC. FastDigest XhoI and EcoRI (Thermo scientific, MA, 
USA) were used for double digestion of the recombinant blunt vector (RBV) 
and pGEx-6P-1 vector (GE Healthcare, Uppsala, Sweden). 
Table 5.2. 9: Double digestion set up for SIRT7.7. 






Xho1 1 4 4 
EcoR1 1 4 4 
RBV / (pGEx-6P-1 
vector) 
6 25 25 
10x FastDigest 
Green buffer 
1 5 5 
Water  1 (q.s. 10 µL) 12 (q.s. 50 µL) 12 (q.s. 50 µL) 
 
Following successful test double digests, the recombinant blunt vector was sent 
for sequencing to Eurofins MWG Operon, Ebersberg, Germany using the M13(-
21) primer. Final double digestion of the RBV and pGEx-6P-1 vector was carried 
out on verification of the sequencing results [Table 5.2.9]. The Rapid DNA 
Ligation kit (Thermo Scientific, MA, USA) was used for ligations. Ligation of 
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the drop out (~1400 bp) from the RBV and the treated pGEx-6P-1 was carried 
out by incubating the ligation reaction (1 µL T4 DNA ligase, 1 µL treated pGEx-
6P-1, 6 µL RBV drop out, 2 µL 5x rapid ligation buffer) for 1 h at 21 ºC. The 
recombinant plasmid was transformed into E. coli TOP10 cells and the DNA 
was extracted for sequence analysis as described in Section 3.4.2. On verification 
of sequence, the final recombinant plasmid was transformed into E. coli 
ArcticExpress (DE3) RIL cells and glycerol stocks were prepared as described in 
Section 3.4.2. Expression trials in LB media were carried out as per the 
manufacturer’s instructions for E. coli ArcticExpress (DE3) RIL cells. 
For large scale expressions, overnight cultures were grown in LB media with 
gentamycin and ampicillin. Large cultures were grown by inoculating modified 
LB media (+10 mM glucose) containing no antibiotics with overnight cultures. 
These cultures were grown for 6 h at 30 oC before being induced with 
1 mM IPTG and grown overnight at 10 oC. Cells were harvested after 18 h of 
induction by centrifugation (4 °C at 12,000 g, 10 min). Induction of protein 
expression was analysed by SDS-PAGE.  
SIRT7.7 was purified using GST-AC followed by GST tag cleavage and a second 
GST-AC to separate the cleaved protein from the tag. Cell pellets were 
resuspended in PBS (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4, pH 7.3) and lysed in an One shot model (Constant systems, U.K.). The 
preparation was then clarified by centrifugation (4 °C at 30,000 g, 30 min). The 
supernatant was loaded on a 5 mL GSTrap FF column (GE Healthcare, Uppsala, 
Sweden) pre-equilibrated with PBS. The column was washed extensively and a 
single step elution (50 mM Tris HCl pH 8.0, 10 mM reduced glutathione) was 
carried out. The eluted fraction was concentrated and desalted using a HiPrep 
26/10 desalting column (GE Healthcare, Uppsala, Sweden). Western blot 
analysis using anti-GST Ab and in–gel tryptic digest mass spectrometric 
analysis of the samples were carried out to confirm the identity of the protein. 
PreScission protease (GE Healthcare, Uppsala, Sweden) was added to the 
eluted protein (one unit protease cleaves 90% 100 µg of GST fusion protein) and 
the sample was dialysed overnight in 50 mM Tris HCl pH 8.0, 10 mM reduced 
220 
glutathione at 4 ºC. The GST cleaved protein was loaded on a 1 mL GSTrap FF 
column (GE Healthcare, Uppsala, Sweden) pre-equilibrated with final buffer 
(50 mM Tris HCl pH 8.0, 200 mM NaCl). SIRT7 was collected in the flow through 
and crystallisation experiments were set up.  
5.2.2.2. SIRT7 activity assay 
To detect the ADP-ribosylation activity of SIRT7, western blot analysis using 
Biotinylated NAD+ (Trevigen, MD, USA) and horseradish peroxidase (HRP)-
conjugated streptavidin (Thermo scientific, MA, USA) was performed. 
Biotinylated NAD+ was supplied at 25 µM in water. Refolding and activity of 
SIRT7.1 was confirmed by this assay. SIRT7.1 samples were prepared (7µL 
SIRT7 at 3 mg/mL + 10 µL biotinylated NAD+ 3 µL water) and analysed as per 
western blot analysis described in 3.5.3.2. However, 1% [w/v] bovine serum 
albumin (BSA) was used in place of milk powder throughout the experiment.  
5.2.2.3. Crystallisation experiments 
Crystallisation trials for SIRT7 started with sparse-matrix commercial 
conditions (Section 3.7.2). The vapour diffusion sitting drop method was the 
preferred crystallisation technique. A variety of conditions were tried at 
different incubation temperatures (4 ºC, 16 ºC and 21 ºC), with drops containing 
the protein solution and the reservoir solution in ratios of 1:1, 1:2 and 1:3.  
The protein obtained from constructs SIRT7.1, 7.1a, 7.6a and 7.7 were used for 
setting up expression trials as described in section 3.7.2. Initial crystallisation 
trials of native SIRT 7 were set up in their respective final purification buffers. 
Protein concentrations of 2 mg/mL, 6 mg/mL and 8 mg/mL were used for 
these experiments. Additional trials after dialysis of native SIRT7 into five other 




Table 5.2. 10: Buffers used for the dialysis of SIRT7 prior to setting up 
crystallisation screens.  
Buffer Components 
Buffer 1 50 mM Tris HCl pH 7, 200 mM NaCl 
Buffer 2 100 mM Tris HCl pH 8, 150 mM NaCl 
Buffer 3 50 mM Tris HCl pH 7.4, 200 mM NaCl, 0.01% v/v TCEP 
Buffer 4 50 mM HEPES pH 7.4, 150 mM NaCl 
Buffer 5 50 mM HEPES pH 6, 150 mM NaCl 
 
Commercial crystallisation screens for SIRT7.6 in complex with NAD+ and 
SIRT7.6 (6 mg/mL) in complex with ADPR were set up at molar ratios of 1:1, 
1:2, 1:4 and 1:10 of protein to NAD+ or ADPR. Systematic screening of hits was 




5.2.3.1. SIRT7 construct SIRT7.1 
The recombinant gene for full length SIRT7 was cloned into the pTriEx-4 
Ek/LIC vector in order to facilitate its expression with a covalently linked His-
tag. The expressed protein is expected to have a theoretical mass of 50 kDa. 
Following verification of a correct DNA sequence and subsequent 
transformation, expression trials in LB, TB and AI media at 37 oC for construct 
SIRT7.1 were carried out. SIRT7 expression was observed in all three media 
[Figure 5.2.2]. Positive results for forward DNA sequencing was obtained. The 
alignment of the translated DNA sequence of SIRT7.1 with SIRT7 is given in 
appendix E2.1. As expression in LB media showed the lowest level of 
impurities, it was selected as the growth medium for further expressions. 
However, SIRT7 was expressed in the form of inclusion bodies as opposed to a 
soluble form [Figure 5.2.2]. 
 
Figure 5.2. 2: SIRT7.1 expression trials analysed by SDS-PAGE.  
(A) SIRT7.1 expression trial in AI, LB and TB media at 37 oC. (B) The soluble 
fraction and the pellet after cell disruption of the I-16h expression sample in LB 
media analysed by SDS-PAGE. The molecular weights of the SDS-PAGE 




Figure 5.2. 3: SIRT7.1 expression in LB media analysed by SDS-PAGE.  
SIRT7.1 expression trials analysed by SDS-PAGE. (A) Expression trial at 37 ºC. 
(B) Expression trial at 16 ºC. The molecular weights of the SDS-PAGE marker 
(M) are labelled. 
 
To confirm the insoluble expression observed was not due to expression at a 
high temperature, expression trials at 16 ºC were carried out in LB. This trial 
confirmed that insoluble expression at 37 oC was more favourable as no protein 
expression was not observed at 16 oC [Figure 5.2.3]. Solubilisation and refolding 
trials were performed to select the appropriate conditions for treatment of the 
inclusion bodies. Condition C (100 mM Tris HCl pH 8, 500 mM NaCl, 7 M 
guanidine HCl, 150 mM reduced glutathione) in the solubilisation trial was 
identified as most suitable. This was based on the protein being observed in the 
soluble fraction while the impurities remained in the pellet [Figure 5.2.4]. 
Refolding of the protein was achieved using conditions E8 (50 mM Tris HCl pH 
8, 500 mM L-Arginine) and F3 (50 mM Tris HCl pH 8, 100 mM NaCl, 0.1% [w/v] 
PEG 6000). Successful purification of SIRT7.1 was achieved using the E8 
refolding condition followed by IMAC and SEC [Figure 5.2.5 and 5.2.6]. A yield 
of 5-7 mg per litre of culture was observed. The identity of the sample was 
confirmed using mass spectrometric analysis [Figure 5.2.7] and western blot 
analysis using anti-His Ab [Figure 5.2.8]. Additionally, CIEX of the refolded 
protein (referred to as SIRT7.1a) was attempted to attain higher purity and yield 
of SIRT7.1 [Figure 5.2.9 and 5.2.10]. A yield of 10-15 mg per litre of culture was 
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obtained using this method. Crystallisation screening, which was set up using 
both SIRT7.1 and SIRT7.1a protein, is discussed in section 5.2.3.4.  
A major concern for proteins expressed as inclusion bodies is correct refolding 
of the protein after denaturation. Correct refolding of the protein is crucial for 
the protein to be active. To confirm the retention of activity and correct 
refolding of SIRT7.1a, SIRT7 activity assay was performed which is discussed in 
section 5.2.3.4. This purified protein was also used to set up crystallisation 
experiments discussed in section 5.2.3.5. 
 
Figure 5.2. 4: Example of solubilisation and refolding of SIRT7.1 analysed by 
SDS-PAGE.  




Figure 5.2. 5: SIRT7.1 purification.  
Example chromatogram of (A) IMAC utilising the HisTrap FF column for 
purification of His-tagged SIRT7.1 followed by (B) SEC using a superdex 200 
column. Blue line represents the absorbance at A280 and the brown line 




Figure 5.2. 6: Example of SIRT7.1 purification analysed by SDS-PAGE.  
SIRT7.1 purification analysed by SDS-PAGE (A) samples from IMAC (lanes 1-4) 
followed by (B) SEC (lanes 5-8). The molecular weights of the SDS-PAGE 
marker (M) are labelled. 
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Figure 5.2. 7: Mass spectrometric analysis of SIRT7.1. 
Purified sample of SIRT7.1 analysed by mass spectrometric analysis. The peak 
corresponding to SIRT7.1 (49.6 kDa) is indicated. 
 
 
Figure 5.2. 8: Example of SIRT7.1 western blot analysis using anti-His Ab. 
Samples of SIRT7.1 analysed by western blotting (WB) using anti-His Ab. The 





Figure 5.2. 9: SIRT7.1a purification. 
Example chromatogram of CIEX by a manually packed SP sepharose column 
for purification of SIRT7.1a. 
 
 
Figure 5.2. 10: Example of SIRT7.1a purified by CIEX analysed by SDS-
PAGE. 
Purification of SIRT7.1a analysed by SDS-PAGE. The molecular weights of the 
SDS-PAGE marker (M) are labelled. 
 
5.2.3.2. SIRT7 construct SIRT 7.6 
The construct SIRT7.6 was designed to enable the soluble expression of SIRT7. 
The recombinant gene for SIRT7.6 was cloned in a pET41-EK/LIC vector to 
facilitate the expression of SIRT7 with a covalently linked GST-tag to aid 
protein expression. The presence of this tag may also facilitate its crystallisation 
was unsuccessful with His-tagged SIRT7.1. 
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The primers SIRT7.6fwd and SIRT7.6rev were used for PCR amplification of the 
SIRT7.1 expression vector where a band of ~1400 bp was observed on analysis 
of the sample on an agarose gel [Figure 5.2.11]. The resulting gene of interest 
was used for annealing with the vector pET41-Ek/LIC followed by the 
successful transformation into E. coli TOP10 cells and DNA extraction. On 
verification of the DNA sequencing, transformation of SIRT7.6 recombinant 
plasmid into E. coli Rosetta-gamiTM 2(DE3)pLysS cells were carried out. The 
alignment of the translated DNA sequence of SIRT7.6 with SIRT7 is given in 
appendix E2.2. Expression trials were initially performed in LB and TB media 
which showed expression of SIRT7.1 as inclusion bodies [Figure 5.2.11]. Further 
expression trials in nine additional media at 37 ºC yielded similar results 
[Figure 5.2.12]. To confirm the insoluble expression observed was not due to 
expression at high temperature, expression trials at 16 ºC in superbroth media 
were carried out which showed no expression of SIRT7.6 [Figure 5.2.12]. 
As soluble expression of SIRT 7.6 was sought, the recombinant plasmid for 
SIRT7.6 was transformed into E. coli ArcticExpress (DE3) RIL cells (referred to 
as SIRT7.6a) and expression trials in LB media showed soluble expression of the 
protein [Figure 5.2.13]. E. coli ArcticExpress (DE3) RIL cells are engineered to 
enable efficient expression of heterologous protein at lower temperatures to 
ensure its soluble expression. However, leaky expression was observed in 
addition to the chaperonin Cpn60 getting co-purified with SIRT7.6a during 
initial purification trials. Addition of 10 mM MgCl2 and 10 mM glucose to the LB 
media during expression solved both the problems [Figure 5.2.13]. Successful 
purification of SIRT7.6a using GST-AC followed by desalting and SEC was 
achieved [Figure 5.2.14 and 5.2.15]. An yield of 10-15 mg of the GST-tagged 
SIRT7.6 was obtained using this method. This purified protein was used to set 




Figure 5.2. 11: Cloning and expression trials for SIRT7.6.  
(A) Agarose gel of the PCR product for SIRT7.6. (B) Expression trials for SIRT7.6 
in LB and TB at 37 oC. The base pairs of the DNA ladder (M2) and molecular 
weights of the SDS-PAGE marker (M) are labelled. 
 
 
Figure 5.2. 12: Expression trials for SIRT7.6 analysed by SDS-PAGE.  
(A-C) Samples from SIRT7.6 expression trials at 37 ºC (D) Large scale expression 
in superbroth at 16 ºC and 37 ºC. The molecular weights of the SDS-PAGE 




Figure 5.2. 13: Example of SDS-PAGE analysis of expression of SIRT7.6a in 
LB media.  
Cultures after induction incubated at 16 ºC. (A) Expression in LB media. (B) 
Expression in modified LB media (+ 10 mM MgCl2 and 10 mM glucose). (C) SDS-
PAGE of SIRT7.6a after cell disruption.  
 
 
Anti-GST Ab was used for western blot analysis of SIRT7.6a to confirm the 
identity of the protein [Figure 5.2.14]. As dialysis of SIRT7.6a in water for intact 
mass spectrometric analysis resulted in precipitation of the protein, tryptic 
digest of in-gel protein for mass spectrometric analysis was employed which 
confirmed the identity of the protein On treatment with enterokinase restriction 
enzyme to cleave the GST-tag from the purified protein, precipitation of the 
protein was observed. Thus, all crystallisation experiments were set up using 
the GST-tagged protein. 
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Figure 5.2. 14: Example of purification of SIRT7.6a analysed by SDS-PAGE 
and western blot analysis using anti-GST Ab.  
The molecular weights of the SDS-PAGE marker (M) and the western blot 




Figure 5.2. 15: Purification of SIRT7.6a. 
Example chromatogram of (A) GST-AC utilising the GSTrap FF column for 
purification of GST-tagged SIRT7.6a followed by (B) desalting and (C) SEC 
using a superdex 200 column. Blue line represents the absorbance at A280 and 





5.2.3.3. SIRT7 construct SIRT7.7 
As GST-tag cleavage of SIRT7.6a, to obtain untagged SIRT7, resulted in 
precipitation of the protein, SIRT7.7 construct was designed. The recombinant 
gene for construct SIRT7.7 was cloned in a pGEx-6P-1 vector to facilitate the 
expression of SIRT7 with a covalently linked GST-tag to aid protein expression. 
The primers SIRT7.7fwd and SIRT7.7rev were used for PCR amplification of 
SIRT7.1 expression vector where a band of ~1400 was observed on analysis of 
the sample on an agarose gel [Figure 5.2.16]. The resulting gene of interest was 
used for annealing with the PCR Blunt vector and was successfully transformed 
into E. coli TOP10 cells for DNA extraction and sequencing. Positive results for 
forward DNA sequencing was obtained. The alignment of the translated DNA 
sequence of SIRT7.7 in the PCR blunt vector with SIRT7 is given in appendix 
E2.3. 
On verification of the DNA sequencing, double digestion of pGEx-6P-1 vector 
and SIRT7.7 PCR blunt vector with EcoRI and XhoI restriction enzymes were 
carried out [Figure 5.2.16]. A drop out at ~1400 bp for the blunt vector and 
~4000 bp for pGEx-6P-1 was observed. These bands were extracted and ligation 
of the double digested vector with drop out from the blunt vector was carried 
out. The ligated recombinant plasmid was transformed into Top 10 cells and the 
DNA was extracted for sequencing. Positive results for forward DNA 
sequencing was obtained. The alignment of the translated DNA sequence of 
SIRT7.7 in pGEx-6P-1 vector with SIRT7 is given in appendix E2.4. On 
verification of the DNA sequencing, the plasmid was transformed into E. coli 
ArcticExpress (DE3) RIL cells to enable soluble expression of the protein at low 
temperatures. To avoid leaky expression, 10 mM glucose was added to the LB 
media during expression [Figure 5.2.17]. Purification of SIRT7.7 was attained 
using GST-AC followed by desalting. [Figure 5.2.17 and 5.2.18]. Tryptic digest 
of in-gel protein for mass spectrometric analysis confirmed the identity of the 
protein. PreScission protease treatment for GST-tag cleavage was performed 
and the resulting untagged protein (~41 kDa) was collected in the flow through. 
An yield of ~3-5 mg of untagged SIRT7 per litre of cell culture was obtained. 
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This sample was used for crystallisation experiments discussed in section 
5.2.3.5.  
 
Figure 5.2. 16: SIRT7.7. cloning.  
(A) Agarose gel of the PCR product for SIRT7.7. (B) Double digestion for 




Figure 5.2. 17: Example gel for expression and purification of SIRT7.7 
analysed by SDS-PAGE.  
(A) SIRT7.7 expression in LB media. (B) Purification of SIRT7.7 by GST-AC, 
desalting followed by PreScission Protease treatment and GST-AC. The 




Figure 5.2. 18: SIRT7.7 purification. 
Example chromatogram using GSTrap FF column for purification of GST 
tagged SIRT7.7. Blue line represents the absorbance at A280. 
 
5.2.3.4. SIRT7 activity assay 
The SIRT7 activity assay was performed for SIRT7.1a to ensure correct refolding 
of the protein after denaturation during its purification. Incorrect refolding of 
the protein and the resulting inactive protein remain two major concerns for 
crystallisation of proteins expressed as inclusion bodies.  
To confirm that the protein was active, an assay was designed to detect the 
binding of NAD+ to SIRT7. This was done through western blot analysis using 
biotinylated NAD+ which binds to the protein and is detected using HRP-
conjugated streptavidin. The DAB colorimetric detection method was used to 
visualise the final product. Figure 5.2.19 shows the western blot membrane after 
detection with DAB. The detection of the SIRT7-NAD+ complex at the expected 




Figure 5.2. 19: NAD+ activity assay for SIRT7.1.  
(A) Membrane after transfer stained with Ponceau S stain. (B) Membrane after 
detection using HRP-conjugated streptavidin followed by colorimetric detector, 
DAB. The molecular weights of the western blot marker (M1) are labelled. 
 
5.2.3.5. Crystallisation trials for SIRT7 
In an attempt to determine the experimental variables and a suitable condition 
for crystal growth, various experiments based on a coarse grid were designed. 
Crystallisation trials for SIRT7 started with setting up of sparse-matrix 
commercial conditions (Section 3.7.2). In an attempt to crystallise SIRT 7, 
purified protein from constructs SIRT7.1, SIRT7.1a, SIRT 7.6, SIRT7.6a and 
SIRT7.7 were used for setting up automated preliminary crystallisation 
screening. All 12 commercial crystallisation screens (12 screens x 96 conditions 
each x 3 ratios x 3 temperatures x 5 protein constructs x 5 buffers) were set up to 
facilitate the crystallisation of native SIRT7. The vapour diffusion sitting drop 
method was the preferred crystallisation technique. A variety of conditions 
were tried at different temperatures (4 ºC, 16 ºC and 21 ºC), with drops 
containing the protein solution and the reservoir solution in a ratio of 1:1, 1:2 
and 1:3.  
Of the various conditions used for crystallisation screening, many deceptive salt 
crystals were obtained which was confirmed on X-ray exposure at the 
synchrotron. Some screens including Clear Strategy I HT-96, Clear Strategy II 
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HT-96 and Morpheus HT-96 produced clear drops while screens such as the 
Stura Footprint Combination HT-96, JCSG-plus HT-96 and Morpheus HT-96 
predominantly produced cloudy amorphous precipitate. 
 
Figure 5.2. 20: Examples of crystallisation hits observed for SIRT7.  
(A) Native SIRT7.6a crystals (B) SIRT7.1 in complex with ADPR (C and F) 
SIRT7.6a in complex with ADPR (D) Native SIRT7.6a crystals (E) Native 
SIRT7.1a Conditions: (A) B9-Heavy + Light twin pack (B-C) E9-Heavy + Light 
twin pack (D) C9 JCSG-plus HT-96, (E) A9-Heavy + Light twin pack. (F) D9-
Heavy + Light twin pack. 
 
However, conditions B9 (0.2 M sodium citrate , 0.1 M Tris pH 8.5, 30% v/v PEG 
400) and D9 (0.2 M sodium citrate , 0.1 M Tris pH 8.5, 21% v/v PEG 400) of the 
Heavy + Light twin pack HT-96 yielded microcrystals for SIRT7.6a at 4 mg/mL 
after 95 days of incubation at 16 ºC [Figure 5.2.20]. In addition to a systematic 
screening of these conditions, crystallisation trials for SIRT7.6a in complex with 
NAD and with ADPR were also designed. Commercial crystallisation screens 
for SIRT7.6a in complex with NAD and SIRT 7.6a in complex with ADP-ribose 
were set up at molar ratios of 1:1, 1:2, 1:4 and 1:10 of protein to ligand (12 
screens x 96 conditions each x 4 ratios of protein to ligand x 2 protein 
concentrations x 2 ligands). A protein concentration of 4 mg/mL and 6 mg/mL 
were opted for these trials. A similar screening with NAD+ and ADPR was set 
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up for SIRT7.1 (12 screens x 96 conditions each x 4 ratios of protein to ligand x 2 
protein concentrations x 2 ligands). Of the various screens, very small crystals 
were obtained for SIRT7.6a in complex with ADPR at a ratio of protein to ligand 
of 1:4 in A9 (0.2M zinc acetate, 0.1M sodium cacodylate pH 6.5, 18% [w/v] PEG 
8000 ) and D9 (0.2 M sodium citrate , 0.1 M Tris pH 8.5, 21% v/v PEG 400) of the 
Heavy + Light twin pack HT-96 [Figure 5.2.20]. These crystals took 3 months of 
incubation at 16 ºC to grow. Similar crystals grew in C9 JCSG-plus HT-96 (0.1M 
Na/K phosphate, 25% v/v 1,2-propanediol, 10% [w/v] glycerol) on incubation 
at 16 ºC. However, on repeating this screen, it was observed that a protein to 
reservoir solution ratio of 1:2 was most preferred for crystal growth. These 
crystals were exposed to X-ray diffraction on beam-line I04 but no diffraction 
was observed.  
Although SIRT7 was expressed and purified, its crystallisation to date has been 
unsuccessful. Possible reasons for this are discussed in section 5.4. 
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5.3. Sirtuin 1 
5.3.1. Introduction 
The human Sir2 orthologue, SIRT1, is an NAD+ dependent deacetylase that is 
localised in the nucleus (Imai et al., 2000, Vaziri et al., 2001). It is the most widely 
studied member of the sirtuin family. SIRT1 interacts with a wide range of 
substrates and has been identified in several pathological conditions including 
ageing and age-related diseases. SIRT1 deacetylates a number of histone and 
non-histone proteins including histone H3 and H4, p53, NF-κB, PGC-1α, HIF1α, 
among others (Blander and Guarente, 2004, Feldman et al., 2012, Houtkooper et 
al., 2012, McGuinness et al., 2011). The dual role of SIRT1 as a tumour 
suppressor and a tumour promoter has been a topic of discussion and has 
eluded our understanding of its role in cancer. The known SIRT1 substrates and 
the role of SIRT1 in various pathological conditions are discussed in detail in 
sections 2.4 and 2.6 respectively.  
Despite progress over the last decade, relatively less is known about the 
regulatory mechanism of SIRT1. SIRT1 is actively promoted or inhibited by 
endogenous proteins, AROS (active regulator of SIRT1) and DBC1 (deleted in 
breast cancer 1) (Kim et al., 2007, Kim et al., 2008, Zhao et al., 2008). 
Table 5.3. 1: Overview of the results of a sequence comparison of SIRT1 with 
other human sirtuins. 
ClustalO was used for sequence comparison (UniProt, 2014). 
  Identity (%) Identical positions 
SIRT1 SIRT2 17.806 138 
SIRT1 SIRT3 17.25 133 
SIRT1 SIRT4 10.013 78 
SIRT1 SIRT5 10.78 83 
SIRT1 SIRT6 10.39 80 
SIRT1 SIRT7 10.35 82 
 
Two splice variants of SIRT1 have been reported, isoform-1 and -2 with 747 and 
561 residues, respectively (UniProt, 2014). The canonical SIRT1, isoform 1, is the 
longest member of the sirtuin family comprised of 747 residues. It is an 81.7 
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kDa protein with regions for two nuclear localisation signals and two nuclear 
export signals [Figure 5.3.1]. The deacetylase domain of SIRT1 is the most 
conserved domain among sirtuins. SIRT2 and SIRT3 are the closest homologues 
of SIRT1 while SIRT4 and SIRT7 are the least similar [Table 5.3.1]. 
 
Figure 5.3. 1: Key features of the structure of SIRT1.  
A schematic representation of the structure of SIRT1. The structurally important 
cysteine (C) residues involved in zinc binding are indicated along with the 
histidine (H) residue that behaves as a proton acceptor.  
 
Of the seven human sirtuins, SIRT1 contains the most extended N- and C-
terminal segments. The region between residues 200–500 forms the highly 
conserved catalytic core domain. However, various regions in the long and 
mostly unstructured N- and C-termini that flank the SIRT1 catalytic domain 
have been shown to affect SIRT1 deacetylation activity through autoregulation 
(Kang et al., 2011, Pan et al., 2012). The terminal segments were shown to 
potentiate the catalytic efficiency of the core domain by 12-45 fold, with the N-
terminal domain contributing significantly to the rate of catalysis and the C-
terminal contributing to the enzyme’s affinity to NAD+ (Pan et al., 2012). 
In the recent years, three crystal structures of truncated SIRT1 domains have 
been elucidated. The first crystal structure of SIRT1 determined was the 
catalytic core domain (residues 214-516) in complex with a NAD+ analogue and 
the SIRT1 inhibitor EX-527 analogue (Zhao et al., 2013). This was followed by 
the publication of two additional structures of SIRT1 (Davenport et al., 2014). 
The first showed residues 234-510 and additional residues 641–665 forming the 
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C-terminal regulatory segment while the second structure was a high resolution 
structure of the apo-form of SIRT1. Davenport et al. suggested that the C-
terminal regulatory segment (residues 641-665) contributes to SIRT1 activity by 
influencing the conformational changes that are required for substrate and 
cofactor binding. 
With the aim to elucidate the crystal structure of SIRT1 in its native form and 
in complex with other ligands, structural biology work on SIRT1 (isoform-1) 





5.3.2.1. Cloning, Expression and Purification 
Table 5.3.2 enlists the constructs of SIRT1 that were designed for its expression 
with covalently linked affinity tags to aid expression and purification of the 
protein. The vector maps are provided in appendix A. The final optimised 
cloning, expression and protein purification protocols for each construct are 
given below. 







1.1 140-747 pTriEx-4 Ek/LIC 
N-term His and 
S-tag 
73.2 
1.5 140-747 pET-41 Ek/LIC 
N-term GST, 
His and S-tag 
99.3 
1.6 160-747 pET-41 Ek/LIC 
N-term GST, 
His and S-tag 
97.0 




1.8 160-665 pET-41 Ek/LIC 
N-term GST, 
His and S-tag 
70.8 






The gene coding for SIRT1 was cloned into pTriEx-4 Ek/LIC vector (Novagen, 
Darmstadt, Germany) with a cleavable N-terminal poly-histidine and S-tag. 
This recombinant plasmid was named SIRT1.1. The plasmid was transformed 
into E. coli BL21-CodonPlus (DE3)-RIPL cells. The glycerol stocks of this 
transformant were available in the laboratory. Cells were grown in AI media 
with ampicillin at 37 °C for 6 h and then incubated at 16 ºC for 16 h. Cells were 
harvested after 22 h of inoculation by centrifugation (4 °C at 12,000 g, 10 min). 
Cell pellets were resuspended in wash buffer (50 mM HEPES pH 7.4, 
200 mM NaCl, 15 mM imidazole) and lysed in an One shot model (Constant 
systems, U.K.). The preparation was then clarified by centrifugation (4 °C at 
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75,000 g, 25 min). The supernatant was loaded on a 5 mL HisTrap FF column 
(GE Healthcare, Uppsala, Sweden) pre-equilibrated with wash buffer. The 
column was washed extensively and a gradient elution of 0-100% over 50 mL 
(50 mM HEPES pH 7.4, 200 mM NaCl, 500 mM imidazole) was carried out. The 
eluted fraction was dialysed overnight in wash buffer at 4 °C and loaded on a 
gel filtration column (16/600 Superdex 200 pg; GE Healthcare, Uppsala, 
Sweden) pre-equilibrated with final buffer (50 mM HEPES pH 7.4, 
200 mM NaCl). The eluted samples were analysed by SDS-PAGE. Anti-SIRT1 
Ab and anti-His Ab (Sigma-Aldrich Co., Kent, U.K.) were used to confirm the 
identity of the protein by western blot analysis.  
SIRT1.1a 
On confirming that the protein purified was not SIRT1, the recombinant 
plasmid for SIRT1.1 was transformed into E. coli TOP10 cells and the DNA was 
extracted for sequencing. This transformant was named SIRT1.1a. On 
verification of DNA sequencing, transformation into E. coli Rosetta-gamiTM 
2(DE3)pLysS cells followed by preparation of fresh glycerol stocks was carried 
out as described in Section 3.4.2. Extracted DNA was sent for sequencing to 
Eurofins MWG Operon, Ebersberg, Germany using T7 primer for forward 
sequencing and TriExDOWN primer for reverse sequencing.  
Expression trials were carried out by inoculating AI, LB and TB media with 
ampicillin and chloramphenicol as described in Section 3.5.1 followed by 
induction with 1 mM IPTG. Samples were collected at regular intervals and 
analysed for protein expression by SDS-PAGE. 
SIRT1.5 
The gene coding for SIRT1 was cloned into pET-41 Ek/LIC vector (Novagen, 
Darmstadt, Germany) with a cleavable N-terminal GST-tag. The recombinant 
plasmid was named SIRT1.5.  
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The recombinant plasmid SIRT1.1 was used for PCR amplification as described 
in Section 3.4.2. The primers used for PCR amplification are given in table 5.3.3, 
while the components of the reaction mixtures and the parameters for thermal 
cycling are given in tables 5.3.4 and 5.3.5, respectively. 
Table 5.3. 3: Primers used for PCR reaction of SIRT1.5 
Primer Sequence (5’-3’) 
SIRT1.5fwd GAC GAC GAC AAG ATG ATT GGG TAC CGA GAT AAC CTT CTG 
SIRT1.5rev 
GAG GAG AAG CCC GGT TAT GAT TTG TTT GAT GGA TAG TTC 
ATG TCT GTT ACT 
 
 Table 5.3. 4: PCR reaction for SIRT1.5 
Reaction Tube 1 (µL) Tube 2 (µL) Tube 3 (µL) 
DNA template  
(SIRT1.1) 
(100ng/µL) 








1.5 1.5 1.5 
KOD polymerase 
(1U/µL) 
1 1 1 
10x Buffer 5 5 5 
dNTPs  
(2mM each) 
5 5 5 
MgSO4 (25 mM) 3 3 3 
Betaine - 10 - 
DMSO - - 2 
Water (q.s. 50 µL) 31 21 29 
 
Table 5.3. 5: PCR thermal cycle for SIRT1.5 
Cycle Conditions 
Initial denaturation 94 ºC, 2 min 
Denaturation 94 ºC, 30 sec 
Annealing 58 ºC, 1 min 
Extension 72 ºC, 1 min 
Back to step 2 for 35x  
Final extension 72 ºC, 10 min 
Hold at 4oC  
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The PCR product was analysed by running the samples on an agarose gel as 
described in section 3.4.1. and the final clean-up product was cloned into a pET-
41 Ek/LIC vector (Novagen, Darmstadt, Germany) with a cleavable N-terminal 
GST, poly-histidine and S-tag. The final recombinant plasmid was transformed 
into E. coli Rosetta-gamiTM 2(DE3)pLysS cells followed by preparation of 
glycerol stocks as described in Section 3.4.2. Extracted DNA was sent for 
sequencing to Eurofins MWG Operon, Ebersberg, Germany using T7 primer 
and S-tag primer for forward sequencing. 
Expression trials were carried out by inoculating AI, LB and TB media with 
kanamycin and chloramphenicol as described in Section 3.5.1 followed by 
induction with 1 mM IPTG. Samples were collected at regular intervals and 
analysed for protein expression by SDS-PAGE.  
SIRT1.6, SIRT1.7, SIRT1.8 and SIRT1.9 
Recombinant plasmids with further truncation of SIRT1 were prepared to 
facilitate expression of the truncated protein with either a GST-tag or His-tag. 
Table 5.3.2 gives an overview of the truncation and vectors used for these 
constructs.  
The recombinant plasmids were prepared as described for SIRT1.5. The primers 
used for PCR amplification are given in table 5.3.3 and 5.3.6, while the 
components of the reaction mixtures and the parameters for thermal cycling are 
given in tables 5.3.7 and 5.3.8, respectively. 
Table 5.3. 6: Primers used for PCR reaction of SIRT1.6-1.9. 
Primer Sequence (5’-3’) 
SIRT1.6fwd GAC GAC GAC AAG ATG TGT GAA AGT GAT G 







Table 5.3. 7: PCR reaction of SIRT1.6-1.9. 
Reaction 
Tube 1 (µL) 
(160-747) 
Tube 2 (µL) 
(160-747) 
Tube 3 (µL) 
(160-665) 
Tube 4 (µL) 
(160-665) 
DNA template  
(SIRT1.1) 
(100ng/µL) 


























1 1 1 1 
10x Buffer 5 5 5 5 
dNTPs  
(2mM each) 
5 5 5 5 
MgSO4 (25 mM) 3 3 3 3 
DMSO - 2 - 2 
Water 
(q.s. 50 µL) 
31 29 31 29 
 
Table 5.3. 8: PCR thermal cycle for SIRT1.6-1.9. 
Cycle Temperature (ºC) 
Time (min) 
Initial denaturation 95 2 
Denaturation 95 0.5 
Annealing 57 1 
Extension 72 1 
Back to step 2 
(Denaturation) for 35x 
  
Final extension 72 10 
Hold at 4oC   
 
The PCR products were analysed by running the samples on an agarose gel as 
described in section 3.4.1. The final purified product was ligated with either 
pTriEx-4 Ek/LIC or pET-41 Ek/LIC vectors (Novagen, Darmstadt, Germany) as 
indicated in table 5.3.2. The recombinant vectors were transformed into E. coli 
TOP10 cells and the DNA were extracted as described in section 3.4.2. Extracted 
DNA was sent for sequencing to Eurofins MWG Operon, Ebersberg, Germany 
using T7 primer and S-tag primer for sequencing of insert in pET-41 Ek/LIC or 
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T7 primer and TriExDOWN primer for sequencing of insert in pTriEx-4 
Ek/LIC. The verified recombinant plasmids were transformed into E. coli 
Rosetta-gamiTM 2(DE3)pLysS cells followed by preparation of glycerol stocks as 
described in Section 3.4.2.  
Expression trials were carried out by inoculating AI, LB and TB media as 
described in Section 3.5.1. Antibiotics, kanamycin and ampicillin, were used for 
constructs cloned in pET-41 Ek/LIC and pTriEx-4 Ek/LIC vectors, respectively. 
Samples were collected at regular intervals and analysed for protein expression 
by SDS-PAGE.   
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5.3.3. Results 
5.3.3.1. SIRT1 construct SIRT1.1 
SIRT1.1 is a truncated protein of residues 140-747. The recombinant gene was 
cloned into pTriEx-4 Ek/LIC vector in order to facilitate the expression with a 
covalently linked His-tag. The expressed protein is expected to have a 
theoretical mass of 73.2 kDa.  
Initial expression in TB media followed by IMAC and SEC of SIRT1.1 resulted 
in a protein at ~55 kDa and ~66kDa being observed on a SDS-PAGE [Figure 
5.3.2 and 5.3.3]. Western blot analysis using anti-SIRT1 Ab and anti-His Ab 
confirmed that the purified protein was not SIRT1. 
 
Figure 5.3. 2: SIRT1.1 purification.  
Example chromatogram of (A) IMAC utilising the HisTrap FF column for 






 Figure 5.3. 3: SIRT1.1 purification and western blot analysis.  
(A) Purification of SIRT1.1 after IMAC and SEC analysed by SDS-PAGE. (B) 
Western blot analysis of SIRT1.1 after SEC. The molecular weights of the SDS-
PAGE marker (M) and western blot marker (M2) are labelled. 
 
DNA extracted from the E. coli TOP10 cells glycerol stock was used for 
successful DNA sequencing (referred to as SIRT1.1a). Positive results for 
forward and reverse DNA sequencing were obtained. The alignment of the 
translated DNA sequences of SIRT1.1 with SIRT1 are given in appendix E3.1 
and E3.2. The recombinant plasmid was successfully transformed into E. coli 
Rosetta-gamiTM 2(DE3)pLysS cells and expression trials were performed in LB, 
TB and AI media at 37 ºC. On analysis by SDS-PAGE no expression of SIRT1 at 




Figure 5.3. 4: Expression trials for SIRT1.1a analysed by SDS-PAGE. 
SIRT1.1a expression in LB, TB and AI media at 37 oC analysed by SDS-PAGE. 
The molecular weights of the SDS-PAGE marker (M) are labelled. 
 
 
5.3.3.2. SIRT1 construct SIRT1.5 
Following SIRT1.1a, the recombinant gene for construct SIRT1.5 was cloned in a 
pET41-EK/LIC vector to facilitate the expression of SIRT1 with a covalently 
linked GST-tag to aid soluble protein expression. The primers SIRT1.5fwd and 
SIRT1.5rev were used for PCR amplification of SIRT1.1 expression vector where 
a band of ~1800 bp was observed on analysis of the sample on an agarose gel 
[Figure 5.3.5]. The resulting gene of interest was used annealed with pET41-
Ek/LIC vector followed by the successful transformation into E. coli TOP10 cells 
and DNA extraction. On verification of the DNA sequencing, transformation of 
SIRT1.5 recombinant plasmid into E. coli Rosetta-gamiTM 2(DE3)pLysS cells 
were carried out. The alignment of the translated DNA sequences of SIRT1.5 
with SIRT1 is given in appendix E3.3. Expression trials were performed in LB, 
TB and AI media at 16 ºC and 37 ºC which showed no expression of SIRT1 at 




Figure 5.3. 5: Cloning and expression trials for SIRT1.5.  
(A) Agarose gel of the PCR product for SIRT1.5. (B) Expression trials for SIRT1.5 
in LB, TB and AI media at 37 ºC. The base pairs of the DNA marker (M2) and 
molecular weights of the SDS-PAGE marker (M) are labelled. 
 
 
Figure 5.3. 6: Expression trials for SIRT1.5.  
Expression trials for SIRT1.5 in LB, TB and AI media at 16 ºC analysed by SDS-
PAGE. The molecular weights of the SDS-PAGE marker (M) are labelled. 
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5.3.3.3. SIRT1 constructs SIRT1.6, SIRT1.7, SIRT 1.8 and SIRT1.9 
As no expression of SIRT1 (residues 140-747) was observed, constructs with 
further truncation of SIRT1 to exclude the predicted unstructured regions 
including the complete nuclear export signal at the N-terminal end and with or 
without the residues following the C-terminal regulatory segment [Table 5.3.2] 
were designed.  
The primers SIRT1.6fwd and SIRT1.5rev for residues 160-747 and primers 
SIRT1.6fwd and SIRT1.8rev for residues 160-665 were used for successful PCR 
amplification of SIRT1.1 expression plasmid [Figure 5.3.7] and final PCR 
product after clean-up was used for annealing with the respective expression 
vectors as indicated in table 5.3.2 followed by the successful transformation into 
E. coli TOP10 cells for DNA extraction. The extracted DNA was sent for 
sequencing analysis. On verification of the sequencing results, SIRT1.6, SIRT1.7, 
SIRT1.8 and SIRT1.9 recombinant plasmids were transformed into E. coli 
Rosetta-gamiTM 2(DE3)pLysS cells. Positive results for forward and reverse 
DNA sequences were obtained. The alignment of the translated DNA sequences 
of SIRT1.6-SIRT1.9 with SIRT1 is given in appendix E3.4-E3.9. Expression trials 
were performed in LB, TB and AI media at 16 ºC and 37 ºC which showed no 
expression of SIRT1 at the expected molecular weights on analysis by SDS-
PAGE [Figure 5.3.8 – 5.3.10]. 
 
Figure 5.3. 7: Cloning of SIRT1.6, SIRT1.7, SIRT1.8 and SIRT1.9. 
PCR products for SIRT1.6, SIRT1.7, SIRT1.8 and SIRT1.9 analysed on an agarose 
gel. The base pairs of the DNA ladder (M2) are labelled. 
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Figure 5.3. 8: Expression trials for SIRT1.6, SIRT1.7, SIRT1.8 and SIRT1.9 in 
AI media.  
Expression trials for SIRT1.6, SIRT1.7, SIRT1.8 and SIRT1.9 in AI media 
analysed by SDS-PAGE. The molecular weights of the SDS-PAGE marker (M) 





Figure 5.3. 9: Expression trials for SIRT1.6, SIRT1.7, SIRT1.8 and SIRT1.9 in 
LB media. 
Expression trials for SIRT1.6, SIRT1.7, SIRT1.8 and SIRT1.9 in LB media 
analysed by SDS-PAGE. The molecular weights of the SDS-PAGE marker (M) 




Figure 5.3. 10: Expression trials for SIRT1.6, SIRT1.7, SIRT1.8 and SIRT1.9 in 
TB media. 
Expression trials for SIRT1.6, SIRT1.7, SIRT1.8 and SIRT1.9 in TB media 
analysed by SDS-PAGE. The molecular weights of the SDS-PAGE marker (M) 
are labelled.  
 
 
To date, expression and purification of SIRT1 has been unsuccessful. Possible 





Crystallisation of proteins to elucidate their molecular structure using X-ray 
crystallography is accomplished via a sequential multi-stage process. One of the 
largest challenges in obtaining crystal structures is the need for milligram 
quantities of highly purified, soluble, active protein. Once this hurdle is 
overcome, the next obstacle is the crystallisation of the protein in a form that 
yields diffraction quality crystals. This study demonstrates the challenges faced 
in the structural studies on sirtuins and the methods employed to overcome 
these barriers.  
The members of the sirtuin family have been extensively studied in order to 
understand their role in NAD+ dependent acylation of diverse substrates and 
their implication in ageing and ageing related diseases (as discussed in section 
2.5). Several sirtuin proteins were cloned, expressed and purified in an attempt 
to crystallise the proteins in their native forms as well as in complex with 
various substrates and inhibitors. 
5.4.1. Protein expression and purification 
Overexpression of eukaryotic proteins in bacteria in their soluble form has been 
a major bottleneck in structural biology (Smyth et al., 2003). Over the years 
various large affinity tags such as SUMO (11 kDa), GST (26 kDa), and MBP (40 
kDa) among others, have been used to overcome this problem. However, the 
subsequent cleavage of these tags may lead to problems such as low yield, 
precipitation of the target protein, and/or failure to recover active or 
structurally intact protein (Baneyx, 1999). In addition, protein cleavage often 
requires tedious optimisation and the proteases can be very costly. The 
alternative, to circumvent the cleavage and re-purification steps, is to leave the 
affinity tag in place for crystallisation. Unfortunately this brings about a new 
challenge as multidomain proteins are less conducive to forming well-ordered, 
diffracting crystals, which is likely to be due to the conformational 
heterogeneity allowed by flexible linker regions (Bucher et al., 2002). Thus, 
smaller affinity tags, such as the His-tag, are often selected for structural 
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biology applications as they do not significantly increase the size of the protein 
and cleavage of the tags is not essential for crystal growth. However, the usage 
of smaller tags can compromise soluble overexpression of the protein. Each 
type of tag has its own advantages and disadvantages (Smyth et al., 2003). 
Hence, the careful selection of a suitable affinity tag to aid soluble expression, 
purification, tag cleavage (if required) and crystallisation is a crucial step in 
structural biology. With these parameters in mind, various sirtuin constructs 
were designed which included truncated forms of the protein, as well as a 
variety of affinity tags and E. coli expression cell lines. 
SIRT2 
Four constructs with a range of SIRT2 truncations and affinity tags were 
expressed and purified for crystallisation trials [Table 5.1.2]. Mass spectrometric 
analysis and western blot analysis, using anti-SIRT2 Ab and anti-His Ab or anti- 
GST Ab, confirmed the identity of the protein. SIRT2 activity studies showed 
that the SIRT2 construct SIRT2.6 (residues 34-389) was the most active of the 
four constructs. This difference in activity could be due to the presence of fusion 
tags or the truncation of the protein. The C-terminal fragment of SIRT2 
(residues 356 – 389) have not been crystallised to date and may be involved in 
the activity of the protein as observed in other sirtuins (Davenport et al., 2014).  
Substrate and inhibitor interactions with sirtuins have been known to result in 
dynamic structural changes. Recently, inhibitor binding was shown to induce 
structural changes of SIRT2 resulting in the formation of a closed conformation 
on comparison with the apo-SIRT2 structure (Yamagata et al., 2014). 
Additionally, the co-factor binding loop was shown to change in close relation 
to the catalytic events which comprise the formation of a covalent 1’-O-
alkylamidate intermediate between the two substrates (NAD+ and acetyl lysine) 
under nicotinamide release (Sanders et al., 2010). This loop is in close proximity 
to the proposed region for the C-terminal flanking extensions (residues 356-389) 
and may also be involved in the catalytic activity of SIRT2 [Figure 5.4.1]. As a 
result of this, removal of the C-terminal flanking region (residues 356-389) 
would result in a decrease in SIRT2 activity as observed in constructs SIRT2.1, 
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SIRT2.4 and SIRT2.7 (residues 34-356). The crystal structure of SIRT2.6 or other 
full length constructs would help in understanding the role of the C-terminal 
flanking region in the catalytic activity of SIRT2.  
 
Figure 5.4. 1: Crystal structure of apo-form of SIRT2. 
(PDB code: 3ZGO) The proposed region for the SIRT2 C-terminal flanking 
extension is indicated in the figure.  
 
SIRT7 
Three constructs of full length SIRT7 with a His-tag or a GST-tag were 
expressed and purified for crystallisation trials [Table 5.2.2]. Soluble expression 
of the protein was initially achieved using a combination of larger affinity tags, 
such as the GST-tag, and E. coli  ArcticExpress cells which aid slow expression 
of the protein at lower temperatures to ensure correct refolding and enhance 
solubility of the protein. However, precipitation of SIRT7.6 due to cleavage of 
the tag prompted the design of construct SIRT7.7, which took advantage of a 
different vector and protease for tag cleavage. Untagged SIRT7 was successfully 
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obtained on cleavage of the GST-tag from purified SIRT7.7. The differences in 
the linker region between pGEx-6P-1 and pET-41 Ek/LIC may also contribute 
to the cleaved SIRT7.7 remaining soluble following cleavage. Mass 
spectrometric analysis and western blot analysis using anti-His or anti-GST Ab 
confirmed the identity of the protein. As insoluble expression of SIRT7.1a was 
observed, its retention of NAD+ binding activity following refolding was 
confirmed using the SIRT7 activity assay. This assay was performed with 
biotinylated-NAD+ and the results analysed via a modified Western blot.  
 SIRT1 
Various constructs of SIRT1 were designed for expression and purification of 
SIRT1. However, difficulties in expression of this protein were encountered. 
The difference in primary and secondary structure, such as length of loops and 
longer terminal flanking regions, of SIRT1 compared to other members of the 
sirtuin family may be a contributing factor for these results. Further trials such 
as eukaryotic expression of this protein or its expression using other affinity 
tags such as SUMO or MBP-tags may yield favourable results.  
5.4.2. Protein Crystallisation  
Protein crystallographers are often confronted with recalcitrant proteins that are 
not readily crystallisable, or which crystallise in problematic forms. A general 
problem in protein crystallisation is that the crystallisation conditions required 
for crystallisation of a given protein, which include a combination of pH, ionic 
strength, temperature, protein concentration, the presence of various salts, 
ligands or additives, the type of precipitant and the actual crystallization 
method to use (hanging drop, sitting drop, dialysis, etc.), are practically 
impossible to predict in advance. Additionally, minor changes in these factors 
could result in non-reproducible the crystallisation results.  
Nucleation and crystal growth are affected by chemical and physical 
parameters, as well as the crystallisation method used. A wide range of 
different conditions based on various screening kits were used in attempts to 
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crystallise SIRT2 and SIRT7. Almost all conditions tried, resulted in clear drops, 
amorphous precipitate or phase separation. A few conditions yielded 
crystalline precipitate and potential crystallisation hits for both SIRT2 and 
SIRT7 were obtained. In spite of varying several parameters in these conditions, 
the attempts to crystallise both proteins to produce diffraction quality crystals 
were unsuccessful.  
Despite the inability to arrive at the right conditions, some basic observations 
were made based on the trials so far. The protein seems to prefer lower 
temperatures rather than room temperature or higher for incubation. At 
temperatures above 10 ºC, lower concentrations (below 5 mg/mL) of protein 
ensured it remained in solution and heavy precipitation was minimised. It was 
also observed that lower pH at any concentration caused turbidity of the 
protein solution in the drop over a period of time.  
One of the ways to overcome the obstacle of crystal growth is to set up 
crystallisation trials of the proteins with their affinity tags as this may 
contribute to crystal contacts and nucleation of the protein. Additionally, 
conformational heterogeneity is introduced by the flexible linker between the 
affinity tag and the protein of interest. To this end, crystallisation trials for 
SIRT2.7, SIRT7.6a and SIRT7.7 were set up with their respective affinity tags. 
Activity assays for SIRT2 and SIRT7 were also performed to confirm that the 
final purified protein used for crystallisation was active. However, no 
diffraction quality crystals were obtained. This could be due to the intrinsic 
disorder of sirtuins which may be overcome by co-crystallisation of the proteins 
with their respective substrates or ligands. 
The inability of SIRT7.6a crystals to diffract may be indicative of its ability to 
nucleate and crystallise. However, optimisation of these crystallisation 
conditions would be required to yield diffraction quality crystals. If future trials 
also result in crystals that do not diffract, optimisation experiments to help in 
the formation of ordered crystals would be required. This is because the 
internal order of the crystals is crucial in protein crystallography and not the 
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outward appearance alone. Often the two go hand in hand but a true 
assessment of a crystal’s quality can only be determined by X-ray diffraction. 
The minor variations in protein preparation and crystallisation may contribute 
to non-reproducibility of published SIRT2 crystals as observed in this study. 
These differences may include variation in the chemicals used due to purchase 
from different manufacturer’s or simply the environment in which the 
experiments were performed. Idiosyncratic variation of individual procedures 
would also contribute to the inability of the protein to crystallise. 
Currently, there are numerous ‘uncrystallisable’ proteins but, as molecular 
biology methodologies improve and the knowledge of crystallisation advances, 
these unyielding cases may be solved. With respect to sirtuins, there are still 
many approaches that can be explored to attain diffraction quality crystals. 
These approaches include changes in both protein preparation and protein 
crystallisation techniques. One of the routes for protein preparation includes 
variation of mammalian sirtuin expression hosts such as mammalian, or insect 
cells through incorporation of the gene of interest in a baculovirus vector. These 
methods ensure a high level of protein expression with the refolding and post-
translational modifications, an ability that bacterial hosts lack. However, these 
methods were beyond the scope of this study. Another approach would be to 
modify the expression tags to enable the expression of mammalian sirtuins 
covalently linked to other tags such as cleavable SUMO-His, thioredoxin or 
MBP-tags. These tags aid in soluble expression of the protein and can help in 
affinity purification of the protein. Modification to bio-macromolecular crystal 
growth techniques by using methods such as sandwich drop, free interface 
diffusion or microdialysis may help crystallisation of sirtuins.  
Over the past few decades, much work in the field of sirtuins has been devoted 
to SIRT1 and SIRT2. However, the interplay of sirtuins demands that we 
deepen our understanding of each sirtuin to help modulate their activity such 
that the effect is beneficial to our health rather than it being detrimental (Cen et 
al., 2011).  
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The known crystal structures of sirtuins have helped us build limited 
knowledge of the structural requirements for sirtuin activation and inhibition, 
however elucidating the full length structures of all sirtuins would greatly 
potentiate this study and help its effective modulation.  
Such studies, can be used to identify regions of the protein responsible for its 
function by comparing it with proteins that are structurally similar and yet 
functionally different (as seen among members of the sirtuin family). 
Elucidating the full length structures of SIRT1, SIRT2 and SIRT7, will serve as a 
starting point for a rational program of experimentation such as site directed 
mutagenesis, ligand binding studies, rational drug design and molecular 
dynamic studies. This might lead to additional therapeutic opportunities as 
well as refinement of current strategies that are aimed at ageing and ageing 
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APPENDIX A: Vector maps 
 
 PCR blunt vector 
 




 pET-41 Ek/LIC 
 





 pGEx-6P-1 vector 
 
 





APPENDIX B: Composition of bacterial cell growth media 
 
LB Media (q.s. 1000 mL) TB Media (q.s. 1000 mL) 
5 g Yeast extract 24 g  Yeast extract 
10 g  Tryptone 12 g Tryptone 
10 g  Sodium Chloride 4 mL  Glycerol 
 (q.s.) 900 mL 
TB Salts ( q.s. 100 mL) 
2.31 g Potassium phosphate (monobasic) 
12.54 g Potassium phosphate (dibasic) 
 
 
HIS Media (q.s. 1000 mL)  ZXY7 Media (q.s. 1000 mL) 
50 g  Yeast extract  16 g Tryptone 
10 g  Casamino acid  10 g Yeast extract 
52.3 g  MOPS  5 g Sodium chloride  
33 g  Tris HCl  25 mL  Glucose (20% [w/v]) 
100 mL  Glucose (20% [w/v])    
 
 
SOC Media (q.s. 1000 mL)  Modified TB (q.s. 1000 mL) 
20 g Tryptone  12 g Tryptone 
5 g Yeast extract  24 g Yeast extract 
700 mg Sodium chloride  5 g  Glycerol 
250 mg Potassium chloride  5 g Sodium chloride  
 10 mL Magnesium sulfate (1 M)  25 mL  Glucose (20% [w/v]) 
18 mL  Glucose (20% [w/v])    
 
 
Glucose M9Y Media (pH 6.9)  
(q.s. 1000 mL) 
 Super Broth Media (pH 7.5)  
(q.s. 1000 mL) 
6 g  Sodium phosphate dibasic  35 g Tryptone 
3 g  Potassium phosphate monobasic  20 g Yeast extract 
5 g  Yeast extract  1 g Sodium chloride 
750 mg  Sodium chloride  25 mL  Glucose(20% [w/v]) 
1 mL Calcium chloride (1 M)    
1 mL Magnesium sulfate (1 M)    
 
TYGPN Media (pH 7.2)  
(q.s. 1000 mL) 
 NZCYM Media (pH 7.0) 
(q.s. 1000 mL) 
20 g Tryptone  1 g  NZ-amine 
10 g Yeast extract  14 g  Casamino acid 
6 g  Sodium phosphate dibasic  5 g  Yeast extract 
10 g  Potassium nitrate  8 g  Sodium chloride 
25 mL  Glucose (20% [w/v])  800µL  Magnesium sulfate (1 M)  
   25 mL  Glucose (20% [w/v]) 
AI Media (q.s. 1000 mL) 
293 
5 mL  Sodium sulfate (1 M) 
2 mL  Magnesium sulfate (1 M) 
200 µL 1000 x metals 
20 mL 50x 5052 
50 mL 20x NPS 
900 mL ZY media 
 
 
50x 5052 (q.s. 100 mL) 20x NPS (pH 6.8) (q.s. 100 mL) 
25 g Glycerol 5.4 g  Ammonium chloride 
2.5 g  Glucose 6.8 g  Potassium phosphate (monobasic) 
10 g  α-lactose 7.1 g  Sodium phosphate (dibasic) 
 
 
1000x metals (q.s. 100 mL) ZY media (q.s. 900 mL) 
2 mL  Calcium chloride (1 M) 10 g  NZ-amine 
1 mL Manganese chloride dihydrate (1 M) 5 g  Yeast extract 
1 mL  Zinc sulfate heptahydrate (1 M)  
1 mL Cobalt chloride hexahydrate (0.2 M) 
2 mL Copper chloride dehydrate (0.1 M) 
1 mL  Nickel chloride heptahydrate (0.2 M) 
2 mL  Sodium molybdate pentahydrate (0.1 M) 
2 mL Sodium selenite pentahydrate (0.1 M) 
2 mL Boric acid 
50 mL  Iron chloride hexahydrate  




APPENDIX C: Atom labelling of dendrons 
 










 Dendron D3 
 
297 
APPENDIX D: Ramachandran plots 












 hGal-7 in complex with Dendron D3 
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APPENDIX E: Protein sequences 
Appendix E1: SIRT2 
E1.1: Protein sequence alignment for SIRT2.6a. Alignment of the translated 
DNA sequencing result after forward sequencing (T7 primer) of the expression 
vector carrying the gene of interest SIRT2.6a with the expected SIRT2 sequence 
using clustal 2.1. His-tag sequence highlighted in blue. 
 
Result          MAHHHHHHVDDDDKEADMDFLRNLFSQTLSLGSQKERLLDELTLEGVARYMQSERCRRVI 60 
Expected        MAHHHHHHVDDDDKEADMDFLRNLFSQTLSLGSQKERLLDELTLEGVARYMQSERCRRVI 60 
                ************************************************************ 
 
Result          CLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYP 120 
Expected        CLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYP 120 
                ************************************************************ 
 
Result          GQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASC 180 
Expected        GQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASC 180 
                ************************************************************ 
 
Result          RHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVM 240 
Expected        RHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVM 240 
                ************************************************************ 
 
Result          GTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKK------- 293 
Expected        GTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAW 300 
                *****************************************************        
 
Result          ------------------------------------------------------------ 
Expected        LGECDQGCLALAELLGWKKELEDLVRREHASIDAQSGAGVPNPSTSASPKKSPPPAKDEA 360 
                                                                             
 
Result          ------- 




E1.2: Protein sequence alignment for SIRT2.6a. Alignment of the translated 
DNA sequencing result after reverse sequencing (T7 term primer) of the 
expression vector carrying the gene of interest SIRT2.6a with the expected 
SIRT2 sequence using clustal 2.1. His-tag sequence highlighted in blue. 
 
Result          ------------------------------------------------------------ 
Expected        MAHHHHHHVDDDDKEADMDFLRNLFSQTLSLGSQKERLLDELTLEGVARYMQSERCRRVI 60 
                                                                             
 
Result          CLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYP 60 
Expected        CLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYP 120 
                ************************************************************ 
 
Result          GQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASC 120 
Expected        GQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASC 180 
                ************************************************************ 
 
Result          RHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVM 180 
Expected        RHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVM 240 
                ************************************************************ 
 
Result          GTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAW 240 
Expected        GTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAW 300 
                ************************************************************ 
 
Result          LGECDQGCLALAELLGWKKELEDLVRREHASIDAQSGAGVPNPSTSASPKKSPPPAKDEA 300 
Expected        LGECDQGCLALAELLGWKKELEDLVRREHASIDAQSGAGVPNPSTSASPKKSPPPAKDEA 360 
                ************************************************************ 
 
Result          RTKEKPQ-TGLLLKSRVW-RNRCCEI-TPAHGLVY-RS- 334 
Expected        RTKEKPQ-------------------------------- 367 
 
E1.3: Protein sequence alignment for SIRT2.1. Alignment of the translated 
DNA sequencing result after forward sequencing (T7 primer) of the expression 
vector carrying the gene of interest SIRT2.1 with the expected SIRT2 sequence 
using clustal 2.1. His-tag sequence highlighted in blue. 
 
Result          ELSGTFNSTQHNIL-LNKNYYQIICILIKILYCKLHFIYNQRRYTMAHHHHHHSSGKETA 59 
Expected        ---------------------------------------------MAHHHHHHSSGKETA 15 
                                                             *************** 
 
Result          AAKFERQHMDSPPPSGLVPRGSAGSGTIDDDDKMEADMDFLRNLFSQTLSLGSQKERLLD 119 
Expected        AAKFERQHMDSPPPSGLVPRGSAGSGTIDDDDKMEADMDFLRNLFSQTLSLGSQKERLLD 75 
                ************************************************************ 
 
Result          ELTLEGVARYMQSERCRRVICLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFE 179 
Expected        ELTLEGVARYMQSERCRRVICLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFE 135 
                ************************************************************ 
 
Result          ISYFKKHPEPFFALAKELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQ 239 
Expected        ISYFKKHPEPFFALAKELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQ 195 
                ************************************************************ 
 
Result          EDLVEAHGTFYTSHCVSASCRHEYPLSWMKEKIFSE------------------------ 296 
Expected        EDLVEAHGTFYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLP 255 
                ************************************                         
 
Result          ------------------------------------------------------------ 
Expected        ARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMI 315 
                                                                             
 
Result          -------------------------------------------------------- 
Expected        MGLGGGMDFDSKKAYRDVAWLGECDQGCLALAELLGWKKELEDLVRREHASIDAQS 371 
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E1.4: Protein sequence alignment for SIRT2.1. Alignment of the translated 
DNA sequencing result after reverse sequencing (TriExDOWN primer) of the 
expression vector carrying the gene of interest SIRT2.1 with the expected SIRT2 
sequence using clustal 2.1. His-tag sequence highlighted in blue. 
 
Result          ------------------------------------------------------------ 
Expected        MAHHHHHHSSGKETAAAKFERQHMDSPPPSGLVPRGSAGSGTIDDDDKMEADMDFLRNLF 60 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        SQTLSLGSQKERLLDELTLEGVARYMQSERCRRVICLVGAGISTSAGIPDFRSPSTGLYD 120 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        NLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYPGQFKPTICHYFMRLLKDKGLLLRCY 180 
                                                                             
 
Result          -------------------------------SASCRHEYPLSWMKEKIFSEVTPKCEDCQ 29 
Expected        TQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQ 240 
                                               ***************************** 
 
Result          SLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLI 89 
Expected        SLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLI 300 
                ************************************************************ 
 
Result          NKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAWLGECDQGCLALAELLGWKKELEDLV 149 
Expected        NKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAWLGECDQGCLALAELLGWKKELEDLV 360 
                ************************************************************ 
 
Result          RREHASIDAQS-PGFSSTISELVDPNSQISARLQVDGTGSKLAAAQLYTRASQPELAPED 208 
Expected        RREHASIDAQS------------------------------------------------- 371 
                ***********                                                  
 
Result          PEDLEHHHHHHHH-VINLRCRLPIRRWW 235 
Expected        ---------------------------- 
 
E1.5: Protein sequence alignment for SIRT2.4. Alignment of the translated 
DNA sequencing result after forward sequencing (T7 primer) of the expression 
vector carrying the gene of interest SIRT2.4 with the expected SIRT2 protein 
sequence using clustal 2.1. His-tag sequence highlighted in blue. 
 
Result          LE-FCLL-EGDIHMEADMDFLRNLFSQTLSLGSQKERLLDELTLEGVARYMQSERCRRVI 58 
Expected        -------------MEADMDFLRNLFSQTLSLGSQKERLLDELTLEGVARYMQSERCRRVI 47 
                             *********************************************** 
 
Result          CLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYP 118 
Expected        CLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYP 107 
                ************************************************************ 
 
Result          GQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASC 178 
Expected        GQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASC 167 
                ************************************************************ 
 
Result          RHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVM 238 
Expected        RHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVM 227 
                ************************************************************ 
 
Result          GTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKKPTG--TW 296 
Expected        GTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAW 287 
                *****************************************************.    :* 
 
Result          P------------------------------------------- 297 




E1.6: Protein sequence alignment for SIRT2.4. Alignment of the translated 
DNA sequencing result after forward sequencing (T7 term primer) of the 
expression vector carrying the gene of interest SIRT2.4 with the expected SIRT2 
protein sequence using clustal 2.1. His-tag sequence highlighted in blue. 
 
Result          ----------ASAGRADLG-RGGPVHAERTLS------QSH------LLVGAGISTSAGI 37 
Expected        MEADMDFLRNLFSQTLSLGSQKERLLDELTLEGVARYMQSERCRRVICLVGAGISTSAGI 60 
                            :   .** :   :  * **.      **.       ************ 
 
Result          PDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYPGQFKPTICHYFMR 97 
Expected        PDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYPGQFKPTICHYFMR 120 
                ************************************************************ 
 
Result          LLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASCRHEYPLSWMKEKI 157 
Expected        LLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASCRHEYPLSWMKEKI 180 
                ************************************************************ 
 
Result          FSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLI 217 
Expected        FSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLI 240 
                ************************************************************ 
 
Result          SKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAWLGECDQGCLALAE 277 
Expected        SKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAWLGECDQGCLALAE 300 
                ************************************************************ 
 
Result          LLGWKKELEDLVRREHASIDAQSLEHHHHHH-DPAANKAR 316 
Expected        LLGWKKELEDLVRREHASIDAQSLEHHHHHH--------- 331 
                *******************************   
 
E1.7: Protein sequence alignment for SIRT2.7. Alignment of the translated 
DNA sequencing result after forward sequencing [M13(-21) primer] of the PCR 
blunt vector carrying the gene of interest SIRT2.7 with the expected SIRT2 
protein sequence using clustal 2.1.  
 
Result          -GDWAL-MHARAAASVMDICRIQGSEADMDFLRNLFSQTLSLGSQKERLLDELTLEGVAR 58 
Expected        -------------------------EADMDFLRNLFSQTLSLGSQKERLLDELTLEGVAR 35 
                                         *********************************** 
 
Result          YMQSERCRRVICLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPE 118 
Expected        YMQSERCRRVICLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPE 95 
                ************************************************************ 
 
Result          PFFALAKELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGT 178 
Expected        PFFALAKELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGT 155 
                ************************************************************ 
 
Result          FYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQS 238 
Expected        FYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQS 215 
                ************************************************************ 
 
Result          DFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLG----- 293 
Expected        DFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDF 275 
                *******************************************************      
 
Result          ----------------------------------------------- 
Expected        DSKKAYRDVAWLGECDQGCLALAELLGWKKELEDLVRREHASIDAQS 322 






E1.8: Protein sequence alignment for SIRT2.7. Alignment of the translated 
DNA sequencing result after forward sequencing (pGEx forward primer) of the 
expression vector carrying the gene of interest SIRT2.7 with the expected SIRT2 
protein sequence using clustal 2.1. 
 
Result          ATSSKSDLEVLFQGPLGSEADMDFLRNLFSQTLSLGSQKERLLDELTLEGVARYMQSERC 60 
Expected        ------------------EADMDFLRNLFSQTLSLGSQKERLLDELTLEGVARYMQSERC 42 
                                  ****************************************** 
 
Result          RRVICLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAK 120 
Expected        RRVICLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAK 102 
                ************************************************************ 
 
Result          ELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCV 180 
Expected        ELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCV 162 
                ************************************************************ 
 
Result          SASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDL 240 
Expected        SASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDL 222 
                ************************************************************ 
 
Result          LLVMGTSLQVQPFASLISKAPLSTPRLLINKGES-------------------------- 289 
Expected        LLVMGTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKKAYR 282 
                ******************************* ::                           
 
Result          ---------------------------------------- 299 
Expected        DVAWLGECDQGCLALAELLGWKKELEDLVRREHASIDAQS 322 




Appendix E2: SIRT7 
E2.1: Protein sequence alignment for SIRT7.1. Alignment of the translated 
DNA sequencing result after forward sequencing (T7 primer) of the expression 
vector carrying the gene of interest SIRT7.1 with the expected SIRT7 sequence 
using clustal 2.1. His-tag sequence highlighted in blue. 
 
Result          RS-SGTFNSTQHNIL-LNKNYYQIICILIKILYCKLHFIYNQRRYTMAHHHHHHSSGKET 58 
Expected        ----------------------------------------------MAHHHHHHSSGKET 14 
                                                              ************** 
 
Result          AAAKFERQHMDSPPPSGLVPRGSAGSGTIDDDDKMAAGGLSRSERKAAERVRRLREEQQR 118 
Expected        AAAKFERQHMDSPPPSGLVPRGSAGSGTIDDDDKMAAGGLSRSERKAAERVRRLREEQQR 74 
                ************************************************************ 
 
Result          ERLRQVSRILRKAAAERSAEEGRLLAESADLVTELQGRSRRREGLKRRQEEVCDDPEELR 178 
Expected        ERLRQVSRILRKAAAERSAEEGRLLAESADLVTELQGRSRRREGLKRRQEEVCDDPEELR 134 
                ************************************************************ 
 
Result          GKVRELASAVRNAKYLVVYTGAGISTAASIPDYRGPNGVWTLLQKGRSVSAADLSEAEPT 238 
Expected        GKVRELASAVRNAKYLVVYTGAGISTAASIPDYRGPNGVWTLLQKGRSVSAADLSEAEPT 194 
                ************************************************************ 
 
Result          LTHMSITRLHEQKLVQHVVSQNCDGLHLRSGLPRTAISELHGNMYIEVCTSCVPNREYVR 298 
Expected        LTHMSITRLHEQKLVQHVVSQNCDGLHLRSGLPRTAISELHGNMYIEVCTSCVPNREYVR 254 
                ************************************************************ 
 
Result          VFDVTERTALHRHQTG-------------------------------------------- 314 
Expected        VFDVTERTALHRHQTGRTCHKCGTQLRDTIVHFGERGTLGQPLNWEAATEAASRADTILC 314 
                ****************                                             
 
Result          ------------------------------------------------------------ 
Expected        LGSSLKVLKKYPRLWCMTKPPSRRPKLYIVNLQWTPKDDWAALKLHGKCDDVMRLLMAEL 374 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        GLEIPAYSRWQDPIFSLATPLRAGEEGSHSRKSLCRSREEAPPGDRGAPLSSAPILGGWF 434 
                                                                             
 
Result          -------------- 









E2.2: Protein sequence alignment for SIRT7.6. Alignment of the translated 
DNA sequencing result after forward sequencing (S-tag primer) of the 
expression vector carrying the gene of interest SIRT7.6 with the expected SIRT7 
sequence using clustal 2.1. GST-tag sequence highlighted in blue. 
 
Result          ------------------------------------------------------------ 
Expected        SPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDG 60 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        DVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVD 120 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        FLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKK 180 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        RIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDGSTSGSGHHHHHHSAGLVPRG 240 
                                                                             
 
Result          ---------------------------GGSGDDDDKMAAGGLSRSERKAAERVRRLREEQ 33 
Expected        STAIGMKETAAAKFERQHMDSPDLGTGGGSGDDDDKMAAGGLSRSERKAAERVRRLREEQ 300 
                                           ********************************* 
 
Result          QRERLRQVSRILRKAAAERSAEEGRLLAESADLVTELQGRSRRREGLKRRQEEVCDDPEE 93 
Expected        QRERLRQVSRILRKAAAERSAEEGRLLAESADLVTELQGRSRRREGLKRRQEEVCDDPEE 360 
                ************************************************************ 
 
Result          LRGKVRELASAVRNAKYLVVYTGAGISTAASIPDYRGPNGVWTLLQKGRSVSAADLSEAE 153 
Expected        LRGKVRELASAVRNAKYLVVYTGAGISTAASIPDYRGPNGVWTLLQKGRSVSAADLSEAE 420 
                ************************************************************ 
 
Result          PTLTHMSITRLHEQKLVQHVVSQNCDGLHLRSGLPRTAISELHGNMYIEVCTSCVPNREY 213 
Expected        PTLTHMSITRLHEQKLVQHVVSQNCDGLHLRSGLPRTAISELHGNMYIEVCTSCVPNREY 480 
                ************************************************************ 
 
Result          VRVFDVTERTALHRHQTGRTCHKCGTQLRDTIVHFGERGTLGQPLNWEAATEAASRADTI 273 
Expected        VRVFDVTERTALHRHQTGRTCHKCGTQLRDTIVHFGERGTLGQPLNWEAATEAASRADTI 540 
                ************************************************************ 
 
Result          LCLGSSLKGSKEVPTPLVHDQAP------------------------------------- 296 
Expected        LCLGSSLKVLKKYPRLWCMTKPPSRRPKLYIVNLQWTPKDDWAALKLHGKCDDVMRLLMA 600 
                ********  *: *      :.*                                      
 
Result          ------PAA--------------------------------------------------- 299 
Expected        ELGLEIPAYSRWQDPIFSLATPLRAGEEGSHSRKSLCRSREEAPPGDRGAPLSSAPILGG 660 
                      **                                                     
 
Result          ---------------- 




E2.3: Protein sequence alignment for SIRT7.7. Alignment of the translated 
DNA sequencing result after forward sequencing [M13(-21) primer] of the PCR 
blunt vector carrying the gene of interest SIRT7.7 with the expected SIRT7 
sequence using clustal 2.1.  
 
Result          RAIGPSRCMLERPPV-WISAEFREFMAAGGLSRSERKAAERVRRLREEQQRERLRQVSRI 59 
Expected        -------------------------MAAGGLSRSERKAAERVRRLREEQQRERLRQVSRI 35 
                                         *********************************** 
 
Result          LRKAAAERSAEEGRLLAESADLVTELQGRSRRREGLKRRQEEVCDDPEELRGKVRELASA 119 
Expected        LRKAAAERSAEEGRLLAESADLVTELQGRSRRREGLKRRQEEVCDDPEELRGKVRELASA 95 
                ************************************************************ 
 
Result          VRNAKYLVVYTGAGISTAASIPDYRGPNGVWTLLQKGRSVSAADLSEAEPTLTHMSITRL 179 
Expected        VRNAKYLVVYTGAGISTAASIPDYRGPNGVWTLLQKGRSVSAADLSEAEPTLTHMSITRL 155 
                ************************************************************ 
 
Result          HEQKLVQHVVSQNCDGLHLRSGLPRTAISELHGNMYIEVCTSCVPNREYVRVFDVTERTA 239 
Expected        HEQKLVQHVVSQNCDGLHLRSGLPRTAISELHGNMYIEVCTSCVPNREYVRVFDVTERTA 215 
                ************************************************************ 
 
Result          LHRHQTGRTCHKCGTQLRDTIVHFGERGTLGQPLN------------------------- 274 
Expected        LHRHQTGRTCHKCGTQLRDTIVHFGERGTLGQPLNWEAATEAASRADTILCLGSSLKVLK 275 
                ***********************************                          
 
Result          ------------------------------------------------------------ 
Expected        KYPRLWCMTKPPSRRPKLYIVNLQWTPKDDWAALKLHGKCDDVMRLLMAELGLEIPAYSR 335 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        WQDPIFSLATPLRAGEEGSHSRKSLCRSREEAPPGDRGAPLSSAPILGGWFGRGCTKRTK 395 
                                                                             
 
Result          ----- 
Expected        RKKVT 400 





E2.4: Protein sequence alignment for SIRT7.7. Alignment of the translated 
DNA sequencing result after forward sequencing (pGEx forward primer) of the 
expression vector carrying the gene of interest SIRT7.7 with the expected SIRT7 
sequence using clustal 2.1.  
 
Result          DHPPKSDLEVLFQGPLGSPEFREFMAAGGLSRSERKAAERVRRLREEQQRERLRQVSRIL 60 
Expected        ------------------------MAAGGLSRSERKAAERVRRLREEQQRERLRQVSRIL 36 
                                        ************************************ 
 
Result          RKAAAERSAEEGRLLAESADLVTELQGRSRRREGLKRRQEEVCDDPEELRGKVRELASAV 120 
Expected        RKAAAERSAEEGRLLAESADLVTELQGRSRRREGLKRRQEEVCDDPEELRGKVRELASAV 96 
                ************************************************************ 
 
Result          RNAKYLVVYTGAGISTAASIPDYRGPNGVWTLLQKGRSVSAADLSEAEPTLTHMSITRLH 180 
Expected        RNAKYLVVYTGAGISTAASIPDYRGPNGVWTLLQKGRSVSAADLSEAEPTLTHMSITRLH 156 
                ************************************************************ 
 
Result          EQKLVQHVVSQNCDGLHLRSGLPRTAISELHGNMYIEVCTSCVPNREYVRVFDVTERTAL 240 
Expected        EQKLVQHVVSQNCDGLHLRSGLPRTAISELHGNMYIEVCTSCVPNREYVRVFDVTERTAL 216 
                ************************************************************ 
 
Result          HRHQTGRTCHKCGTQLRDTIVHFGERGTLGQPLNWEAATEAASRADTILCLGSSLKVLKK 300 
Expected        HRHQTGRTCHKCGTQLRDTIVHFGERGTLGQPLNWEAATEAASRADTILCLGSSLKVLKK 276 
                ************************************************************ 
 
Result          YPRLWCMTKPPSRRPKLYIVNLQWTPKDDWAALKLHGKCDDVMR---------------- 344 
Expected        YPRLWCMTKPPSRRPKLYIVNLQWTPKDDWAALKLHGKCDDVMRLLMAELGLEIPAYSRW 336 
                ********************************************                 
 
Result          ------------------------------------------------------------ 
Expected        QDPIFSLATPLRAGEEGSHSRKSLCRSREEAPPGDRGAPLSSAPILGGWFGRGCTKRTKR 396 
                                                                             
 
Result          ---- 
Expected        KKVT 400 
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Appendix E3: SIRT1 
E3.1: Protein sequence alignment for SIRT1.1. Alignment of the translated 
DNA sequencing result after forward sequencing (T7 primer) of the expression 
vector carrying the gene of interest SIRT1.1 with the expected SIRT1 sequence 
using clustal 2.1. His-tag sequence highlighted in blue. 
 
 
Result          PELSGTFNSTQHNIL-LNKNYYQIICILIKILYCKLHFIYNQRRYTMAHHHHHHSSGKET 59 
Expected        ----------------------------------------------MAHHHHHHSSGKET 14 
                                                              ************** 
 
Result          AAAKFERQHMDSPPPSGLVPRGSAGSGTIDDDDKMIGYRDNLLFGDEIITNGFHSCESDE 119 
Expected        AAAKFERQHMDSPPPSGLVPRGSAGSGTIDDDDKMIGYRDNLLFGDEIITNGFHSCESDE  74 
                ************************************************************ 
 
Result          EDRASHASSSDWTPRPRIGPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIV 179 
Expected        EDRASHASSSDWTPRPRIGPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIV 134 
                ************************************************************ 
 
Result          INILSEPPKRKKRKDINTIEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLA 239 
Expected        INILSEPPKRKKRKDINTIEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLA 194 
                ************************************************************ 
 
Result          VDFPDLPDPQAMFDIEYFRKDPRPFFKFAKEIYPAQFQPSLCHKFIALSDKG----RKTT 295 
Expected        VDFPDLPDPQAMFDIEYFRKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYT 254 
                **********************************.****************     *: * 
 
Result          SQLYPEHRHAGTG----CGN----------------------------------PKDNSV 317 
Expected        QNIDTLEQVAGIQRIIQCHGSFATASCLICKYKVDCEAVRGDIFNQVVPRCPRCPADEPL 314 
                .:: . .: **      * .                                  * *:.: 
 
Result          SWF--------------------------------------------------------- 320 
Expected        AIMKPEIVFFGENLPEQFHRAMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILI 374 
                : :                                                          
 
Result          ------------------------------------------------------------ 
Expected        NREPLPHLHFDVELLGDCDVIINELCHRLGGEYAKLCCNPVKLSEITEKPPRTQKELAYL 434 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        SELPPTPLHVSEDSSSPERTSPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEVQT 494 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        SRNVESIAEQMENPDLKNVGSSTGEKNERTSVAGTVRKCWPNRVAKEQISRRLDGNQYLF 554 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        LPPNRYIFHGAEVYSDSEDDVLSSSSCGSNSDSGTCQSPSLEEPMEDESEIEEFYNGLED 614 
                                                                             
 
Result          ------------------------------------------- 
Expected        EPDVPERAGGAGFGTDGDDQEAINEAISVKQEVTDMNYPSNKS 657 










E3.2: Protein sequence alignment for SIRT1.1. Alignment of the translated 
DNA sequencing result after reverse sequencing (TriExDOWN primer) of the 
expression vector carrying the gene of interest SIRT1.1 with the expected  SIRT1 
sequence using clustal 2.1. His-tag sequence highlighted in blue. 
 
Result          ------------------------------------------------------------ 
Expected        MAHHHHHHSSGKETAAAKFERQHMDSPPPSGLVPRGSAGSGTIDDDDKMIGYRDNLLFGD 60 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        EIITNGFHSCESDEEDRASHASSSDWTPRPRIGPYTFVQQHLMIGTDPRTILKDLLPETI 120 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        PPPELDDMTLWQIVINILSEPPKRKKRKDINTIEDAVKLLQECKKIIVLTGAGVSVSCGI 180 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        PDFRSRDGIYARLAVDFPDLPDPQAMFDIEYFRKDPRPFFKFAKEIYPGQFQPSLCHKFI 240 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        ALSDKEGKLLRNYTQNIDTLEQVAGIQRIIQCHGSFATASCLICKYKVDCEAVRGDIFNQ 300 
                                                                             
 
Result           -------------------------------------------LLHVNGSSS-SKTSSI 15 
Expected        VVPRCPRCPADEPLAIMKPEIVFFGENLPEQFHRAMKYDKDEVDLLIVIGSSLKVRPVAL 360 
                                                            ** * ***   :. :: 
 
Result          IPSPYPMKCLRY--LIENLASSAFDVELLRL--CHINELLS-VRW-ICQTCCNPVKLSEI 69 
Expected        IPSSIPHEVPQILINREPLPHLHFDVELLGDCDVIINELCHRLGGEYAKLCCNPVKLSEI 420 
                ***. * :  :     * *.   ******      ****   :    .: ********** 
 
Result          TEKPPRTQKELAYLSELPPTPLHVSEDSSSPERTSPPDSSVIVTLLDQAAKSNDDLDVSE 129 
Expected        TEKPPRTQKELAYLSELPPTPLHVSEDSSSPERTSPPDSSVIVTLLDQAAKSNDDLDVSE 480 
                ************************************************************ 
 
Result          SKGCMEEKPQEVQTSRNVESIAEQMENPDLKNVGSSTGEKNERTSVAGTVRKCWPNRVAK 189 
Expected        SKGCMEEKPQEVQTSRNVESIAEQMENPDLKNVGSSTGEKNERTSVAGTVRKCWPNRVAK 540 
                ************************************************************ 
 
Result          EQISRRLDGNQYLFLPPNRYIFHGAEVYSDSEDDVLSSSSCGSNSDSGTCQSPSLEEPME 249 
Expected        EQISRRLDGNQYLFLPPNRYIFHGAEVYSDSEDDVLSSSSCGSNSDSGTCQSPSLEEPME 600 
                ************************************************************ 
 
Result          DESEIEEFYNGLEDEPDVPERAGGAGFGTDGDDQEAINEAISVKQEVTDMNYPSNKS-TG 308 
Expected        DESEIEEFYNGLEDEPDVPERAGGAGFGTDGDDQEAINEAISVKQEVTDMNYPSNKS--- 657 
                *********************************************************    
 
Result          LLLNDI-ARGSEFSDLGAPAGRRYRFEACGRTAVYTCKPARTRPGRPRGSRAPPSPSPSL 367 
Expected        ------------------------------------------------------------ 
                                                                             
 
Result          SD-PQVQAAYQKVVAVAQVL 386 




E3.3: Protein sequence alignment for SIRT1.5. Alignment of the translated 
DNA sequencing result after forward sequencing (T7 primer) of the expression 
vector carrying the gene of interest SIRT1.5 with the expected  SIRT1 sequence 
using clustal 2.1. GST-tag sequence highlighted in blue. 
 
Result          ------------------------------------------------------------ 
Expected        SPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDG 60 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        DVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVD 120 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        FLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKK 180 
                                                                             
 
Result          ----------------WWFW---------------------------------------- 4 
Expected        RIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDGSTSGSGHHHHHHSAGLVPRG 240 
                                :  *                                         
 
Result          --------------------------------RRQMIGYRDNLLFGDEIITNGFHSCESD 32 
Expected        STAIGMKETAAAKFERQHMDSPDLGTGGGSGDDDDKIGYRDNLLFGDEIITNGFHSCESD 300 
                                                  : ************************ 
 
Result          EEDRASHASSSDWTPRPRIGPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQI 92 
Expected        EEDRASHASSSDWTPRPRIGPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQI 360 
                ************************************************************ 
 
Result          VINILSEPPKRKKRKDINTIEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARL 152 
Expected        VINILSEPPKRKKRKDINTIEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARL 420 
                ************************************************************ 
 
Result          AVDFPDLPDPQAMFDIEYFRKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNY 212 
Expected        AVDFPDLPDPQAMFDIEYFRKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNY 480 
                ************************************************************ 
 
Result          TQNIDTLEQVAGIQRIIQCHGSFATASCLICKYKVDCEAVRGDIFNQVVPRCPRCPADEP 272 
Expected        TQNIDTLEQVAGIQRIIQCHGSFATASCLICKYKVDCEAVRGDIFNQVVPRCPRCPADEP 540 
                ************************************************************ 
 
Result          LAIMKPEIVFFGENLPEQFHRAMKYDKDEVDLLIVIGSSLKVRPVALISKF--------- 323 
Expected        LAIMKPEIVFFGENLPEQFHRAMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQIL 600 
                ************************************************..           
 
Result          ------------------------------------------------------------ 
Expected        INREPLPHLHFDVELLGDCDVIINELCHRLGGEYAKLCCNPVKLSEITEKPPRTQKELAY 660 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        LSELPPTPLHVSEDSSSPERTSPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEVQ 720 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        TSRNVESIAEQMENPDLKNVGSSTGEKNERTSVAGTVRKCWPNRVAKEQISRRLDGNQYL 780 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        FLPPNRYIFHGAEVYSDSEDDVLSSSSCGSNSDSGTCQSPSLEEPMEDESEIEEFYNGLE 840 
                                                                             
 
Result          --------------------------------------------- 
Expected        DEPDVPERAGGAGFGTDGDDQEAINEAISVKQEVTDMNYPSNKS- 884 




E3.4: Protein sequence alignment for SIRT1.6. Alignment of the translated 
DNA sequencing result after forward sequencing (T7 primer) of the expression 
vector carrying the gene of interest SIRT1.6 with the expected  SIRT1 sequence 
using clustal 2.1. GST-tag sequence highlighted in blue. 
 
Result          ------------------------------------------------------------ 
Expected        SPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDG 60 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        DVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVD 120 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        FLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKK 180 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        RIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDGSTSGSGHHHHHHSAGLVPRG 240 
                                                                             
 
Result          ---------------------------GGSGDDDDKMCESDEEDRASHASSSDWTPRPRI 33 
Expected        STAIGMKETAAAKFERQHMDSPDLGTGGGSGDDDDKMCESDEEDRASHASSSDWTPRPRI 300 
                                           ********************************* 
 
Result          GPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRKDINT 93 
Expected        GPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRKDINT 360 
                ************************************************************ 
 
Result          IEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLPDPQAMFDIEYF 153 
Expected        IEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLPDPQAMFDIEYF 420 
                ************************************************************ 
 
Result          RKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLEQVAGIQRIIQC 213 
Expected        RKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLEQVAGIQRIIQC 480 
                ************************************************************ 
 
Result          HGSFATASCLICKYKVDCEAVRGDIFNQVVPRCPRCPADEPLAIMKPEIVFFGENLPEQF 273 
Expected        HGSFATASCLICKYKVDCEAVRGDIFNQVVPRCPRCPADEPLAIMKPEIVFFGENLPEQF 540 
                ************************************************************ 
 
Result          HRAMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPHLHFDVELLG-- 331 
Expected        HRAMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPHLHFDVELLGDC 600 
                **********************************************************   
 
Result          ------------------------------------------------------------ 
Expected        DVIINELCHRLGGEYAKLCCNPVKLSEITEKPPRTQKELAYLSELPPTPLHVSEDSSSPE 660 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        RTSPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEVQTSRNVESIAEQMENPDLKN 720 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        VGSSTGEKNERTSVAGTVRKCWPNRVAKEQISRRLDGNQYLFLPPNRYIFHGAEVYSDSE 780 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        DDVLSSSSCGSNSDSGTCQSPSLEEPMEDESEIEEFYNGLEDEPDVPERAGGAGFGTDGD 840 
                                                                             
 
Result          ------------------------- 
Expected        DQEAINEAISVKQEVTDMNYPSNKS 865 




E3.5: Protein sequence alignment for SIRT1.7. Alignment of the translated 
DNA sequencing result after forward sequencing (T7 primer) of the expression 
vector carrying the gene of interest SIRT1.7 with the expected  SIRT1 sequence 
using clustal 2.1. His-tag sequence highlighted in blue. 
 
Result          FPELSGTFNSTQHNIL-LNKNYYQIICILIKILYCKLHFIYNQRRYTMAHHHHHHSSGKE 59 
Expected        -----------------------------------------------MAHHHHHHSSGKE 13 
                                                               ************* 
 
Result          TAAAKFERQHMDSPPPSGLVPRGSAGSGTIDDDDKMCESDEEDRASHASSSDWTPRPRIG 119 
Expected        TAAAKFERQHMDSPPPSGLVPRGSAGSGTIDDDDKMCESDEEDRASHASSSDWTPRPRIG 73 
                ************************************************************ 
 
Result          PYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRKDINTI 179 
Expected        PYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRKDINTI 133 
                ************************************************************ 
 
Result          EDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLPDPQAMFDIEYFR 239 
Expected        EDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLPDPQAMFDIEYFR 193 
                ************************************************************ 
 
Result          KDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLEQVAGIQRIIQCH 299 
Expected        KDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLEQVAGIQRIIQCH 253 
                ************************************************************ 
 
Result          G----------------------------------------------------------- 300 
Expected        GSFATASCLICKYKVDCEAVRGDIFNQVVPRCPRCPADEPLAIMKPEIVFFGENLPEQFH 313 
                *                                                            
 
Result          ------------------------------------------------------------ 
Expected        RAMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPHLHFDVELLGDCD 373 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        VIINELCHRLGGEYAKLCCNPVKLSEITEKPPRTQKELAYLSELPPTPLHVSEDSSSPER 433 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        TSPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEVQTSRNVESIAEQMENPDLKNV 493 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        GSSTGEKNERTSVAGTVRKCWPNRVAKEQISRRLDGNQYLFLPPNRYIFHGAEVYSDSED 553 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        DVLSSSSCGSNSDSGTCQSPSLEEPMEDESEIEEFYNGLEDEPDVPERAGGAGFGTDGDD 613 
                                                                             
 
Result          ------------------------ 
Expected        QEAINEAISVKQEVTDMNYPSNKS 637 
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E3.6: Protein sequence alignment for SIRT1.7. Alignment of the translated 
DNA sequencing result after reverse sequencing (TriExDOWN primer) of the 
expression vector carrying the gene of interest SIRT1.7 with the expected  SIRT1 
sequence using clustal 2.1. His-tag sequence highlighted in blue. 
 
Result          ------------------------------------------------------------ 
Expected        MAHHHHHHSSGKETAAAKFERQHMDSPPPSGLVPRGSAGSGTIDDDDKCESDEEDRASHA 60 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        SSSDWTPRPRIGPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEP 120 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        PKRKKRKDINTIEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLP 180 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        DPQAMFDIEYFRKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLE 240 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        QVAGIQRIIQCHGSFATASCLICKYKVDCEAVRGDIFNQVVPRCPRCPADEPLAIMKPEI 300 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        VFFGENLPEQFHRAMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPH 360 
                                                                             
 
Result          ------------------------EYAKLCCNPVKLSEITEKPPRTQKELAYLSELPPTP 36 
Expected        LHFDVELLGDCDVIINELCHRLGGEYAKLCCNPVKLSEITEKPPRTQKELAYLSELPPTP 420 
                                        ************************************ 
 
Result          LHVSEDSSSPERTSPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEVQTSRNVESI 96 
Expected        LHVSEDSSSPERTSPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEVQTSRNVESI 480 
                ************************************************************ 
 
Result          AEQMENPDLKNVGSSTGEKNERTSVAGTVRKCWPNRVAKEQISRRLDGNQYLFLPPNRYI 156 
Expected        AEQMENPDLKNVGSSTGEKNERTSVAGTVRKCWPNRVAKEQISRRLDGNQYLFLPPNRYI 540 
                ************************************************************ 
 
Result          FHGAEVYSDSEDDVLSSSSCGSNSDSGTCQSPSLEEPMEDESEIEEFYNGLEDEPDVPER 216 
Expected        FHGAEVYSDSEDDVLSSSSCGSNSDSGTCQSPSLEEPMEDESEIEEFYNGLEDEPDVPER 600 
                ************************************************************ 
 
Result          AGGAGFGTDGDDQEAINEAISVKQEVTDMNYPSNKS-PGFSSTISELVDPNSQISARLQV 275 
Expected        AGGAGFGTDGDDQEAINEAISVKQEVTDMNYPSNKS------------------------ 636 
                ************************************                         
 
Result          DGTGSKLAAAQLYTRASQPELAPEDPEDLEHHHHHHHH-VINLRCRLPIRRWW 327 




E3.7: Protein sequence alignment for SIRT1.8. Alignment of the translated 
DNA sequencing result after reverse sequencing (T7 primer) of the expression 
vector carrying the gene of interest SIRT1.8 with the expected  SIRT1 sequence 
using clustal 2.1. GST-tag sequence highlighted in blue. 
 
Result          ------------------------------------------------------------ 
Expected        SPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDG 60 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        DVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVD 120 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        FLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKK 180 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        RIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDGSTSGSGHHHHHHSAGLVPRG 240 
                                                                             
 
Result          ---------------------------GGSGDDDDKMCESDEEDRASHASSSDWTPRPRI 33 
Expected        STAIGMKETAAAKFERQHMDSPDLGTGGGSGDDDDKMCESDEEDRASHASSSDWTPRPRI 300 
                                           ********************************* 
 
Result          GPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRKDINT 93 
Expected        GPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRKDINT 360 
                ************************************************************ 
 
Result          IEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLPDPQAMFDIEYF 153 
Expected        IEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLPDPQAMFDIEYF 420 
                ************************************************************ 
 
Result          RKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLEQVAGIQRIIQC 213 
Expected        RKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLEQVAGIQRIIQC 480 
                ************************************************************ 
 
Result          HGSFATASCLICKYKVDCEAVRGDIFNQVVPRCPRCPADEPLAIMKPEIVFFGENLPEQF 273 
Expected        HGSFATASCLICKYKVDCEAVRGDIFNQVVPRCPRCPADEPLAIMKPEIVFFGENLPEQF 540 
                ************************************************************ 
 
Result          HRAMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPHLHFDVELLG-- 331 
Expected        HRAMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPHLHFDVELLGDC 600 
                **********************************************************   
 
Result          ------------------------------------------------------------ 
Expected        DVIINELCHRLGGEYAKLCCNPVKLSEITEKPPRTQKELAYLSELPPTPLHVSEDSSSPE 660 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        RTSPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEVQTSRNVESIAEQMENPDLKN 720 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        VGSSTGEKNERTSVAGTVRKCWPNRVAKEQISRRLDGNQYLFLPPNRYIFHGAEVYSDSE 780 
                                                                             
 
Result          --- 
Expected        DDV 783 
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E3.8: Protein sequence alignment for SIRT1.9. Alignment of the translated 
DNA sequencing result after forward sequencing (T7 primer) of the expression 
vector carrying the gene of interest SIRT1.9 with the expected  SIRT1 sequence 
using clustal 2.1. His-tag sequence highlighted in blue. 
 
Result          PELSGTFNSTQHNIL-LNKNYYQIICILIKILYCKLHFIYNQRRYTMAHHHHHHSSGKET 59 
Expected        ----------------------------------------------MAHHHHHHSSGKET 14 
                                                              ************** 
 
Result          AAAKFERQHMDSPPPSGLVPRGSAGSGTIDDDDKMCESDEEDRASHASSSDWTPRPRIGP 119 
Expected        AAAKFERQHMDSPPPSGLVPRGSAGSGTIDDDDKMCESDEEDRASHASSSDWTPRPRIGP 73 
                ************************************************************ 
 
Result          YTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRKDINTIE 179 
Expected        YTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRKDINTIE 133 
                ************************************************************ 
 
Result          DAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLPDPQAMFDIEYFRK 239 
Expected        DAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLPDPQAMFDIEYFRK 193 
                ************************************************************ 
 
Result          DPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLEQVAGIQRIIQCHG 299 
Expected        DPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLEQVAGIQRIIQCHG 253 
                ************************************************************ 
 
Result          ------------------------------------------------------------ 324 
Expected        SFATASCLICKYKVDCEAVRGDIFNQVVPRCPRCPADEPLAIMKPEIVFFGENLPEQFHR 313 
                                                                             
 
Result          ------------------------------------------------------------ 327 
Expected        AMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPHLHFDVELLGDCDV 373 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        IINELCHRLGGEYAKLCCNPVKLSEITEKPPRTQKELAYLSELPPTPLHVSEDSSSPERT 433 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        SPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEVQTSRNVESIAEQMENPDLKNVG 493 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        SSTGEKNERTSVAGTVRKCWPNRVAKEQISRRLDGNQYLFLPPNRYIFHGAEVYSDSEDD 553 
                                                                             
 
Result          - 
Expected        V 554 
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E3.9: Protein sequence alignment for SIRT1.9. Alignment of the translated 
DNA sequencing result after reverse sequencing (TriExDOWN primer) of the 
expression vector carrying the gene of interest SIRT1.9 with the expected  SIRT1 
sequence using clustal 2.1. His-tag sequence highlighted in blue. 
 
Result          ------------------------------------------------------------ 
Expected        MAHHHHHHSSGKETAAAKFERQHMDSPPPSGLVPRGSAGSGTIDDDDKCESDEEDRASHA 60 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        SSSDWTPRPRIGPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEP 120 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        PKRKKRKDINTIEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLP 180 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        DPQAMFDIEYFRKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLE 240 
                                                                             
 
Result          ------------------------------------------------------------ 
Expected        QVAGIQRIIQCHGSFATASCLICKYKVDCEAVRGDIFNQVVPRCPRCPADEPLAIMKPEI 300 
                                                                             
 
Result          -------PEQFHRAMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPH 53 
Expected        VFFGENLPEQFHRAMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPH 360 
                       ***************************************************** 
 
Result          LHFDVELLGDCDVIINELCHRLGGEYAKLCCNPVKLSEITEKPPRTQKELAYLSELPPTP 113 
Expected        LHFDVELLGDCDVIINELCHRLGGEYAKLCCNPVKLSEITEKPPRTQKELAYLSELPPTP 420 
                ************************************************************ 
 
Result          LHVSEDSSSPERTSPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEVQTSRNVESI 173 
Expected        LHVSEDSSSPERTSPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEVQTSRNVESI 480 
                ************************************************************ 
 
Result          AEQMENPDLKNVGSSTGEKNERTSVAGTVRKCWPNRVAKEQISRRLDGNQYLFLPPNRYI 233 
Expected        AEQMENPDLKNVGSSTGEKNERTSVAGTVRKCWPNRVAKEQISRRLDGNQYLFLPPNRYI 540 
                ************************************************************ 
 
Result          FHGAEVYSDSEDDV-PGFSSTISELVDPNSQISARLQVDGTGSKLAAAQLYTRASQPELA 292 
Expected        FHGAEVYSDSEDDV---------------------------------------------- 554 
                **************                                               
 
Result          PEDPEDLEHHHHHHHH-VINLRCRLPIRRWW 322 





 Ramaswamy, S., Sleiman, M. H., Masuyer, G., Arbez-Gindre, C., Micha-
Screttas, M., Calogeropoulou, T., Steele, B. R. and Acharya, K. R. 
Multivalent galactose based dendrimer recognition by human galectin-7. 
2014, FEBS J. [Epub ahead of print] doi: 10.1111/febs.13140. 
POSTER PRESENTATIONS 
 Ramaswamy, S., Masuyer, G. and Acharya, K. R. Structural study of 
human galectin-7 and its interaction with novel carbohydrate based 
dendrimers, 2013, Postgraduate Research Day, University of Bath, U.K. 
 Ramaswamy, S., Masuyer, G and Acharya, K.R. Structural study of 
human galectin-7 and its interaction with novel carbohydrate based 
dendrimers, 2013, Diffraction data collecton using synchrotron radiation, 
Helmholtz-Zentrum, Berlin, Germany. 
 Ramaswamy, S., Masuyer, G. and Acharya, K. R. Multivalent galactose 
based dendrimer recognition by human galectin-7, 2014, Southwest 
structural biology consortium (SWSBC), University of Bath, U.K. 
 Ramaswamy, S., Masuyer, G. and Acharya, K. R. Multivalent galactose 
based dendrimer recognition by human galectin-7, 2014, Postgraduate 
Research Day, University of Bath, U.K. 
 
 
